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Summary 
The α-toxin of Clostridium perfringens is a toxin involved in numerous diseases of humans 
and agriculturally important animals (Songer, 1997).  One of these diseases is necrotic 
enteritis (NE) in chickens, a sporadic enteric disease which affects chicken and other avian 
species world-wide (van der Sluis, 2000).  This study involved the inactivation of alpha-toxin 
(α-toxin) for use as a potential vaccine candidate to combat NE in chickens.  
 
The α-toxin is composed of two domains.  An N-terminal domain composed of nine helices, 
and a C-terminal domain composed of eight anti-parallel β-sheets (Naylor et al., 1998).  The 
N-terminal domain is involved in the catalytic functions of the toxin which requires zinc for 
activation, and the C-terminal domain is essential for binding receptors, through the 
involvement of calcium ions (Naylor et al., 1998; Naylor et al., 1999). 
 
During the course of this research a number of α-toxin recombinant proteins have been 
developed through molecular inactivation of the α-toxin gene, plc.  Proteins plc316 and 
plc204 were developed by the deletion of the first three and seven α-helices of the N-terminal 
domain respectively.  These deletions resulted in proteins which were unstable in solution and 
constantly aggregated into insoluble masses.  They elicited lower overall antibody responses 
when administered to mice, which may in part have been caused by the reduction in the 
number of conformational epitopes present in the misfolded proteins.  
 
A third protein, plcInv3 was developed from the deletion of part of the catalytic domain of the 
α-toxin.  PlcInv3 was highly soluble and upon immunisation of mice elicited a significant 
antibody response which was also capable of protecting mice against a live challenge of 
C. perfringens. 
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The fourth and final protein developed was plc104.  The smallest of the recombinant α-toxin 
proteins, it consisted entirely of the C-terminal domain of α-toxin.  Its small size did not 
affect its ability to induce a strong antibody response when administered to mice, the 
antibodies of which were also protective during a challenge with C. perfringens.   
 
STM1, an attenuated strain of S. Typhimurium was used in the development of a vectored 
vaccine for the expression and oral delivery of plcInv3 and plc104 within the mouse host.  
The use of such a vaccine is considered superior to parenteral administration of vaccine 
antigens targeted against enteric infections as it delivers them directly to the intestinal tract 
and in the case of NE, the natural site of infection (Holmgren et al., 1992).  Oral delivery of 
attenuated S. Typhimurium vectored vaccines induces mucosal immune responses in addition 
to cell-mediated and other humoral responses (Paton et al., 1993; Ward et al., 1999; Wang et 
al., 1999a).  Therefore this system would be beneficial for control of enteric diseases such as 
necrotic enteritis of chickens. 
 
The two proteins, plcInv3 and plc104 were examined for their immune-stimulating abilities in 
mice when administered orally utilising the vaccine strain STM1 as a vector.  The region 
coding for the affinity hexa-his tag of plcInv3 and plc104 was removed prior to cloning into 
plasmids for their expression within STM1 and hence forth the proteins were known as αInv 
and α104 respectively. 
 
Proteins αInv and α104 were expressed within STM1 from expression plasmids containing 
the in vivo inducible promoters PhtrA and PpagC.  A measurable humoral immune response 
against α-toxin was absent following three oral vaccinations with the vectored vaccines.  In 
vivo inducible plasmid expression systems allow for long-term stability of plasmids in the 
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absence of selective pressure (Dunstan et al., 1999), although the plasmids developed in this 
study were fairly unstable within STM1 when examined in vitro, with greater than 90% 
plasmid loss within two days from most of the vaccines examined.  This plasmid loss, which 
would be enhanced in vivo (Dunstan et al., 2003; Foynes et al., 2003), would have led to 
reduced protein expression and is probably one of the reasons why a detectable antibody 
response was absent. 
 
Even though antibody responses were absent, cytokine profiling of splenocytes from 
vaccinated mice revealed an increase in the number of IL-4 secreting cells and the lack of 
IFN-γ secreting cells, indicating the stimulation of a TH2 response towards α-toxin.  These 
responses lead to partial protection against a live C. perfringens challenge. 
 
Mice immunised with toxoid (formalin inactivated α-toxin) via the intraperitoneal route 
elicited strong immune responses including anti-α-toxin IgG antibodies and IL-4 secretion.  
This vaccine was also capable of protecting mice from a live C. perfringens challenge.   
 
This study demonstrated the feasibility of using STMI as a carrier for the in vivo expression of 
the C. perfringens α-toxin recombinant proteins αInv and α104.  It is the first study to 
express C. perfringens antigens within an attenuated strain of S. Typhimurium, STM1.  
Activation of the TH2 arm of the immune system was observed, but it seems at this time, the 
level of activated IL-4 cells stimulated in response to vaccination with STM1 expressing the 
α-toxin truncated proteins αInv and α104 was not efficient enough to induce a detectable 
humoral response or to completely protect mice from a C. perfringens infection. 
 
The partial protection of mice immunised with vaccines composed of STM1 expressing αInv 
and α104 indicate there is potential for this vectored vaccine system to be used in the 
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protection of C. perfringens diseases caused by the α-toxin, although the system needs to be 
optimised for the maximal production of a humoral immune response.   
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 Chapter 1 
Introduction 
1.1 General introduction 
The livestock industry is an integral part of any country’s economy.  The rearing of animals 
for human consumption is complicated and constantly fraught with problems.  The outbreak 
and spread of disease is a re-occurring issue for farmers, particularly in areas of high density 
livestock.  
 
Prevention of diseases is of utmost importance for the maintenance and production of good 
quality meat and can be achieved by various means.  Antibiotics are one of the most popular 
preventative measures, but such management solutions can attract problems such as the rise of 
antibiotic resistant bacteria in the food chain (Molbak, 2004).  There is widespread concern 
that once such bacteria have entered the food chain, some human diseases may stop 
responding to antibiotic treatments.  
 
The advent of vaccinology has paved the way for alternative methods of prophylaxis in 
humans and animals alike (Walker, 1992).  Vaccine research can be traced back over two 
centuries.  In 1796 Edward Jenner injected a dose of the non-pathogenic cowpox into a child, 
protecting him from challenge with lethal smallpox.  Although ethically times have changed, 
vaccine research still requires the basic knowledge of the enemy, and how it strikes.  Vaccine 
research has advanced significantly from our traditional empirical methodology.  Research is 
focused on creating specific products which are completely characterised despite the success 
of traditional vaccines over the last 100 years.  With the advent of molecular and tissue 
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culture techniques, we are now able to create second generation vaccines which consist of 
defined antigens.  
Not only are we constantly searching for new improved antigens, but in recent times there is 
an increased focus on the delivery and presentation of antigens to the correct immune cells, 
known as immunomodulation (Hilleman, 2000). 
 
This introduction will focus on Clostridium perfringens and in particular one of the diseases it 
causes in poultry, necrotic enteritis.  Pathogenesis of the disease will be discussed along with 
methods of prevention.  This will lead to a discussion of vaccine research and technologies 
currently employed to prevent such diseases.  
 
1.2 The Clostridia 
The Genus Clostridium is comprised of Gram positive, spore-forming anaerobic bacilli.  
There are currently over 100 published species within this Genus (Quinn et al., 2002).  Most 
Clostridium species (spp.) ferment sugars or amino acids, but some can ferment both (Brock 
et al., 1994).  The end products of fermentation include acetone, butanol, butyric acid and 
other alcohols, which may give the growth medium a putrid odour (Biberstein, 1990).  One 
method of identifying Clostridium spp. relies on the detection of these acids using gas-liquid 
chromatography (Brock et al., 1994). 
 
Clostridium spp. are widely distributed throughout the environment.  They primarily inhabit 
the anoxic pockets of soil, in addition to sewage, freshwater and marine sediments of the 
world (George and Finegold, 1985; Brock et al., 1994).  Clostridia can also be found as 
commensals of the large intestine of humans and many other mammals (Allen, 1985).  They 
have adapted to the anoxic environment of the intestine and maintain a stable balance with 
other organisms present, and in the majority of cases are considered harmless saprophytes 
Chapter 1 Introduction 
 7
(Allen, 1985; Drasar and Roberts, 1990).  Clostridium spp. are the only known Genus of 
spore-forming anaerobes associated with humans, either as non-pathogens or at infected sites 
(George and Finegold, 1985).  
 
The clostridia are well known largely for their ability to produce some of the deadliest toxins 
known to mankind (Rood et al., 1997).  Botulinum and tetanus neurotoxins are two of the 
most potent toxins produced by clostridia followed by epsilon toxin, a product of 
C. perfringens (Payne and Oyston, 1998).  Both exogenous and endogenous sources of 
clostridia are responsible for disease.  Exogenous sources include C. perfringens food 
poisoning, gas gangrene, tetanus and botulism (Onderdonk and Allen, 1995).  Endogenous (or 
opportunistic) infections are usually acquired through the host’s own microflora.  Infection is 
triggered through trauma, antibiotic treatment, operative procedures, immunosuppressive 
treatments or pre-existing conditions such as leukaemia, carcinoma, and diabetes mellitus 
(Allen, 1985; Onderdonk and Allen, 1995). 
 
1.3 Clostridium perfringens 
Bacillus welchii was first isolated by William H. Welch in 1890 from a man who had died 8 
hours earlier due to a number of complications (Lucey and Hutchins, 2004).  On microscopic 
examination, he described the bacterium as resembling anthrax bacilli, but with boxed edges, 
and always found it in pairs or singularly but never in chains.  Its name was later changed to 
Clostridium welchii and then again to the current Clostridium perfringens. 
 
C. perfringens is ubiquitous in the environment and most strains are able to grow at 
temperatures ranging between 20ºC and 50ºC (Hatheway, 1990).  Two of its major 
fermentation by-products are hydrogen gas and carbon dioxide which help maintain the 
anaerobic environment required for its survival (Shimizu et al., 2002a).  Unlike most other 
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clostridia C. perfringens is amotile and one of the few aerotolerant species (Biberstein, 1990).  
Spores are rarely seen in vivo or under usual in vitro conditions (Krieg, 1984).  Most 
C. perfringens possess a capsule that is largely composed of polysaccharides (Biberstein, 
1990).  C. perfringens has a G+C content of 28% (Shimizu et al., 2002a).  Most strains are 
sensitive to penicillins but resistant to aminoglycosides (Krieg, 1984). Resistance to 
tetracyclines is developing due to antibiotic use and the conjugation of tetracycline resistance 
plasmids to sensitive strains has been observed (Abraham and Rood, 1985). 
 
C. perfringens is a commensal organism of the intestinal flora of humans and many animals 
(Tannock, 1994) and it has been isolated from virtually every animal that has ever been 
investigated (Krieg, 1984).  Numbers tend to remain low and under control through the 
microfloral balance in the gastrointestinal tract.  Conditions that cause instability of the 
gastrointestinal tract may allow for the proliferation of C. perfringens.  This proliferation 
brings about the production of toxins and disease.  The ability of C. perfringens to cause an 
opportunistic infection is often observed in farm-reared neonate animals who have yet to 
establish an intestinal microflora (Kelneric et al., 1996; Songer, 1997; Bueschel et al., 1998; 
Moxley and Duhamel, 1999; Springer and Selbitz, 1999) . 
 
1.4 Typing of C. perfringens strains 
Typing of C. perfringens is dependent upon the detection of four major toxins.  These toxins 
are major virulence factors (Sakurai and Duncan, 1978; Tso and Siebel, 1989; Sakurai and 
Kobayashi, 1995; Miyamoto et al., 1998).  Their effects are lethal and required to cause 
disease.  The expression of the major toxins divides strains into five toxinotypes, A to E 
(Meer and Songer, 1997).  Their distribution amongst the type strains are listed in Table 1.1 
and are represented by the Greek letters alpha (α), beta (β), epsilon (ε), and iota (ι).  
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Table 1.1: Classification of C. perfringens by toxinotype. 
Toxin produced C. perfringens 
type Alpha (α) Beta (β) Epsilon (ε) Iota (ι) 
A + - - - 
B + + + - 
C + + - - 
D + - + - 
E + - - + 
Based on previous tables (Rood and Cole, 1991) 
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Traditionally, typing of C. perfringens strains involved sero-neutralisation of culture filtrates 
in vivo.  Mice or guinea pigs were injected with culture supernatants of C. perfringens, along 
with antitoxin, and death (mice) or dermonecrosis (guinea pigs) was assessed (Sterne and 
Batty, 1975).  This assay was extremely time-consuming as growth of the organism was 
required.  It was also expensive as two of the toxins, epsilon and iota, required trypsin for 
activation, but a third toxin, beta toxin, was inactivated by trypsin.  Therefore each culture 
supernatant was assayed numerous times; with and without trypsin, and with and without the 
five different preparations of neutralising antisera (Hatheway, 1990).   
 
Current techniques such as the polymerase chain reaction (PCR) and enzyme-linked 
immunosorbent assay (ELISA) make the task of identification less time consuming and more 
economical (el Idrissi and Ward, 1992; Moller and Ahrens, 1996; Meer and Songer, 1997; 
Ebert et al., 1999; Kadra et al., 1999). 
 
Classification by toxinotype is convenient for clinical purposes, but does not reflect the 
genetic relationship between strains (Tsutsui et al., 1995).  Genomic mapping studies have 
revealed that there are as many differences within a type strain as there are between type 
strains (Canard et al., 1992).  The growth characteristics of C. perfringens strains is also not 
dependant on respective type designation, but on strain-associated properties (Mollby and 
Holme, 1976).  Even though type designation does not reflect strain properties, each type is 
responsible for a number of specific diseases observed in specific hosts (Section 1.6), and 
hence classification in this manner is satisfactory for the intended diagnostic purposes. 
 
Some strains, predominantly type A are also capable of producing an enterotoxin responsible 
for gastroenteritis in humans (Narayan, 1982).  This enterotoxin is a sporulation associated 
toxin and the only toxin not secreted from vegetative cells (Rood, 1998).  It is not part of the 
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current classification system, due to the increased difficulties in triggering sporulation in vitro 
(Sterne and Batty, 1975), but with new diagnostic processes in place it can now be located at 
the molecular level via PCR (Sterne and Batty, 1975; Fach and Popoff, 1997; Meer and 
Songer, 1997; Kanakaraj et al., 1998). 
 
1.5 Toxins of C. perfringens 
Toxins produced by bacteria aid in their defence and hence survival.  Many bacterial species 
are known to produce toxins, but none as many as the species of C. perfringens (Hatheway, 
1990).  Major and minor toxins are produced, of which over 15 have been identified 
(Hatheway, 1990; Shimizu et al., 2002a).  These toxins may act in a synergistic or additive 
manner to produce the numerous diseases observed in its hosts, including gas gangrene and 
food poisoning in humans, and several enterotoxaemic diseases of animals (Awad et al., 
1995; Stevens and Bryant, 1997; Shimizu et al., 2002a). 
 
1.5.1 Minor toxins 
Minor toxins include collagenase (κ-toxin), protease (λ-toxin), hyaluronidase (µ-toxin) and 
perfringolysin O (θ-toxin) (Katayama et al., 1996).  Many of the minor toxins alone cannot 
produce disease but in conjunction with the major lethal toxins can contribute to pathogenesis.  
In addition to their activity on the host, one of the minor toxins, λ-toxin is also able to activate 
the two major toxins ε- and ι-toxin (Minami et al., 1997; Gibert et al., 2000).   
 
Sequencing of a type A strain of C. perfringens has revealed that it is capable of expressing 
five different µ-toxins (Shimizu et al., 2002a).  The sequencing also revealed a cysteine 
protease with sequence homology to the alpha-clostripain of Clostridium histolyticum 
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previously unknown to exist in C. perfringens (Shimizu et al., 2002a; Shimizu et al., 2002b).  
A detailed description of the known minor toxins produced by C. perfringens is listed in 
Table 1.2.   
 
Minor toxins may play an essential metabolic role in the growth of C. perfringens.  Genomic 
sequence analysis revealed that C. perfringens lacks a number of pathways required for the de 
novo biosynthesis of certain amino acids.  Therefore the bacterium relies on the breakdown of 
extracellular products by the minor toxins to gain its nutritional requirements (Shimizu et al., 
2002a). 
 
The identification of minor toxins from the culture filtrates of C. perfringens is made difficult 
by their breakdown due to the presence of other proteases (Shimizu et al., 2002b).  With the 
addition of protease inhibitors to a culture supernatant, many more proteases may be 
identified in the future. 
 
1.5.2 Major toxins 
As previously mentioned in Section 1.4, the four major toxins of C. perfringens are used in 
the identification of type strains.  Each toxin has the ability to cause death in mice when 
injected in microgram quantities and each has a very different mechanism of action. Only the 
α-toxin gene is chromosomally located, the rest are episomal (Katayama et al., 1996).  The 
characteristics of the four major toxins are listed in Table 1.3 followed by an in depth 
description of each. 
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Table 1.2: Activities of the minor toxins of C. perfringens. 
Minor toxin Biological activity Produced by 
θ-toxin (theta) Perfringolysin-O, haemolysin, 
cytolysin, O2-labile 
All types 
κ-toxin (kappa) Collagenase/gelatinase All types 
µ-toxin (mu) Hyaluronidase Types A-D 
λ-toxin (lambda) Protease  Types B, D & E 
ν-toxin (nu) DNase All types 
δ-toxin (delta) Haemolysin Types B & C 
α-clostripain like protease Cysteine protease Type A (not yet tested 
in other types) 
Neuraminidase/sialidase N-Acetylneuraminic acid 
glycohydrolase 
All types 
 
Modified from Hatheway (1990) and Shimizu, et al., (2002b). 
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Table 1.3: Characteristics of the four major toxins of C. perfringens. 
Toxin Structural 
gene 
Size of mature 
protein (kDa) 
LD50 in mice* Role of toxin/characterisation 
α-toxin plc  (also 
known as cpa) 
43 5 µg/kg intravenously (i.v.) Phospholipase C enzyme, lecithinase and sphingomyelinase activity, 
haemolytic , cytolytic (platelets/leukocytes) dermonecrotic 
β-toxin cpb 34  0.3 µg/kg (i.v.) 
4.5 µg/kg intraperitoneally 
(i.p.) 
Cytolytic to human leukaemia 60 cell line, trypsin sensitive, heat 
labile, increases capillary permeability, increases blood pressure, 
decreases heart rate, neurotoxin 
ε-toxin etx 29-32  0.065-0.11 µg/kg (i.v) Protoxin requiring trypsin activation, induces neurotransmitter 
release resulting in hippocampal damage, able to pass blood/brain 
barrier, cytotoxic for Madin-Darby canine kidney cell line, increases 
vascular permeability thus enhancing its own uptake in intestinal 
wall, causes swollen hyperaemic kidneys, edemic lungs, excess 
pericardial fluid 
ι-toxin iab Ia 43-47.5  
Ib 71.5-80 
Ia 24 µg/kg-60 µg/kg and 
Ib 48 µg/kg-100 µg/kg 
Binary toxin: Ia & Ib, protoxin requiring trypsin for activation, Ia; 
ADP-ribosylating enzyme, Ib; binding & translocation, increases 
vascular permeability, dermonecrotic on intradermal and lethal on 
i.v injection 
*LD50 refers to the concentration of toxin required to kill 50% of mice 
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1.5.2.1 Alpha-toxin 
Alpha-toxin is the most studied of the major toxins of C. perfringens, and was the first 
bacterial toxin established to possess enzymatic activity (MacFarlane and Knight, 1941).   
 
It is a phospholipase C (plc) enzyme which hydrolyses the phosphate group in 
phosphatidylcholine, a common phospholipid of eukaryotic biological membranes to liberate 
free phosphorylcholine (PC) and diacylglyceride (DAG) (MacFarlane and Knight, 1941).  It is 
also readily able to hydrolyse sphingomyelin, another common component of the eukaryotic 
phospholipid membrane (Saint-Joanis et al., 1989).  Its action is influenced by membrane 
factors such as cholesterol content, saturation of phospholipids, and membrane fluidity 
(Nagahama et al., 1996) with the general rule that the lower the melting temperature of a 
membrane, the more sensitive it is to α-toxin attack (Nagahama et al., 1998). 
 
Alpha-toxin is a lethal toxin with an LD50 between 1.5-5.0 µg/kg body weight when 
administered intravenously to mice (Tso and Siebel, 1989).  It is haemolytic, necrotic and 
cytolytic, lysing platelets and leukocytes, and damaging fibroblasts and muscle cell 
membranes (MacFarlane and Knight, 1941; McDonel, 1980; Titball et al., 1993; Ninomiya et 
al., 1994).  
 
Characterisation of the α-toxin has previously been impeded due to degradation of the toxin 
in the supernatant during purification, and contamination with other extracellular proteins 
produced by the bacterium, notably θ-toxin, µ-toxin and κ-toxin (MacFarlane and Knight, 
1941; Mollby et al., 1973; Nord et al., 1974; Mollby and Holme, 1976).  The difficulties in its 
purification were overcome in 1989 when plc was cloned and expressed from E. coli (Leslie 
et al., 1989; Titball et al., 1989; Tso and Siebel, 1989). 
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The molecular weight (MW) of the cloned α-toxin is 43,000 dalton (Leslie et al., 1989), 
which is synonymous to the native toxin (Fujii et al., 1986).  The α-toxin consists of 398 
amino acids of which the first N-terminal 28 residues are cleaved upon release into the 
supernatant (a 3 kDa signal sequence), or in the case of E. coli the periplasmic space (Leslie et 
al., 1989).  
 
The α-toxin of C. perfringens is part of a family of proteins known as the zinc 
metalloproteases (Kurioka and Matsuda, 1976).  These are a group of enzymes that require 
Zn2+ for activity.  They include a number of clostridial plc’s and the Gram positive Bacillus 
cereus phosphatidylcholine-preferring plc (PC-PLC) (Table 1.4).  All the plc’s share a higher 
degree of homology towards their amino (N)-terminus particularly in their zinc binding 
domains, which are important for catalytic function (Tso and Siebel, 1989; Tsutsui et al., 
1995; Karasawa et al., 2003; Hauer et al., 2004).  This supports the hypothesis that this region 
is a prototype of bacterial phospholipases (Tsutsui et al., 1995).   
 
The powerful cytotoxicity observed with α-toxin results from the effects of its unique 
hydrophobic carboxy (C)-terminal domain, which interacts directly with the tail group of 
phospholipids at specific carbon atoms for enhanced hydrophobic contact (Naylor et al., 
1998).  Many of the other plc’s do not have this carboxy region (Leslie et al., 1989), or if they 
do, their structure does not allow them the same tight affinity for the hydrophobic binding to 
phospholipids (Tsutsui et al., 1995; Guillouard et al., 1997; Naylor et al., 1998).  The C-
terminus of α-toxin may also be involved in signalling endogenous plc activities within cells 
leading to disregulation of host inflammatory responses and cell lysis (Sakurai et al., 1993; 
Sakurai et al., 1994; Titball, 1997).   
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Table 1.4: Family of zinc metalloprotease phospholipases C 
Species Toxin Homology with 
C. perfringens 
(% amino acid)  
Reference 
C. bifermentans CB-PLC 51 (Tso and Siebel, 1989) 
C. novyi γ-toxin 58 (Tsutsui et al., 1995) 
C. sordellii Csp 53.4 (Karasawa et al., 2003) 
C. haemolyticum β-toxin 53.5 (Hauer et al., 2004) 
C. absonum α-toxin 60 (Clark et al., 2003) 
B. cereus phosphatidylcholine 
preferring plc (PC-
PLC) 
28 (Leslie et al., 1989; Tso 
and Siebel, 1989) 
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In comparison to other bacterial plc’s, over time the α-toxin has evolved in terms of both 
enhanced expression and activity making it one of the most toxic plc’s (Tsutsui et al., 1995).  
 
Whilst the N-terminal domain is very similar when compared to a number of other bacterial 
plc’s, the C-terminal domain is unique with no known structural similarities in prokaryotes.  
However, it does share a great deal of homology with the eukaryotic C2 calcium binding cell 
signalling proteins (Newton, 1995; Rizo and Sudhof, 1998).  The α-toxin C-terminus shares 
34% amino acid homology with the human arachidonate-5-lipoxygenase (HA5L) signalling 
protein (Titball et al., 1991) and structural similarities with pancreatic lipase, and soybean 
lipoxygenase (Naylor et al., 1998).  HA5L is a member of the leukotriene synthetic pathway 
which is disrupted by α-toxin.  The α-toxin might use its C2-like domain to bind membranes 
in a similar manner to this signalling protein and initiate the disregulation of host 
inflammatory responses as discussed below (Naylor et al., 1998). 
 
The α-toxin is not only able to damage cell membranes directly by hydrolysing 
phospholipids, but it is also able to trigger the disregulation of local and systemic host 
responses leading to tissue dysfunction, shock and death (Figure 1.3) (Bryant and Stevens, 
1996; Titball, 1997).  The binding of α-toxin to phospholipids may activate GTP-binding 
protein, which inturn activates endogenous plc’s such as phosphatidylinositol plc (PI-PLC) 
and phospholipase D (Sakurai et al., 1993; Sakurai et al., 1994; Ochi et al., 1996).  On the 
other hand, product formation from direct α-toxin activity on membranes may also be able to 
trigger these events (Sakurai et al., 1993; Sakurai et al., 1994).  Activation of endogenous PI-
PLC by α-toxin catalyses membrane phosphatidylinositol 4,5-bisphosphate (PIP2) to produce 
inositol 1,4,5-triphosphate (IP3) and diacylglyceride (DAG).  In turn IP3 induces the release of 
Ca2+ from internal reservoirs in the endoplasmic reticulum (Gustafson and Tagesson, 1989; 
Sakurai et al., 1994). 
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Figure 1.1: Induction of endogenous phospholipases and arachidonic acid cascade by 
α-toxin in a eukaryotic endothelial cell. 
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This burst of cytosolic Ca2+ mediates the influx of Ca2+ through membrane channels and the 
activation of endogenous phospholipase A2 (PLA2) (Gustafson and Tagesson, 1989; Bryant et 
al., 2003).  The second product of PIP2 and phosphatidylcholine hydrolysis by PI-PLC and α-
toxin respectively, DAG, is inturn directly catalysed by DAG lipase to form arachidonic acids 
(AA).  Alternatively DAG can activate protein kinase C, which then activates PLA2 
(Gustafson and Tagesson, 1989; Sakurai et al., 1994; Bunting et al., 1997).  The activation of 
PLA2 results in the release of arachidonic acids from the membrane and the production of its 
metabolites which include thromboxanes, leukotrienes, and prostaglandins (Titball et al., 
1999), all of which play an important role in the local inflammatory response of the host. 
 
Alpha-toxin stimulates the production of platelet activation factor and prostacyclin from AA 
(Bunting et al., 1997), the upregulation of cell-leukocyte surface adhesion markers, and the 
production of interleukin-8 (Bryant and Stevens, 1996).  This leads to the aggregation of 
platelets which remain free flowing in blood vessels, followed by the attachment of 
leukocytes to the platelets.  These larger aggregates then bind to endothelial cells and 
eventually block the flow of blood (Barzaghi et al., 1988; Bryant et al., 2000a).  Interleukin-8 
may enhance leukocyte migration and enhance respiratory burst activity resulting in local 
vascular damage adjacent to, but not at the site of infection with C. perfringens (Bryant and 
Stevens, 1996).  The products released from α-toxin induction and the AA cascade result in 
thrombosis, vasodilation and leukostasis, all of which restrict the blood flow in the host and 
provide an anoxic environment suitable for C. perfringens proliferation (Ninomiya et al., 
1994; Ellemor et al., 1999).  This can eventually lead to shock and death of the host (Bunting 
et al., 1997; Stevens and Bryant, 1997).  
 
The effects of the α-toxin in gas-gangrene are well established, however, what is not known is 
how big a part the α-toxin plays in other diseases of type A strains, particularly diseases of 
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veterinary importance (Ninomiya et al., 1994; Awad et al., 1995; Bryant and Stevens, 1996; 
Bryant et al., 2000a; Bryant et al., 2000b; Awad et al., 2001).   
 
1.5.2.2 Beta-toxin 
The β-toxin is recognised as an important agent in necrotic enteritis of animals and humans.  
The β-toxin is a heat-labile, trypsin sensitive single polypeptide (Sakurai and Duncan, 1978).  
The structural gene cpb has been cloned and shown to express a polypeptide of 347 amino 
acids, of which the first 27 amino acids are removed upon extracellular secretion (Hunter et 
al., 1992).  The MW of the mature protein is 34,000 dalton (Sakurai and Duncan, 1978; 
Sakurai et al., 1984; Hunter et al., 1992).  Beta-toxin is the second most lethal C. perfringens 
toxin following ε-toxin.  Intravenous injection of β-toxin results in an LD50 of between 0.3 
µg/kg (Sakurai and Fujii, 1987) and 1.1 µg/kg (Steinthorsdottir et al., 1998). 
 
Genetic analysis of the β-toxin reveals sequence homology with the alpha-toxin, gamma-
toxin, and leukocidin of Staphylococcus aureus (Hunter et al., 1993).  These proteins are 
pore-forming cytolysins, and β-toxin has exhibited some cytolytic activity in a human 
leukaemia (HL) cell line (Nagahama et al., 2003).  The areas of homology suggests that β-
toxin is likely to be a membrane spanning protein that oligomerises to form channels in 
susceptible cells (Hunter et al., 1993; Steinthorsdottir et al., 2000; Nagahama et al., 2003; 
Smedley et al., 2004).  These channels cause a change in the membrane permeability of the 
cell which results in an efflux of potassium ions and an influx of calcium, sodium and 
chloride ions resulting in cell swelling and lysis (Steinthorsdottir et al., 2000; Nagahama et 
al., 2003).  While the monomeric form of β-toxin is quite susceptible to protease and heat 
treatment, the multimeric form is very resistant to urea, detergent and heat treatment 
(Steinthorsdottir et al., 2000)  The process of toxin binding to receptors is irreversible, and 
administration of antitoxins post-injection cannot neutralise the toxin (Sakurai et al., 1981).  
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Recent data suggests that the β-toxin may primarily act as a neurotoxin (Shatursky et al., 
2000), rather than a cytolysin, acting on preganglionic fibres or central nervous system 
components of the autonomic nervous system (Sakurai et al., 1981; Shatursky et al., 2000).  
Some neurological symptoms caused by β-toxin in agriculturally important animals includes 
tetany and opisthotomus (Tweten, 2001).  Binding of the toxin to as yet unidentified 
susceptible neuronal cells causes the formation of membrane channels which allows the influx 
of K2+ and Na2+ ions.  This may induce a rapid, irreversible depolarisation of the cell causing 
neuronal damage (Shatursky et al., 2000).   
 
1.5.2.3 Epsilon-toxin 
Epsilon-toxin (ε-toxin) is the most potent of the C. perfringens toxins, and the third most 
potent neurotoxin from the Clostridium spp., following botulinum and tetanus toxins (Mantis, 
2005).  Intravenous delivery of 75 ng of the toxin to mice kills them within 90 minutes 
(Nagahama et al., 1990).  The rapid speed in which it is able to impart its toxicity on its host 
can also be attributed to the fact that it is able to penetrate the blood/brain barrier 
(Worthington and Mulders, 1975).   
 
The ε-toxin is expressed as a 33 kDa protoxin (Hunter et al., 1992), of which the N- and C- 
termini are cleaved to form the extremely potent mature ε-toxin of 29 kDa (Hunter et al., 
1992; Minami et al., 1997).  The LD50 in mice is between 65 and 320 ng/kg depending upon 
the cleavage site of the protoxin.  Trypsin and chymotrypsin cleave the N-terminus after the 
13th amino acid, whereas λ-toxin, another product of C. perfringens, cleaves the protoxin after 
the 10th amino acid (Minami et al., 1997).  Cleavage by the former is the more potent 
(Minami et al., 1997). 
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The ε-toxin of C. perfringens type D causes enterotoxaemia of lambs and kids (Uzal and 
Kelly, 1997).  The toxins’ ability to increase blood pressure (Sakurai et al., 1983), and 
vascular permeability (Worthington and Mulders, 1975) assists in its transit from the 
intestines to the blood system and finally to the brain, where it imparts neuronal damage 
(Miyamoto et al., 1998; Finnie et al., 1999).  Neurotoxicity involves the stimulation of 
neurotransmitter release from the glutamatergic system.  The release of glutamate from 
presynaptic vesicles leads to neuronal damage (Miyamoto et al., 1998).  It also indirectly 
causes contraction of muscles by activating Na2+ channels.  Activation of these channels 
results in acetylcholine release from cholinergic nerve endings which in turn promotes 
calcium availability thereby causing contractions (Sakurai et al., 1989). 
 
The ε-toxin requires binding to specific cell receptors to impart its effects.  These 
sialoglycoprotein receptors are thought to be present in the brain, lungs and kidney tissues, the 
primary targets of the toxin (Nagahama and Sakurai, 1991; Nagahama and Sakurai, 1992; 
Uzal and Kelly, 1997; Tamai et al., 2003).  The toxin oligomerises to form heptamers on the 
cell surface (Miyata et al., 2002).  These heptamers then act by forming pores in the 
membrane.  Pore formation results in loss of transepithelial resistance and consequently an 
increase in ion permeability and a net influx of water creating oedema of the cell (Petit et al., 
1997).   
 
1.5.2.4 Iota-toxin 
The ι-toxin is a binary toxin dependent on two non-linked domains for activity (Stiles and 
Wilkins, 1986).  The two genes coding for the binary toxin, lap and Ibp, reside on the same 
sequence, are expressed by the same promoter but are separated by 40 non-coding nucleotides 
(Perelle et al., 1993; Perelle et al., 1995).  The sizes of the mature proteins Ia and Ib are 
approximately 45,000-47,500 dalton (Stiles and Wilkins, 1986; Popoff and Boquet, 1988a; 
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Perelle et al., 1993) and 71,500-80,000 dalton (Stiles and Wilkins, 1986; Perelle et al., 1993) 
respectively.  Due to their sizes, Ia is known as the light chain, and Ib as the heavy chain.  Ia 
functions as an ADP-ribosyltransferase, while Ib is required for cell receptor binding and 
translocation of component Ia across the cell membrane (Simpson et al., 1987; Perelle et al., 
1993).  Intravenous injection of Ia or Ib alone in mice and guinea pigs causes no significant 
changes to the animals, but simultaneous injection of the two causes death in mice and 
dermonecrotic lesions in guinea pigs (Stiles and Wilkins, 1986; Sakurai and Kobayashi, 
1995).  Lethal doses of Ia/Ib intravenously injected into mice vary between 24/48 µg/kg (Ia 
component) (Sirard et al., 1997) and 60/100 µg/kg (Ib component) (Sakurai and Kobayashi, 
1995) making it the least toxic of the major toxins of C. perfringens. 
 
Both Ia and Ib proteins are secreted as protoxins which require cleavage by λ-toxin (a 
product of C. perfringens) or chymotrypsin (within the host) for activation (Gibert et al., 
2000).  The C-terminus of activated Ib binds to sensitive cells which are most likely 
proteinaceous in nature (Stiles et al., 2000).  Once Ib is bound, docking of Ia occurs at the 
protease treated N-terminus of Ib (Perelle et al., 1993; Perelle et al., 1995).  Binding of Ia to 
Ib triggers rapid internalisation of Ia followed by cell membrane embedment or 
internalisation of Ib (Stiles et al., 2000).  Once in the cytosol, Ia binds nicotinamide adenine 
dinucleotide (NAD), cleaves the ADP-ribose moiety and transfers it to arginine-177 of 
globular actin (G-actin) (Vandekerckhove et al., 1987).  The ADP ribosylation of G-actin 
actively interferes with actin filament polymerisation by capping of actin filament at the 
barbed end (fast growing end), and causes depolymerisation at the opposite end, which 
results in the collapse of the microfilament network (Wegner and Aktories, 1988).  Rounding 
of cells occurs, due to the disorganisation of the actin cytoskeleton and cell death ensues 
(Perelle et al., 1996).   
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The exact mechanism of Ia docking to Ib along with the specific receptors for Ib binding are 
still a mystery and recent X-ray crystallography of ι-toxin may shed some light on these 
matters (Tsuge et al., 2003).  Iota-toxin may become a useful biological tool for the delivery 
of proteins into cells.  Marvaud, et al., (2002) successfully delivered protein C3 of 
C. botulinum into Vero cells by using Ib for internalisation of a chimaeric C3:Ia protein 
(Marvaud et al., 2002).  
 
1.5.2.5 Enterotoxin 
Although C. perfringens enterotoxin (CPE) is not classified as one of the major toxins of 
C. perfringens, it is the third most common cause of food poisoning in industrialised nations 
(Johnson, 1989).  The cpe gene can be either plasmid-borne or found on the chromosome 
(Cornillot et al., 1995).  The chromosomally located cpe has been associated with food-borne 
gastroenteritis and the episomal cpe with non-food-borne gastroenteritis, such as antibiotic 
associated diarrhoea and sporadic diarrhoea (Collie and McClane, 1998).  The plasmid-borne 
cpe may also be responsible for a number of enteric diseases observed in animals (Bueschel 
et al., 1998).   
 
CPE is a 35 kDa protein (McClane et al., 1988) that is not secreted from the cells of growing 
bacteria but is released only with the sporulation of C. perfringens (Czeczulin et al., 1996).  
Up to 13% of the total protein in a sporulating C. perfringens cell consists of enterotoxin 
(Czeczulin et al., 1993).  Even though there are no signal sequences identified at the N- or C- 
terminus of CPE, trypsin treatment of CPE cleaves 25 amino acids of the N-terminal sequence 
and creates a toxin that is 2- to 3- fold more toxic than the native CPE (Hanna et al., 1992; 
Kokai-Kun and McClane, 1997).  This enhanced activation of CPE may be physiologically 
important to increase the potency of CPE at its natural site of action, the small intestine of the 
host (Hanna et al., 1992).  
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The mechanism of action for enterotoxin involves binding of enterotoxin to protein receptors 
of sensitive cells which primarily consist of enterocytes in the small intestine (Katahira et al., 
1997b).  Two of its receptors have been identified as claudin-3 (formerly known as the human 
homologue of rat ventral prostate 1 protein-RVP-I) and claudin-4 (formerly known as CPE 
receptor) (Katahira et al., 1997a; Katahira et al., 1997b; Morita et al., 1999).  Claudins play a 
central role in tight junction (TJ) barrier function  which controls the membrane permeability 
of the cell (Sonoda et al., 1999). 
 
Binding of CPE to claudin-3 and claudin-4 results in the formation of a small 90 kDa 
complex which destabilises the membrane barrier allowing the influx or efflux of molecules 
up to the size of 10 kDa (McClane et al., 1988; Wieckowski et al., 1994; Sonoda et al., 1999; 
Kondoh et al., 2005).  Further binding of other membrane proteins to the small complex 
results in its membrane insertion (Wnek and McClane, 1989).  This insertion results in pore 
formation and the onset of major membrane permeability alterations, allowing the efflux of 
larger molecules (Wieckowski et al., 1998).  Occludin, another TJ associated protein binds to 
the large complex to form a 200 kDa complex which causes further structural damage to 
membranes (Singh et al., 2000; Singh et al., 2001).  These changes cause rapid fluid and 
electrolyte loss from the gastrointestinal tract of infected individuals and animals resulting in 
diarrhoea (Sarker et al., 1999). 
 
1.5.2.6 Beta2-toxin 
The discovery of a new cytotoxic toxin, the β2-toxin, may affect the future of the typing of 
C. perfringens strains.  This toxin was isolated and cloned by Gibert et al., (1997).  PCR 
typing studies have identified the β2-toxin gene in many diarrhoeic piglets (Gibert et al., 
1997; Klaasen et al., 1999; Garmory et al., 2000; Waters et al., 2003; Jost et al., 2005) and 
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horses (Gibert et al., 1997; Herholz et al., 1999; Bacciarini et al., 2003; Waters et al., 2005), 
which may implicate this new toxin in diseases of these animals previously thought to have 
been caused by other toxins of C. perfringens.  Until further studies are complete this finding 
is speculative, particularly for β2-toxin involvement in horse enteritis as it is not consistently 
detected in isolates from diarrhoeic horses (Bacciarini et al., 2003; Waters et al., 2005).  A 
more definitive role for β2-toxin has thus far been achieved for pig enterocolitis (Bueschel et 
al., 2003; Jost et al., 2005; Waters et al., 2005). 
 
Given the name β2-toxin due to its analogous nature with the β-toxin and its discovery from a 
pathogenic type C strain isolated from a piglet with lethal necrotising enterocolitis, the toxin 
has no significant homology with any other known proteins (Gibert et al., 1997).  As with 
most other toxins of C. perfringens it contains an N- terminal signal sequence for secretion to 
the extracellular environment (Gibert et al., 1997).  The size of the mature protein is 
approximately 28 kDa (Gibert et al., 1997).  The β2-toxin is lethal to mice when 3 µg is 
administered intravenously, and like β-toxin is trypsin sensitive, and causes blebbing and cell 
death in CHO cells (Gibert et al., 1997).  
 
No further structure-function studies have been done with β2-toxin to date but its effects 
mimic the effects of β-toxin suggesting that it too may be a pore-forming toxin (Smedley et 
al., 2004). 
 
1.6 Diseases of C. perfringens 
C. perfringens is known widely for its ability to cause a variety of human and veterinary 
diseases.  It is responsible for the majority of clostridial enteric diseases observed in domestic 
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livestock and is an important pathogen in humans (Songer, 1996).  Some of these diseases are 
outlined below with a detailed description of necrotic enteritis, the focus of this work. 
 
1.6.1 Human diseases 
1.6.1.1 Gas-gangrene 
Myonecrosis, or gas-gangrene as it is more commonly known, is an opportunistic disease 
caused by C. perfringens type A (Onderdonk and Allen, 1995; Rood, 1998).  Prior to the 
discovery of penicillin, gas gangrene was a major cause of amputations in World War I.  
These days it is more common in post-operative or illegal surgeries (Allen, 1985). 
 
The disease is relatively localised, with early symptoms including limb swelling and gross 
inflammation.  C. perfringens toxin production within the host causes muscle necrosis and 
destruction, and haematuria, and if left untreated, the disease progresses rapidly, leading to 
shock and death (Awad et al., 1995; Stevens and Bryant, 1997; Awad et al., 2000). 
 
The α-toxin is the major necrotising toxin responsible for the observed disease (Awad et al., 
1995; Awad et al., 2000).  It also contributes to shock by direct inhibition of myocardial 
contractility (Stevens and Bryant, 1997).  Without the initial and continual effects of α-toxin 
the infection does not display signs of the fulminating disease (Awad et al., 1995).  Other 
extracellular toxins important for the spread of the disease through deeper tissues include κ-
toxin, neuraminidase and θ-toxin (Shimizu et al., 2002a).  Gas-gangrene is controlled by the 
use of antibiotics, in severe cases a hyperbaric chamber is required and amputation of the 
affected limb(s) may be necessary. 
Chapter 1 Introduction 
 29
1.6.1.2 Gastroenteritis 
C. perfringens type A is responsible for a very common food-borne disease which usually 
appears 7-15 hours after the consumption of improperly cooled or reheated meat (Allen, 
1985).  The onset of the disease is associated with the sporulation of C. perfringens in the 
intestinal tract of its host (Czeczulin et al., 1996).  Sporulation and hence release of 
enterotoxin from bacterial cells triggers an accumulation of fluids and electrolytes in the 
intestine followed by the onset of diarrhoea.  Severe abdominal cramps appear prior to 
diarrhoea but vomiting is absent (Narayan, 1982).  Not all type A strains carry the enterotoxin 
gene and studies have indicated the incidence of C. perfringens carrying the cpe vary from 
1.3% to 12.8% (Daube et al., 1996; Meer and Songer, 1997).  Due to its self-limiting nature 
and the voluntary reporting of the disease in most countries, C. perfringens gastroenteritis is 
an often underestimated disease worldwide (Labbe, 1991).  
 
1.6.1.3 Enteritis necroticans 
Termed Darmbrand in Germany or Pig-bel in Papua New Guinea, enteritis necroticans has 
been a major cause of mortality in the highland regions of Papua New Guinea and other third 
world countries where protein malnutrition and poor hygiene standards are common.  It is 
caused by C. perfringens type C producing the β-toxin (Davis, 1984).  The disease primarily 
occurs due to lack of the protease trypsin in the host's intestine as trypsin is an inhibitor of the 
β-toxin (Sakurai and Duncan, 1978).  Reduction in trypsin levels result from low protein diets 
and diets containing high levels of trypsin inhibitors such as the sweet potato.  During times 
of feast, ingestion of rich protein foods, particularly undercooked pork (a common food 
vehicle of C. perfringens) allows the proliferation of C. perfringens and the subsequent 
production of the β-toxin in the intestines (Davis, 1984).  The term Darmbrand in German 
translates to “firebowels” which is an accurate description of what occurs in the intestines 
during infection.  The bowels become inflamed and necrotic lesions develop.  The incidence 
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of Pig-bel has decreased dramatically due to the development of a β-toxin vaccine (Lawrence 
et al., 1990).  There have been isolated incidences where enteritis necroticans has been 
diagnosed in the absence of β-toxin.  In these cases only C. perfringens type A is isolated and 
so the term pseudo-bel has been coined (Sargeant et al., 2000). 
 
1.6.2 Animal diseases 
Although C. perfringens primarily causes histotoxic (tissue destroying) infections in humans, 
most infections observed in animals are of an enteric nature, and require the production of one 
or more of the major toxins (Onderdonk and Allen, 1995; Songer, 1997).  
 
A summary of the major animal diseases caused by the various type strains of C. perfringens 
is outlined in Table 1.5.  For a more detailed review of clostridial enteric diseases refer to 
reviews by Songer (Songer, 1996; Songer, 1998).  In most cases the age of the animal dictates 
the severity of disease.  As the normal intestinal flora of a neonate is yet to be established, the 
colonisation and/or proliferation of enteropathogenic C. perfringens in the gut occurs rapidly 
(Timoney et al., 1988).  
 
The use of multicomponent vaccines and the prophylactic application of antitoxins prevent 
the spread of disease in most cases.  The vaccines are targeted for use in ruminants and 
consist of toxoid preparations of types C and D C. perfringens, or formalin inactivated β-, and 
ε- toxins with inactivated toxins of other clostridial species (Younan et al., 1995; Kelneric et 
al., 1996).  Vaccines for diseases caused by type A strains such as necrotic enteritis in poultry 
are yet to be developed. 
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Table 1.5: C. perfringens toxinotype and associated veterinary diseases 
Toxin type Diseases 
A Necrotic enteritis in fowl;  
Enterotoxaemia in cattle and lambs;  
Necrotizing enterocolitis in piglets;  
Possibly equine colitis;  
Canine haemorrhagic gastroenteritis 
B Dysentery in newborn lambs;  
Chronic enteritis in older lambs (pine);  
Haemorrhagic enteritis in neonatal calves and foals;  
Haemorrhagic enterotoxaemia in adult sheep 
C Necrotic enteritis in fowl;  
Haemorrhagic or necrotic enterotoxaemia in neonatal pigs, lambs, 
calves, goats, foals;  
Acute enterotoxaemia (struck) in adult sheep 
D Enterotoxaemia in lambs (pulpy kidney) and calves; 
Enterocolitis in neonatal and adult goats;  
Possibly enterotoxaemia in adult cattle 
E Enterotoxaemia likely in calves and lambs; enteritis in rabbits; 
Host range and disease type unclear 
A-E (enterotoxin +) Canine and porcine enteritis;  
Possibly bovine and equine enteritis 
Reproduced from a review by Songer (1996). 
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1.6.3 Necrotic enteritis 
Necrotic enteritis (NE) was first described by Parish in 1961 (Parish, 1961a; Parish, 1961b).  
It is an enterotoxaemia affecting wild and captive birds (particularly poultry and turkeys) 
worldwide (Gazdzinski and Julian, 1992; Stuve et al., 1992; Droual et al., 1994; van der Sluis, 
2000).  As the name suggests, NE is characterised by the destruction of villi within the small 
intestine accompanied by host inflammatory responses. 
 
NE usually presents itself within 2-6 weeks of the birds’ life.  It is a sporadic disease (Cowen 
et al., 1987), thought to be caused by a disruption in the chickens own microflora.  The 
causative organism, C. perfringens is found in massive numbers around the site of infection, 
which is usually localised to the jejunum and ileum (Parish, 1961b; Long et al., 1974; Al-
Sheikhly and Truscott, 1977b).  Both lesions and C. perfringens can sometimes be detected in 
the caeca as well (Long et al., 1974; Elwinger et al., 1992). 
 
Morbidity and mortality rates of natural outbreaks range from 5-10% and 0.5-1.0% 
respectively (Shane et al., 1985).  Levels of experimentally induced NE can range from as 
low as 1.3-10% to as high as 5.6-37.3% (Cowen et al., 1987), as the clinical disease is not 
very easily reproduced (Helmboldt and Bryant, 1971; Al-Sheikhly and Truscott, 1977b; 
Cowen et al., 1987; Elwinger et al., 1992; Kaldhusdal et al., 1999). 
 
Acute and chronic cases of NE have been described (Parish, 1961a).  Acute NE is lethal and 
birds die within 3-4 days of developing the infection.  Birds display a loss of appetite and 
usually do not eat in their last 24 hours of life.  The last stages of acute NE are characterised 
by the lack of ability to stand, drooping of the head and wings, and closing of eyes.  Death 
occurs within a few hours of these signs.  There is no significant weight loss and internal 
organs are occasionally heavier than normal (Parish, 1961a).  As symptoms occur within their 
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last few hours of life (Parish, 1961a; Helmboldt and Bryant, 1971), it is difficult to detect at 
any earlier stage, and birds are usually found dead on the farm.  Acute NE is likely the 
outcome of toxins of C. perfringens infiltrating the internal organs and damaging these cells 
(Vissiennon et al., 1996).  
 
Chronic, or sub-clinical NE, as it is more commonly known, is an insidious infection often 
left untreated due to difficulties in its detection (Parish, 1961a).  Some sub-clinical signs that 
may be seen during the course of the outbreak include diarrhoea, depression, ruffled feathers, 
and huddling (Al-Sheikhly and Truscott, 1977b; Shane et al., 1985; van der Sluis, 2000). 
 
Diagnosis is most commonly attained through on-farm necropsy (van der Sluis, 2000).  
Unfortunately, this retrospective diagnosis leads to high economic losses from the early stages 
of NE where many of the early clinical signs appear to be overlooked.  This is exacerbated by 
the fact that most farmers (71%) do not begin treatment when any primary symptoms are 
observed (van der Sluis, 2000). 
 
Economic losses are also noted throughout the course of chronic NE due to an impaired food 
conversion ratio observed in the birds.  This causes sub-optimal performance where birds 
display a gradual weight loss over 1-4 weeks without a decrease in food consumption.  This 
impacts negatively on the economy of the farm due to the increased feed expenditure 
(Kaldhusdal and Hofshagen, 1992; Lovland and Kaldhusdal, 1999). 
 
C. perfringens associated hepatitis (CPH) is another sub-clinical symptom which may be 
associated with NE.  Lovland and Kaldhusdal (1999) reported that a large number of livers 
with abnormalities causing carcass condemnations at a Norwegian chicken processing plant 
were associated with C. perfringens infections.  Increased numbers of C. perfringens in the 
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small intestine may increase the risk of clostridia accessing the biliary ducts and possibly the 
portal blood stream through a damaged intestinal mucosa (Vissiennon et al., 1996; Lovland 
and Kaldhusdal, 1999).   
 
The cost of sub-clinical enteritis is estimated to be as high as AUD$0.10/bird and where 
turnover is considered (each broiler lives for about 6-7 weeks) this number turns into 
hundreds of thousands of dollars in revenue losses per year.  These estimates are highest in 
Europe followed by North Africa and the Middle East (van der Sluis, 2000).  
 
1.6.3.1 Histopathology of NE 
C. perfringens primarily attaches to the apical villi of the jejunum, whereby it proliferates and 
produces toxins (Kaldhusdal et al., 1999).  These toxins, particularly the α-toxin, destroy the 
villous creating necrotic lesions (Al-Sheikhly and Truscott, 1977b; Shane et al., 1985).  The 
epithelial cells are sloughed off into the lumen and along with erythrocytes and lysed 
heterophils create a mass of fibrino-necrotic exudates also known as coagulative necrosis 
(Long et al., 1974; Al-Sheikhly and Truscott, 1977b; Shane et al., 1985).  Oedema occurs in 
the surrounding lamina propria and this results in further detachment of the epithelial layer 
(Long et al., 1974; Al-Sheikhly and Truscott, 1977b).  In severe cases the entire mucosal 
surface of the duodenum and jejunum is covered by a necrotic diphtheritic membrane (a 
greyish thickened mucosa) and the intestines become weak and friable (Al-Sheikhly and 
Truscott, 1977b; Shane et al., 1985).  Colonisation of C. perfringens at necrotic regions is 
prominent and lesions are usually demarcated by patches of normal, healthy tissue.  Sub-
clinical NE is less conspicuous and on macroscopic examination the intestines appear normal, 
but on microscopic examination, focal lesions can be seen and are of similar character to the 
acute lesions (Kaldhusdal and Hofshagen, 1992).  
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C. perfringens is rarely found in internal organs of the infected host, but congestion of blood 
vessels in some internal organs is prominent, particularly the liver and spleen (Parish, 1961a; 
Al-Sheikhly and Truscott, 1977b; Shane et al., 1985).  Toxins produced by C. perfringens, 
particularly the α-toxin, may be able to enter the circulatory system through the intestinal 
mucosa and reach other organs, namely the liver and kidneys where it can act as an 
endothelio-, hepato-, and nephro- toxin (Vissiennon et al., 1996) and cause other sub-clinical 
features such as cholangiohepatitis (Lovland and Kaldhusdal, 1999). 
 
1.6.3.2 Host responses to NE 
Host inflammatory responses observed in cases of NE include an influx of heterophils in the 
early stages of the infection, followed by a slight (if any) influx of monocytes (Parish, 1961a; 
Long et al., 1974; Al-Sheikhly and Truscott, 1977b).  This lack of monocyte infiltration is 
also observed in gas-gangrene (Ninomiya et al., 1994).  Leukocytes are a target of the 
clostridial toxin(s) and it has been shown that the α- and to a lesser extent the θ-toxin of 
C. perfringens are able to impede the migration of leukocytes to the site of infection (Awad et 
al., 1995; Ellemor et al., 1999). 
 
Birds have been shown to “spontaneously recover” from a bout of NE and on 
histopathological examination regeneration of villi has been observed.  The regenerated 
epithelial cells result in a shorter fatter villus with reduced absorptive properties (Long et al., 
1974; Al-Sheikhly and Truscott, 1977a; Al-Sheikhly and Truscott, 1977b).  
 
1.6.3.3 Predisposing Factors 
Most C. perfringens isolated from outbreaks of NE are type A strains (Das et al., 1997a; 
Nauerby et al., 2003), but type C have been known to experimentally reproduce the disease 
(Shane et al., 1985).  Type A strains are naturally present in the microflora of healthy 
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chickens, and since infection of chickens with C. perfringens alone does not consistently 
reproduce the disease (Cowen et al., 1987) several predisposing factors are believed to 
contribute to the spontaneous outbreaks of necrotic enteritis.  
 
C. perfringens is normally found in the lower, large intestines (Allen, 1985) and during 
necropsy high C. perfringens counts are seen in small intestine particularly the jejunum and 
ileum (Parish, 1961b; Long et al., 1974; Al-Sheikhly and Truscott, 1977b).  This migration 
suggests sufficient numbers of C. perfringens and minor intestinal damage to the small 
intestine is required for the initiation of the disease (Al-Sheikhly and Truscott, 1977a).  The 
minor small intestinal damage provides an anaerobic environment where C. perfringens can 
multiply rapidly.  This damage can be brought about by a number of factors, including diet, 
prior infections and inadequate husbandry practices. 
 
1.6.3.3.1 Diet 
Poor feed has been shown to damage the intestines and allow for multiplication of 
C. perfringens in the gastrointestinal tract (GIT) of birds (Stuve et al., 1992).  The diet of 
broilers is usually dictated by cost and for this reason, ingredients such as wheat and fishmeal 
are utilised.  Unfortunately it is the inclusion of these substances in the diet that enhances the 
risk of NE in a flock.  
 
A wheat based diet increases the incidence of NE, whereas the incidence of NE is decreased 
when a corn based diet is used (Riddell and Kong, 1992; Branton et al., 1997; Craven, 2000). 
Barley, wheat, rye, and oats contain higher levels of indigestible non-starch polysaccharides, 
which are known to lead to increased digesta viscosity, decreased digesta passage rate and 
nutrient digestibility (Hubener et al., 2002).  The decrease in passage rate increases the 
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likelihood of anaerobe overgrowth, particularly C. perfringens, leading to production of 
toxins which can then attack the epithelial lining (Shane et al., 1985).  
 
Feeds high in protein content such as fishmeal, meat, or bonemeal also increase the incidence 
of NE.  High levels of fish meal have been reported to predispose animals to NE or exacerbate 
outbreaks of NE.  These high protein diets may also cause some intestinal damage which 
favours the subsequent establishment and multiplication of C. perfringens (Truscott and Al-
Sheikhly, 1977). 
 
1.6.3.3.2 Prior infections 
Diet is not the only factor that damages the intestinal wall of birds leading to outbreaks of NE.  
Concurrent or prior infection with enteropathogenic agents, particularly coccidia (Eimeria 
spp.) can dramatically increase the risk of NE in a flock (Cowen et al., 1987; Baba et al., 
1992; Williams et al., 2003).  Damage to the intestinal mucosa by subclinical infection with 
Eimeria spp. leads to retardation of intestinal motility allowing for the proliferation of 
C. perfringens and its toxins (Shane et al., 1985).  Control of coccidiosis is maintained 
through the use of coccidiostats, mainly ionophores.  Unfortunately the development of drug 
resistance to ionophores has lead to an increased prevalence of coccidiosis and hence NE 
(Lister, 1996; Allen and Fetterer, 2002).  Vaccines against Eimeria spp. are now available 
(Williams et al., 1999) but as NE is a multifactorial disease, it can still occur in the absence of 
coccidiosis (Cowen et al., 1987; Riddell and Kong, 1992; Branton et al., 1997). 
 
1.6.3.3.3 Other factors 
NE affects both wild and captive birds, but captive birds are more likely to succumb to the 
disease as they are more likely to encounter stress factors which affect the balance of the GIT 
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flora or the immune system (Stuve et al., 1992).  Such stress factors include transportation, 
sudden environmental changes, litter conditions, high stocking density, no in-feed additives 
(such as antibacterials/anticoccidials) and immunocomprimising agents such as 
cyclophosphamide (Truscott and Al-Sheikhly, 1977; Cowen et al., 1987; Stuve et al., 1992; 
Kaldhusdal et al., 1999; Lovland et al., 2003).  
 
The introduction of a new strain of C. perfringens through a vector such as the house-hold fly 
has also been shown to cause NE in chickens who consumed the flies or their deposits 
(Dhillon et al., 2004).  
 
1.6.3.4 Aetiology of NE 
The presence of large numbers of C. perfringens in the small intestine and caeca during an 
outbreak of NE in chickens indicates the importance of this bacterium in the disease, but 
factors leading up to pathogenesis are still unclear.  Questions that still need to be answered 
include:  
Can all toxinotypes of C. perfringens cause NE?  
Can all strains of the same type induce disease under the right conditions?  
How large a role does α-toxin play in the pathogenesis?  
 
1.6.3.4.1 Can all toxinotypes of C. perfringens cause NE? 
A number of studies analysing the distribution of toxinotype amongst natural outbreaks of NE 
identified all C. perfringens isolates causing NE as toxinotype A (Das et al., 1997a; Engstrom 
et al., 2003; Nauerby et al., 2003) . This may indicate that type A are the cause of NE, but this 
is not the case.  Shane et al., (1985) was able to use a type C strain of C. perfringens to induce 
NE in an experimental model in broilers.  It may be plausible that any strain of C. perfringens 
producing the required amount of toxins is able to induce NE, but the fact that natural 
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outbreaks of NE are linked to type A strains can be explained by the bacterium’s natural 
habitat (Allen, 1985).  Type A is the only type found as a commensal in animals, and it is 
abundant in soil and water, therefore it has the opportunity to cause an infection when the host 
is stressed. 
 
Toxin levels also differ between type strains.  Type A strains generally produce more α-toxin 
than B-E strains (Katayama et al., 1993).  As α-toxin is regarded as the major virulence 
determinant in NE, strains producing elevated levels of this toxin would be considered more 
virulent than others. 
 
1.6.3.4.2 Are all C. perfringens type A isolates capable of causing NE? 
There is a high genetic diversity of C. perfringens type A between and within flocks of 
poultry (Nauerby et al., 2003).  Healthy chickens can carry numerous strains of 
C. perfringens type A at one time.  A dendrogram developed from pulsed-field gel 
electrophoresis (PFGE) of C. perfringens strains isolated from healthy and diseased chickens 
could not separate the NE causing strains from the avirulent strains (Nauerby et al., 2003).  
What was noted though, was the lack of strain variability in the NE affected chickens.  They 
carried only one or two clones of C. perfringens, suggesting that the proliferation of these 
specific clones led to NE.  This leads back to the importance of predisposing factors such as 
diet and prior infection in influencing the development of NE, particularly since experimental 
infection of chickens with C. perfringens alone does not consistently reproduce the disease 
(Cowen et al., 1987).   
 
Unfortunately, the study by Nauerby, et al., (2003) did not detail the husbandry and dietary 
parameters of the chickens examined at the different farms.  Therefore it cannot be known 
what external factors (if any) were involved in the proliferation of these particular type A 
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clones.  Until further studies are carried out looking at the gene expression (under different 
conditions e.g. differential display, microarray analysis) of these different strains, it will not 
be known whether they all have the same potential to cause NE.  No standardised methods are 
currently used to differentiate between normal and NE causing C. perfringens strains.   
 
1.6.3.4.3 Does α-toxin alone cause NE? 
There is evidence demonstrating the importance of α-toxin in the development of NE.  The 
extracellular toxins of C. perfringens type A have been shown to reproduce similar 
histopathological effects as that obtained with a natural outbreak of NE and anti-α-toxin 
antibodies are able to neutralise the effects of C. perfringens cell-free broth cultures when 
administered to chickens (Al-Sheikhly and Truscott, 1977b; Fukata et al., 1988).  Moreover, 
high levels of anti-α-toxin antibodies are frequently recovered from natural outbreaks of NE 
implicating α-toxin in the pathology of the disease (Lovland et al., 2003) or at the very least 
its presence as an indicator of C. perfringens activity and a potential indicator of NE 
occurrence. 
 
The reduction of, or lack of, monocyte infiltration to the site of NE infection also suggests 
that α-toxin is important in the development of the disease (Parish, 1961a; Al-Sheikhly and 
Truscott, 1977b).  Studies of α-toxin mutants in mouse gas-gangrene models indicate that α-
toxin is the major toxin involved in leukostasis (Ellemor et al., 1999). This impediment of 
monocyte migration in the mouse gas-gangrene model may also explain the lack of monocyte 
infiltration in NE. 
 
Expression of α-toxin differs between strains of C. perfringens (Katayama et al., 1993; 
Bullifent et al., 1996) and a critical level must be exceeded in order to cause disease 
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(Ninomiya et al., 1994).  The production of α-toxin is controlled by at least two regulatory 
systems (Lyristis et al., 1994; Ba-Thein et al., 1996; Bullifent et al., 1996; Matsushita et al., 
1996; Ohtani et al., 2002a).  The control of α-toxin production by these systems may be 
regulated by as yet unidentified external stimuli.  This may also include the autoinducer 2 
(AI2) like molecules, implicating quorum sensing in α-toxin production (Ohtani et al., 
2002b).  The presence of autoinducers and their cell-cell signalling activity may co-ordinate 
the levels of toxins produced in certain environments or in response to increased cell density 
(Miller and Bassler, 2001).  For example, in vitro polyclonal anti-α-toxin antibody co-
administration with C. perfringens neutralised the effects of α-toxin as observed by the 
Nagler reaction but when the two were co-administered to mice, the antibodies were 
insufficient for passive protection (Traub et al., 1991).  One possible explanation for this 
observation is the enhanced expression of α-toxin in a different environmental setting (Traub 
et al., 1991).  More regulatory studies are required to better understand the regulation of the 
toxin genes and the environmental factors that may be involved. 
 
C. perfringens expresses numerous other enzymes and toxins which may also play a role 
(albeit a minor one) in the development of NE.  Das et al., (1997a), demonstrated that 
C. perfringens from 12 different outbreaks of NE contained the genes for the expression of 
the α-toxin along with sialidase (an enzyme which causes necrotic effects on intestinal 
mucosa), µ-toxin (spreading factor which attacks the lamina propria) and θ-toxin 
(perfringolysin O, cholesterol-dependent haemolysin). 
 
The α-toxin acts in synergy with the θ-toxin to cause gas-gangrene in mice (Awad et al., 
1995; Ellemor et al., 1999) and with the β2-toxin to cause bovine enterotoxaemia (Manteca et 
al., 2002).  It may also act in synergy with other toxins to cause NE in chickens. 
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A second generation vaccine based on recombinant toxins or toxoids will provide direct 
evidence regarding the exact role of the α-toxin in this disease. 
 
1.6.4 Prevention and treatment of NE 
 
1.6.4.1 Antibiotics 
Until recently, prevention of diseases in domestic livestock relied on the heavy use of 
antibiotics as prophylactic agents and as growth promoters.  Antibiotic growth promoters 
(AGP) are sub-therapeutic quantities of antibiotics administered to the animals throughout 
their growing season (USDA, 1999).  As their name suggests, they help increase the growth 
of the animal by suppressing the growth of unwanted bacteria in the gut, particularly Gram 
positive bacteria which are known to disrupt the digestive process and slow the growth of 
their host (USDA, 1999; WHO, 2000).  Some prophylactic, therapeutic and AGP antibiotics 
used to treat and prevent NE in the past have included: avoparcin (Hofshagen and Kaldhusdal, 
1992; Kaldhusdal and Hofshagen, 1992), nitrovin (Wierup, 2001), virginiamycin (Wierup, 
2001), bacitracin (Kondo, 1988; Watkins et al., 1997), lincomycin (Watkins et al., 1997), 
penicillin (Kondo, 1988), tetracycline (Kondo, 1988) salinomycin, tylosin, avilamycin and 
flavomycin (Devriese et al., 1993). 
 
Many reports indicate that overuse, or sub-therapeutic use of antibiotics is causing an increase 
in the number of antibiotic resistant bacteria including C. perfringens in the domestic 
livestock population (Molbak, 2004; Shea, 2004).  Resistance to bacitracin, streptomycin, 
virginiamycin, lincomycin and the tetracyclines in C. perfringens and other host bacteria has 
been demonstrated (Kondo, 1988; Watkins et al., 1997; Das et al., 1997b; Williams et al., 
1999; Aarestrup et al., 2000; Johansson et al., 2004; Martel et al., 2004).  
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In recent years the use of many AGP’s and prophylactic antibiotics has ceased due to bans 
imposed by the regulating bodies of many countries.  Antibiotics with human-use antibiotic 
analogues are banned from use as AGP’s (Schwarz et al., 2001; Aarestrup, 2002).  This is to 
prevent the possible horizontal transfer of human-use antibiotic resistance to bacteria in 
humans (Linton et al., 1977; Levy, 1978; Lyons et al., 1980; Abraham and Rood, 1985; 
Simonsen et al., 1998; Luh et al., 2000; Jensen et al., 2002), and to appease the increasing 
public concern on the development of antibiotic resistant bacteria (WHO, 2000).  
 
Avoparcin is an effective AGP for the prevention of clostridial diseases in chickens 
(Hofshagen and Kaldhusdal, 1992; Kaldhusdal and Hofshagen, 1992).  Vancomycin is an 
analogue of avoparcin and bacteria harbouring the gene for avoparcin resistance automatically 
confer resistance to vancomycin.  The overuse of avoparcin has led to increased incidences of 
vancomycin resistant enterococci (VRE) (Aarestrup et al., 2000; Wierup, 2001) and perhaps 
their transfer to the human population (Simonsen et al., 1998; Shea, 2004).  There are also 
indications that human isolates of VRE in Europe developed through the use of avoparcin in 
poultry and other food animals (Shea, 2004).  Avoparcin is now banned from use as an AGP 
(Elwinger et al., 1998; APVMA, 2001; Heuer et al., 2002). 
 
The American Association of Avian Pathologists have developed guidelines for the judicious 
use of antibiotics in animals, although because these are only guidelines, they are not strictly 
adhered to (AVMA, 2005).  They also recommend the use of bacitracin, penicillin, 
lincomycin, and erythromycin to effectively treat clostridial infections in poultry (Watkins et 
al., 1997) of which the last (erythromycin) is also used in human medicine (AVMA, 2005).  
Other countries such as Sweden, Denmark, Norway, and the European Union (EU) have gone 
a step further and banned all AGP use in animals and incidentally, a decrease in antibiotic 
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resistant bacteria has been noticed in these areas (Aarestrup, 2002; Boel and Anderson, 2002; 
Jensen et al., 2002; Casewell et al., 2003).  
 
The Australian Pesticides and Veterinary Medicines Authority (APVMA) has recently banned 
the use of avoparcin for the growth promotion of poultry and severely restricted the use of 
virginiamycin.  No other AGP’s with human-use analogues are allowed in the Australian 
poultry industry to prevent NE.  Some antibiotics that can be used to treat NE in Australia 
include zinc bacitracin, which is also used as an AGP, salinomycin, lincomycin and the 
tetracyclines (APVMA, 2006). 
 
The lack of availability of prophylactic antibiotics has generated a number of problems in the 
maintenance of a healthy poultry flock.  An increase in NE disease and mortality is observed 
(Lovland and Kaldhusdal, 1999; Lovland and Kaldhusdal, 2001; Wierup, 2001; Tornoe, 2002; 
Casewell et al., 2003; Grave et al., 2004), there are increased costs to the management of the 
farm as new additives may be required, a change in feed may be essential (Branton et al., 
1997), and a reduction in stocking densities may be unavoidable (Wierup, 2001; PoultrySite, 
2006).  This inevitably reduces the number and size of broilers available in the market place.  
The ban of prophylactic antibiotics has seen the use of therapeutic antibiotics increase 
markedly (Wierup, 2001; Casewell et al., 2003) and unfortunately the use of therapeutic 
antibiotics does not prevent the reoccurrence of NE within the same flock (Lovland et al., 
2003).  
 
Ionophores primarily used to treat coccidial infections in poultry have been discovered to act 
on Gram positive bacteria such as C. perfringens (Elwinger et al., 1992; Elwinger et al., 
1998).  Narasin in particular, is quite often used to prevent both coccidiosis and NE and is 
commonly used in the feed of poultry (Wierup, 2001; Grave et al., 2004; Johansson et al., 
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2004).  Some other ionophores such as monensin, nicarbazin and salinomycin are not as 
effective at preventing NE (Williams et al., 1999; Grave et al., 2004).  The development of 
anticoccidial vaccines (Williams et al., 1999; Williams et al., 2003) may see an end to the use 
of narasin and other ionophores which may in turn lead to an increase in NE (Tornoe, 2002).  
One other drawback of the use of ionophores in poultry is the possibility of resistance 
developing in C. perfringens strains as has developed in E. faecium (SVARM, 2002; 
Johansson et al., 2004). 
 
1.6.4.2 Competitive exclusion 
The state of the natural intestinal flora of chickens is integral in the protection of foreign and 
invading pathogens.  Young chickens are at higher risk of becoming overgrown or infected 
with opportunistic bacteria such as C. perfringens due to the lack of a pre-established 
microflora (Fukata et al., 1988).  Competitive exclusion (CE), first developed by Nurmi and 
Rantala in 1973 to control and reduce Salmonella colonisation in chickens, are products that 
contain harmless bacteria able to colonise the GIT without causing adverse effects on their 
host (Nurmi and Rantala, 1973).  When administered to chickens, CE products help to 
establish an undesirable environment for pathogen colonisation or growth by a number of 
mechanisms such as the creation of a restrictive physiological environment by the production 
of volatile fatty acids, the competition for bacterial receptors, the depletion of essential 
substrates, the production of toxic compounds such as bacteriocins, and the stimulation of an 
immune response (Mead, 2000; Patterson and Burkholder, 2003; La Ragione et al., 2004). 
 
A number of CE products developed and registered for the control of Salmonella colonisation 
in chickens include Aviguard®, Broilact®, Avifree®, MSC®, and Preempt® (Schneitz, 2005).  
The success of these products in terms of Salmonella inhibition has lead to their assessment in 
Chapter 1 Introduction 
 46
the prevention of C. perfringens colonisation and growth in chickens (Elwinger et al., 1992; 
Hofacre et al., 1998a; Hofacre et al., 1998b; Craven et al., 1999).   
 
Aviguard® (Hofacre et al., 1998b) and Broilact® (Elwinger et al., 1992) were both able to 
reduce the occurrence of NE demonstrated by an increase in weight gain, a normal feed 
conversion ratio and a reduction in lesion scores, although complete inhibition of NE was not 
observed in the studies.  Inconsistencies between trials was observed in the Broilact® study 
and these have been attributed to a number of variables including the condition of the newly 
hatched chicks, immune status, infection pressure and diet (Elwinger et al., 1992).  Another 
study using two undefined normal gut flora products were unable to reduce the severity of 
gross intestinal lesions (Hofacre et al., 1998a).  
 
Other products such as Mucosal Starter Culture (MSC®), which consists of scrapings of the 
caecal mucosal and intestinal tract of adult broilers (Craven et al., 1999), or defined products 
such as Bacillus subtilis PY79hr spores (La Ragione and Woodward, 2003) and Lactobacillus 
johnsonii FI9785 (La Ragione et al., 2004) may reduce intestinal proliferation of 
C. perfringens.  While CE may have a promising future in the prevention of NE, reproducible 
trials including protection studies using NE models are required to definitively prove its 
viability. 
 
1.7 Vaccination 
The development of antibiotic resistance in the developed world has rekindled an interest in 
vaccination as a prophylactic measure in human and agricultural communities (Walker, 1991).  
Prevention is better than cure and vaccination offers the advantage of life-long immunity 
against deadly diseases, potentially without the costs and continual administration associated 
with sub-therapeutic and prophylactic antibiotics (Dougan et al., 1989).  
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There is potential for the development of a vaccine against NE.  Co-administration of the 
supernatant of a broth culture of C. perfringens and anti-α-toxin antisera inhibits the 
characteristic NE lesions observed, providing evidence for the involvement of α-toxin in the 
disease (Al-Sheikhly and Truscott, 1977a; Fukata et al., 1988).  Levels of anti-α-toxin serum 
IgG are higher in broilers with a history of NE (Lovland et al., 2003), suggesting chicks 
confronted with an increase in intestinal α-toxin levels are able to develop antibodies 
targeting the toxin, but not in time to prevent any observable symptoms.  Investigations 
concerning re-infection of chickens with NE have not been reported in order to correlate the 
pre-existing antibodies with re-infection. 
 
Not only may it be possible to immunise chicks, but the immunisation of laying hens may be 
able to protect their progeny from NE (Heier et al., 2001).  Naturally occurring maternal 
antibodies to α-toxin of C. perfringens have been detected using an ELISA in day old chicks 
(Heier et al., 2001).  As these antibodies were maternal, their levels decreased at the time of 
slaughter.  Flocks with high titers of specific maternal antibodies against α-toxin had lower 
levels of mortality during the production period than flocks with low titers (Heier et al., 
2001).  No NE outbreak occurred in any of the flocks in this study by Heir et al., (2001), 
therefore the hypothesis that anti-α-toxin antibodies definitively protected chicks from 
developing NE could not be examined (Heier et al., 2001).  However, data by Lovland, et al., 
(2004) suggested that there is a protective effect of maternal anti-α-toxin antibodies on 
progeny against subclinical NE and C. perfringens hepatitis.  The short maternal IgG half-life 
in broilers (1-2 weeks) (Lovland et al., 2003), and the lack of a maternal IgA supply (Lovland 
et al., 2004) may not allow enough time for the progeny to remain protected from NE during 
their most vulnerable period (between 2-6 weeks of age).  Therefore, even though vaccinating 
the laying hens might be a cheaper and less laborious option, it may not be plausible.  Another 
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option is live orally delivered vaccines, which are simple to administer, and antibody 
responses remain life-long (Lovland et al., 2003). 
 
A great deal more is known about how the toxins of C. perfringens initiate gas-gangrene in 
humans than how they initiate NE in poultry.  The α-toxin is thought to play a major role in 
both diseases but how it interacts in the intestines is little studied.  A specific vaccine 
targeting the α-toxin may help to clarify the matter of whether or not α-toxin is solely 
responsible for the enteritis observed, and whether or not a multi-component vaccine is 
required. 
 
1.7.1 Inactivated bacterial vaccines 
The chemical treatment of organisms to render them immunogenic but non-viable is one of 
the simplest methods of producing an antigenic cocktail for use as a vaccine.  Vaccines for 
cholera, typhoid and poliomyelitis were developed in this manner (Roit, 1994).  
 
Inactivated clostridial vaccines such as Ultrabac® and 7/Somubac® produced by formalin 
preservation and adjuvanting of a collection of Clostridium species have been marketed 
world-wide for many years for use in sheep, goat and cattle (Pfizer, 2006). 
 
Some immune responses require the activation of specific T-cells for immunity, and the 
administration of inactivated bacteria is ineffective at producing this specific cell-mediated 
immunity (Walker, 1992).  Other drawbacks of using killed organisms are the potential of 
toxicity due to endotoxin production of Gram negative bacteria (Walker, 1992; Makela, 2000) 
and the development of side-effects such as pain, swelling and redness at the site of 
vaccination (Janeway et al., 2005). 
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1.7.2 Subunit/toxoid vaccines 
Subunit vaccines are also very effective against pathogens that rely on exotoxin production 
for virulence.  These include the tetanus toxin of C. tetani, diphtheria toxin of 
Corynebacterium diphtheriae, and cholera toxin of Vibrio cholera (Janeway et al., 2005).  
The immune stimulus is maximally directed to the molecule relevant for protection, and as 
subunit vaccines are defined in composition, the problem of unknown associated components 
causing adverse reactions is avoided (Makela, 2000).  
 
Although many subunit vaccines are deemed safer than whole cell inactivated vaccines, they 
are not always as effective at priming the full repertoire of immune cell types required for 
protection against a pathogen and its toxins (Janeway et al., 2005).  One example is the 
purified polysaccharide vaccine of Haemophilus influenzae type B, which is unable to 
stimulate an immune response on its own.  The discovery of linking this polysaccharide 
vaccine to proteins such as tetanus toxoid, diphtheria toxoid or mycobacterial heat shock 
protein, which elicited a T-cell response, led to the development of the highly effective 
conjugate vaccines (Schneerson et al., 1980).  This was then used in other polysaccharide 
vaccines such as the pneumococci and meningococci vaccines (Beuvery et al., 1982; 
Anderson et al., 1994).  In other cases chemical adjuvants can be used to enhance an immune 
response to the subunit vaccine.  Most adjuvants are composed of salts such as aluminium 
hydroxide, aluminium phosphate, and potassium aluminium sulphate.  Mineral oils are the 
most potent adjuvants, however, owing to their reactivity in tissues they are unacceptable in 
human use and severely limited in veterinary medicine (Walker, 1992). 
 
Many early sub-unit vaccines were comprised of purified toxins inactivated by treatment with 
formaldehyde and were given the name toxoid, with many still in use today (Walker, 1992).  
With the development of recombinant technologies a genetically defined toxoid devoid of any 
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toxic activities can be developed through the genetic manipulation of the recombinant protein 
(Makela, 2000). 
 
1.7.3 Live attenuated organisms as vaccines and carriers of vaccines 
The objective of attenuation is to provide a modified organism which mimics the natural 
behaviour of the original microbe without causing any significant disease (Roit, 1994). The 
replication of the living microbe confronts the host with a larger and more sustained dose of 
antigen, and in cases of intracellular pathogens, invasion of cells to mount a good cytotoxic T-
cell response and memory (Roit, 1994).  Another advantage of live vaccines is that the 
immune response largely takes place at the site of the natural infection (Roit, 1994). 
 
Live attenuated vaccines have been shown to provide as good or better protection than their 
inactivated counterparts stimulating both arms of the adaptive immune system: cell-mediated 
and humoral (Dougan et al., 1987; Maskell et al., 1987; Dougan et al., 1989; Brossier et al., 
1999; Shata et al., 2000; Kochi et al., 2003).   
 
Limitations to the development of attenuated organisms include the development of 
attenuations that preserve the immunogenic properties of the cell, the possibility of a lethal 
systemic infection in the immunocompromised with the vaccine  strain (de Jong et al., 1998; 
Mastroeni and Menager, 2003; Janeway et al., 2005), or the possibility of reversion to 
virulence (Walker, 1992).  The latter may be overcome by the development of two or more 
unrelated attenuations in the organism (Dougan et al., 1988; Makela, 2000), and some 
attenuated vaccines have been shown safe even in immunocompromised animals (Izhar et al., 
1990; Strahan et al., 1992). 
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Toxoids can be successful at developing a good immune response in the host, but often they 
require large scale purification from their organism, inactivation via formaldehyde and 
addition of adjuvants to enhance their immunogenicity (Walker, 1992).  Attenuated vaccines 
have the potential to “piggy-back” foreign antigens without the issues above.  This has a 
number of advantages over administration of sub-unit or toxoid vaccines.  No adjuvant is 
required as the host bacterium acts as a natural adjuvant and purification of high 
concentrations of antigen is not necessary as it is produced within the host bacterium (Brown 
et al., 1987; Guzman et al., 1991; Karem et al., 1995; Matsumoto et al., 1998).  Delivery to 
the site of natural infection is possible, and parenteral administration can be avoided, as many 
live attenuated vaccines can be administered orally (Kochi et al., 2003).  This is of particular 
significance to the agricultural industry, where time and money can be saved by the use of an 
orally administered vaccine through the drinking water, feed, or as an aerosol (Coloe et al., 
1995).  
 
Some live vaccines with potential as carriers of foreign antigens are listed in Table 1.6.  Each 
live vaccine vector offers distinctive features.  Shigella flexneri and Listeria monocytogenes 
which usually multiply in the cytosol of an infected cell, present their antigens to MHC class I 
molecules and hence a cytotoxic lymphocyte CD8 T cell response is primed (Goossens and 
Milon, 1992; Goossens et al., 1995).  Salmonella, Mycobacterium (BCG) and Brucella strains 
trigger a TH1 immune response as they survive or replicate within the vacuolar compartments 
of an infected cell and generally present themselves to MHC class II molecules (Shata et al., 
2000; Vemulapalli et al., 2000; Gentschev et al., 2001).  The decision on which vector is the 
best one to use will be influenced by the type of immune response required, by the route of 
administration and the final site of expression of the heterologous antigen. 
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Table 1.6: Attenuated live bacterial vaccines with potential for heterologous antigen delivery 
Bacterium Attenuation(s) Reference 
Salmonella Typhimurium 
 
Interruption of biosynthetic pathways (∆aro) 
pur
− (purine mutants) 
(Hoiseth and Stocker, 1981) 
(O'Callaghan et al., 1988) 
S. Dublin ∆aro mutants (Smith et al., 1984) 
Brucella abortus Rough strain (lack of O-chain in 
lipopolysaccharide) 
(Vemulapalli et al., 2000) 
Bacillus anthracis (spores) Sterne-Brossier strain with inactivated lethal 
factor, oedema factor or protective antigen 
(Sirard et al., 1997; Brossier et al., 1999) 
Salmonella Typhi (Ty21a) galE mutant (Ty21a) 
∆aro A/C 
∆aroA/C-htrA  
(Germanier and Fuer, 1975) 
(Chatfield et al., 1992b) 
(Tacket et al., 1997) 
Listeria monocytogenes actA mutant: lack of intra-and inter-cellular 
movement 
plcB mutant: prevents escape from secondary 
vacuoles 
(Goossens and Milon, 1992; Chakraborty et al., 
1994; Goossens et al., 1995; Shen et al., 1995) 
(Angelakopoulos et al., 2002) 
Mycobacterium bovis bacillus 
Calmette-Guerin strain (BCG) 
Attenuation developed through continual passage 
over 10 years 
(Dougan et al., 1989; Matsumoto et al., 1998) 
Shigella flexneri Numerous (see Phalipon and Sansonetti 1995 for 
review) 
(Phalipon and Sansonetti, 1995; Koprowski et al., 
2000; Barry et al., 2003; Ranallo et al., 2005) 
Vibrio cholerae Partial or complete deletion of cholera toxin gene (Butterton et al., 1995; Ryan et al., 1997) 
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1.7.4 Attenuated Salmonella Typhimurium as carriers of foreign antigens  
Salmonella enterica serovar Typhimurium, from now on referred to as S. Typhimurium, is a 
Gram negative bacterium of the Enterobacteriaceae family.  The bacterium is commonly used 
as a model for typhoid in mice.  Its natural route of infection provides an ideal system for the 
delivery of heterologous antigens directly to the GIT of the target species.  The bacterium is 
able to translocate from the intestinal lumen via the microfold cells (M-cells) of the Peyer’s 
patches (Jones et al., 1994) to the lamina propria and regional lymph nodes which then leads 
to colonisation of the reticuloendothelial system (RES), also known as the mononuclear 
phagocyte system (Dougan et al., 1987; Chong et al., 1996).  This follows replication in the 
liver and spleen (Maskell et al., 1987).  In the mouse model, S. Typhimurium numbers 
increase and at about 7 days post-infection mice begin to die (Maskell et al., 1987).  
S. Typhimurium are able to survive and replicate within eukaryotic cells including 
macrophages (Gahring et al., 1990; Lindgren et al., 1996) and have the ability to cause 
apoptosis in dendritic cells (Monack et al., 1996).  The survival of S. Typhimurium within 
macrophages assists their evasion of the immune system and perhaps their dissemination into 
deeper tissues (Lindgren et al., 1996). 
 
As invasion of S. Typhimurium through the Peyer’s patches of the GIT delivers the pathogen 
directly to the lymphoid system of the host, development of attenuated strains of this pathogen 
are ideal candidates for the delivery and expression of heterologous antigens directly to the 
immune system. 
 
Attenuated strains of S. Typhimurium effectively invade and colonise the small intestine, 
mesenteric lymph nodes, liver, and spleen.  However, instead of replicating and causing a 
severe systemic infection, they grow at a much slower rate and persist at lower levels than 
their virulent counterparts (Dougan et al., 1987; Maskell et al., 1987), and are usually cleared 
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by the immune system within 35 days (Maskell et al., 1987; Stabel et al., 1990).  Their 
survival within the host for 2-5 weeks enables the development of an immune response to the 
bacterium without the detrimental effects to the host (Maskell et al., 1987; Stabel et al., 1990; 
Alderton et al., 1991).   
 
Attenuated S. Typhimurium have the potential to be used as a combined vaccine due to their 
known capacity to elicit circulatory and secretory antibodies and cell-mediated immunity 
(Brown et al., 1987; Dougan et al., 1987; Guzman et al., 1991; Mastroeni et al., 1992; Mitov 
et al., 1992).  Salmonella spp., predominantly aroA- strains of S. Typhimurium, have been 
utilised to express and deliver a variety of foreign antigens (Appendix 1). 
 
Some Salmonella attenuations include the disruption of biosynthetic pathways leading to 
auxotrophy (Hoiseth and Stocker, 1981; Hackett, 1990), the removal of the capacity of a 
strain to make or respond to cyclic AMP inhibiting growth of the strain (Hackett, 1990) and 
mutations leading to increased sensitivity to oxidative stress restricting their survival within 
macrophages (Dougan et al., 1989; Hackett, 1990; Cardenas and Clements, 1992; Chatfield et 
al., 1993). 
 
1.7.4.1 Immune responses to S. Typhimurium 
Live vaccination with S. Typhimurium attenuated strains results in both cell mediated and 
humoral immunity (Moser et al., 1980; Brown et al., 1987; Maskell et al., 1987; Mitov et al., 
1992) whereas vaccination with heat killed strains results in a predominant humoral immune 
response (John et al., 2002).   
 
Interferon gamma (IFN-γ) production by natural killer cells of the innate immune system is 
important for the initial control of salmonellosis (Mastroeni et al., 1992; Hess et al., 1996; 
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John et al., 2002; Norimatsu et al., 2004).  Cell mediated immune responses on the other hand 
are not induced by killed vaccines.  The entry of live S. Typhimurium into antigen presenting 
cells (APC) such as macrophages and dendritic cells stimulates a TH1 T-cell response by 
inducing the expression of specific cell surface molecules and cytokines (Pashine et al., 1999; 
Norimatsu et al., 2004).  Dendritic cells phagocytose and process attenuated S. Typhimurium 
molecules within their vacuolar compartments (Watts, 1997; Norimatsu et al., 2004) and 
display the processed molecules on their cell surface via the MHC class II pathway, ultimately 
leading to their recognition by naїve CD4+ T cells.   
 
Along with the development of cell-mediated immunity (CMI), intragastric vaccination of 
attenuated S. Typhimurium is able to stimulate intestinal antibody production in response to a 
challenge (Moser et al., 1980) which may assist in the prevention of initial colonisation by 
S. Typhimurium.  
 
The predominant TH1 response leads to the clearance of S. Typhimurium from the host 
system by enhanced production and release of oxygen radicals and nitric oxide within the 
macrophage (Cherayil and Antos, 2001; Raupach and Kaufmann, 2001b; Janeway et al., 
2005), stimulation of production of new phagocytic cells and their recruitment to the site of 
infection (Janeway et al., 2005), serum and mucosal antibody production (Moser et al., 1980; 
Pashine et al., 1999) and apoptosis of infected APC’s (Monack et al., 1996).  
 
Important roles for CD8+ cytotoxic lymphocytes (CTL’s) have been identified in the 
recollection of immunity to Salmonella (Lo et al., 1999).  An infection against 
S. Typhimurium in vaccinated mice leads to the up-regulation of intracellular killing by 
CTL’s (Mastroeni et al., 1992; Lo et al., 1999).  B-cell responses are also important in the 
clearance as vaccinated mice unable to produce functional B-cells cannot survive a virulent 
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challenge.  The role of B-cells is not confined to their ability to provide antibodies (Mastroeni 
et al., 1993).  Other B-cell processes that enhance IFN-γ and IL-12 production are required for 
an effective response (Mastroeni et al., 2000). 
 
1.7.4.2 Immune responses to foreign antigens delivered within S. Typhimurium vaccine 
strains 
Heterologous antigen delivery and expression from attenuated S. Typhimurium has shown to 
produce both humoral and CMI responses against the antigen similar to that seen with 
S. Typhimurium alone, including high levels of secretory IgA when delivered directly to the 
mucosal surface (Brown et al., 1987; Dougan et al., 1987; Maskell et al., 1987; Roberts et al., 
1998; Allen et al., 2000; Bullifent et al., 2000) (Appendix 1).  In some cases protective 
immunity induced by S. Typhimurium expressing heterologous antigens in the absence of 
significant levels of antibodies has been noted and the protective responses observed in these 
studies seem to be mediated by CD8+ CTL’s by alternative MHC class I processing pathways 
(Sadoff et al., 1988; Strugnell et al., 1992; Pfeifer et al., 1993; Turner et al., 1993; Karem et 
al., 1997; Medina et al., 1999). 
 
Many S. Typhimurium vaccines expressing foreign antigens induce a high level of secretory 
IgA when administered orally (Guzman et al., 1991; Cardenas and Clements, 1992; Walker et 
al., 1992; Ward et al., 1999).  Secretion of mucosal antibodies is paramount for the prevention 
of bacterial colonisation during a primary infection (Redman et al., 1995), and attenuated 
S. Typhimurium expression of foreign antigens are capable of inducing secretory 
immunoglobulins even when administered at distal sites (Hopkins et al., 1995; Redman et al., 
1995; Allen et al., 2000). 
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1.7.4.3 Vaccination of chickens with S. Typhimurium carrying heterologous antigens 
Immunity developed in chickens infected with S. Typhimurium follows a pattern similar to 
that observed in the mouse model, with high levels of IFN-γ production present during a 
primary infection (Beal et al., 2004; Withanage et al., 2005) and CMI responses necessary for 
the clearance of a secondary infection (Withanage et al., 2005).  S. Typhimurium in chickens 
can migrate and colonise the spleen and liver, but in most instances is primarily localised to 
the intestinal tissues leading to gastroenteritis, whereas in mice it causes a severe systemic 
infection (Henderson et al., 1999; Beal et al., 2004).   
 
Chickens have been shown to respond well to vaccination with attenuated S. Typhimurium.  
The bacterium is able to colonise and invade the chicken host and develop appropriate 
immune mechanisms to counteract the effects of challenge with a wild type strain (Alderton et 
al., 1991; Henderson et al., 1999).  These immune mechanisms include the classical 
production of serum IgM, followed by IgG and IgA, and secretory IgA within the mucosa of 
the GIT (Alderton et al., 1991; Beal et al., 2004; Withanage et al., 2005).   
 
Antibody responses to the vaccination of chickens with S. Typhimurium expressing foreign 
antigens has been recently demonstrated, with the significant production of IgG and IgA 
detected to the foreign protein, including protection against challenge (Pogonka et al., 2003; 
Wyszynska et al., 2004). 
 
1.8 Concluding remarks 
Inducing protective immunity is the goal of vaccine development and to achieve this it is 
necessary to induce an adaptive immune response that has both the antigen-specificity and the 
appropriate functional elements to combat the particular pathogen concerned.  Delivery of 
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antigens via a live bacterial vector such as an attenuated S. Typhimurium, offers the 
advantages of delivery of antigens directly to the source of the natural infection (in this case 
the α-toxin of C. perfringens in the GIT), induction of adaptive immune responses including 
effector T- and B-cells, and in particular the production of secretory IgA at the mucosal sites 
of the GIT.  The possibility exists for vaccination against two diseases such as salmonellosis 
and NE, within the one vaccine, offering savings on costs and time of administration within 
the agricultural poultry industry (Khan et al., 1994; Roberts et al., 1998). 
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 Chapter 2 
General materials and methods 
 
2.1 General procedures 
All chemicals used were of analytical laboratory reagent grade.  All glassware, media and 
solutions were sterilised by autoclaving at 121oC (15 lbs/in2) for 20 min unless otherwise 
stated.  All solutions were prepared with deionised water obtained from a Millipore Milli-Q® 
water system (mH2O) (Liquipure, Melbourne, Australia) excluding media, which was 
prepared with distilled water (dH2O). 
 
Glassware was washed in Pyroneg detergent (Diversey-Lever, Pty. Ltd., Australia), rinsed 
twice in tap water, and then twice in deionised water.  Glassware used for cell culture media 
was washed in Pyroneg detergent, rinsed twice in tap water, and twice in deionised water, and 
then soaked overnight in deionised water. 
 
Solutions were dispensed using the Finnpipette® digital pipette range (Thermo Labsystems) 
which included a 0.5-10 µL, 5.0-40 µL, 20 µL-200 µL, 200-1000 µL, 1 mL-5 mL, 5 mL-10 
mL digital pipette and a 50-300 µL multi-channel pipette. 
 
Volumes of 1.5 mL or less were centrifuged with the Eppendorf microcentrifuge 5415C or 
5415D.  Greater volumes of up to 50 mL were centrifuged in the Beckman Allegra 21R 
centrifuge.  Volumes of up to 200 mL were centrifuged in the Beckman J2-21 M/E centrifuge. 
All products of less than 2 g were weighed on a Sartorius analytical top-loading balance.  
Products of greater than 2 g were weighed on an ISSCO model 300 top loading balance. 
Chapter 2. General materials and methods 
 60
 
Media containing supplements were autoclaved and cooled to 55°C before the addition of the 
supplement(s).  All media were prepared using aseptic technique or in a lamina flow cabinet 
and stored at 4oC until required.  
 
2.2 General chemicals and equipment 
 
2.2.1 Equipment 
ABI Prism BigDye Terminator Cycle  
Sequencing Ready Reaction kit:    Perkin-Elmer Corp., USA. 
Anaerogen gas pack:    Oxoid, England 
Balances:  
Analytical balance    Sartorius Gottingen, Germany;  
Balance (0.1-500 g)    U-Lab, Australia. 
BALB/c mice (female):  Animal resources centre, Canningvale, 
Western Australia.  
Centricon ultracentrifugal devices:  Millipore, USA 
Centrifuges:  
Eppendorf 5414C and 5414D  
bench top centrifuges    Eppendorf Geratebau, Germany 
Beckman Allegra™ 21R Centrifuge  Beckaman Coulter, USA 
Beckman J2-21 M/E Super Centrifuge  Beckman Coulter, USA 
Centrifuge tubes: 
1.5 mL Eppendorf centrifuge tubes.  Treff AG, Switzerland. 
10 mL centrifuge tubes    Sarstedt, Germany 
50 mL centrifuge tubes    Greiner Labortechnik, Germany 
Chapter 2. General materials and methods 
 61
200 mL autoclavable centrifuge bottles  Nalge Nunc International, USA 
Cover slips:      Mediglass, Australia 
Cryogenic tank (liquid nitrogen tank):  Cryo Biological System, USA. 
Cryovials (1.8 mL):     Nalgene Company, USA. 
Dry block heater:     Ratek, Australia 
Electrophoresis power supply: 
PowerPac 300     Biorad Laboratories, USA. 
EPS 3000xi     BioRad Laboratories, USA. 
EPS600 Amersham Pharmacia LKB, Sweden. 
Electrophoresis units: 
DNA: 
(a) Mini gel (GNA-100)    Pharmacia LKIB, Sweden 
(b) Midi gel (wide mini-sub cell GT)  BioRad Laboratories, USA 
Protein: 
(a) Mini Protean III gel system   BioRad Laboratories, USA 
Electroporation cuvettes:  0.2 cm cuvettes chilled at -20°C before 
use, Biorad laboratories, USA 
ELIspot plates:  Multiscreen™ 96-well filtration high 
protein binding immobilon-P membrane, 
Millipore, USA  
Filters, 32 mm sterile  
Acrodisc 0.2 µm and 0.45µm:   Pall, USA 
Gel Doc image system:     BioRad, USA  
Geneclean
®
 kit:      QBIOgene USA 
Incubator for tissue culture (5% CO2):  Forma Scientific, USA  
Microplate reader (96-well) MR7000:  Dynatech (now Dynex), USA  
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Microscopes: 
Light microscope (CH2)    Olympus Optical Co., Japan 
Inverted microscope    Olympus, Japan 
Microscope slides:     LOMB Scientific Co., Australia  
Microtitre plate (96-well, flat bottom):  Nunc, Denmark 
Needles (19, 21, and 26 gauge):   Terumo Pty, Ltd., Australia 
Nitrocellulose membrane (Trans-Blot
®
) 0.2 µm:  BioRad, USA.  
PCR machines: 
GeneAmp2400 PCR system   Perkin-Elmer, USA 
PCR Express gradient thermal cycler:   Thermohybaid, UK. 
Petri dishes:       BioLab, Australia. 
pH meter:       Hanna, U-lab, Australia. 
Platform shaker:  Ratek, Australia. 
Pulse controller & Gene pulser apparatus:  BioRad, USA. 
QIAprep
®
 spin miniprep kit:    QIAGEN, Australia 
Sonicator:       Branson Sonic Power Co., USA.   
Syringe (1, 5, 10, 20, and 60 mL)   Terumo Pty, Ltd, Australia. 
Trans-blot electrophoretic transfer cell (mini): BioRad Laboratories, USA 
Transilluminator (UV):     Novex, Australia.   
Tissue culture flasks (75 cm
2
, 25 cm
2
):   Greiner, Germany. 
Tissue culture plates (24 well, 96 well):  Greiner, Germany.  
Waterbath:  Ratek, Australia. 
Chromatography paper (0.18 mm thick):   Whatman, England. 
Wizard
®
 PCR prep, DNA purification kit:  Promega, USA  
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2.2.2 Materials 
2.2.2.1 General media 
Luria-Bertani broth (LB): 0.5% (w/v) Yeast extract (Oxoid, England.), 1% (w/v) tryptone 
(Oxoid), 0.5% (w/v) sodium chloride (BDH chemicals, UK). 
Luria-Bertani agar (LA): 0.5% (w/v) Yeast extract, (Oxoid), 1% (w/v) tryptone (Oxoid), 
0.5% (w/v) sodium chloride, 1.0% (w/v) bacteriological agar (Oxoid). 
Brain heart infusion broth (BHIB): Brain heart infusion agar base, 3.7% (w/v) (Oxoid) 
dispensed in bottles to a final volume of 10 mL. 
Columbia agar (CA): Columbia agar base, 3.9% (w/v) (Oxoid). 
Cooked meat medium (CMM): Granules (1.0 g) of dehydrated CMM (Oxoid) were added to 
bottles and filled to 10 mL with distilled water.  
Sheep blood agar (SBA): CA cooled to 55oC and supplemented with 5% (v/v) defibrinated 
sheep blood (Oxoid). 
Nagler plate: CA supplemented with 10% egg yolk solution (v/v).  The egg yolk was first 
mixed with saline in a 1:1 ratio and centrifuged at 5,500 x g for 10 min.  The supernatant was 
used for preparing the plates. 
Thioglycollate broth: Thioglycollate (Oxoid) 2.9% (w/v) (alternative) broth was prepared 
and boiled to completely dissolve the medium.  Ten millilitre aliquots were dispensed into 20 
mL bottles. 
XLD plates: 5.3% XLD (w/v) (Oxoid).  The solution was sterilised by heating in a 
microwave set on high with frequent agitation, until it started to boil.  It was then cooled to 
50ºC and poured into petri dishes. 
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2.2.3 General solutions 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT): 5 mg/mL MTT 
(Sigma-Aldrich), dissolved in 10 mM Tris (pH 8.0) and stored at 4ºC away from light. 
5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside (X-gal): 2% (w/v) X-gal (Sigma-
Aldrich) in dimethylformamide (BDH chemicals, UK).  
β-mercaptoethanol: electrophoresis purity (Biorad). 
λ-DNA marker: A solution of 0.1 µg/µl digested λ-DNA was prepared by incubating 20 µg 
λ-DNA (Promega), 18 µL Buffer H (Promega), 10U Pst1 (Promega) and mH2O up to 180 µL, 
at 37oC overnight.  Twenty microlitres of 11x DNA loading buffer was then added to stop the 
digest.  The marker was stored at -20ºC and 10 µL lots used on a DNA agarose gel. 
ACK Lysing buffer: 0.15 M Ammonium chloride (NH4Cl), 10.0 mM potassium bicarbonate 
(KHCO3) and 0.1 mM (EDTA).  The pH was adjusted to 7.2-7.4 with 1 M HCl and filter 
sterilised through a 0.2 µm filter prior to use. 
Acrylamide/bisacrylamide solution: A 40% (w/v) prepared solution containing 38.67% 
(w/v) ultra pure acrylamide and 1.33% (w/v) bisacrylamide (Australia Scientific, Australia). 
Agarose: 1% (w/v) DNA grade agarose (Progen Industries, Australia) in 1×TAE buffer, 
dissolved by heating in a microwave. 
Alkaline phosphatase conjugate substrate kit: Prepared according to manufacturers 
instructions (Biorad). 
Ammonium persulphate (APS): 10% (w/v) Ammonium persulphate (Sigma-Aldrich) stored 
at 4ºC. 
Ampicillin: 100 mg/mL Ampicillin (CSL, Australia), filter sterilised.  
Binding buffer: 25 mM Tris (Astral Scientific), pH 8.0, 0.5 M NaCl (BDH), 60 mM 
imidazole (Sigma-Aldrich). 
Blocking solution (ELISA): Skim milk 5% (w/v) in PBST. 
Bovine serum albumin fraction V (BSA): 1 mg/mL (Sigma-Aldrich), stored at -20°C. 
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Bradford reagent: 100 mg Coomassie Brilliant G-250 (Sigma-Aldrich) dye was dissolved in 
50 mL 95% (v/v) ethanol, then mixed with 100 mL 85% (v/v) phosphoric acid, and brought 
up to 1 L with dH2O.  The solution was stored at 4ºC, and filtered through a 0.45 µm filter 
before use. 
Bromophenol blue: 1% (w/v) Bromophenol blue (BDH). 
Calcium chloride (CaCl2): 1 M CaCl2 (BDH) filter sterilised. 
Cell lysis buffer I: 25 mM Tris, pH 8.0, 0.5 M NaCl, 60 mM imidazole.  Lysozyme (4 
mg/ml) was added to the buffer immediately prior to use. 
Cell lysis buffer II: 50 mM Tris pH 8.0, 100 mM NaCl.  Lysozyme (1 mg/mL) was added to 
the buffer immediately prior to use. 
Chloroform: 100% (v/v) Chloroform (BDH). 
CI: 96% (v/v) Chloroform (BDH), 4% (v/v) isoamyl alcohol (BDH). 
Coating buffer: Stock A: 8.4 g of sodium hydrogen carbonate (Na2HCO3) (BDH) dissolved 
in 100 mL of dH2O. Stock B: 10.6 g sodium carbonate (Na2CO3) (BDH) dissolved in 100 mL 
dH2O.  To make up the coating buffer, 45.3 mL of A was mixed with 18.2 mL of B and made 
up to 1 L with dH2O.  The pH of the final solutions was approximately 9.6. 
Concanavalin A: A lyophilised powder (Sigma-Aldrich) reconstituted in sterile saline. 
Coomassie blue destain solution: 10% (v/v) Ethanol (BDH) and 10% (v/v) glacial acetic 
acid (BDH). 
Coomassie blue stain solution: 0.1% (w/v) Coomassie brilliant blue R-250 (Sigma-Aldrich), 
50% (v/v) methanol (BDH), 10% (v/v) glacial acetic acid (BDH). 
CTAB/NaCl: 4.1 g of NaCl was dissolved in 80 mL mH2O and 10 g CTAB 
(hexadecyltrimethyl ammonium bromide, Sigma-Aldrich) was added and dissolved by 
heating at 65°C. 
Dextran: 10 mg/mL stored at -20ºC (Sigma-Aldrich) 
DMSO: Dimethyl sulfoxide (Sigma-Aldrich). 
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DNA loading buffer 11×: 10% (w/v) Ficoll (Sigma-Aldrich), 50% (v/v) glycerol (BDH), 
0.5% (w/v) Orange G (Sigma-Aldrich), 1% (w/v) SDS (BDH), 10 mM EDTA (BDH), 50 mM 
Tris (pH 8.0). 
dNTPs (deoxynucleoside triphosphates): 10 mM each of dATP, dGTP, dTTP and dCTP 
(Boehringer Mannheim-BM, Germany) 
Dulbecco’s Modified Eagle’s Medium (DMEM):  
100 mL 5 × DMEM (Trace, Biosciences, Castle Hill, Aust.) 
10.0 mL Hepes buffer (1 M) (Trace)  
13.5 mL Sodium bicarbonate (7.5%) (Trace)  
4.5 mL L-Glutamine (200 mM) (Trace) 
372.0 mL mH2O. 
Elution Buffer: 25 mM Tris, pH 8.0, 0.5 NaCl, 200 mM imidazole. 
Ethanol: 70% (v/v), 95% (v/v), 100% (v/v) analytic ethanol (BDH). 
Ethidium bromide (EtBr): A stock solution of 10 mg/mL EtBr (BM). This solution was not 
autoclaved. 
Ethylenediaminetetra-aetate (EDTA) buffer: 0.25 M EDTA (BDH), pH 8.0.  
EXTRAvidin: Purchased from Sigma and used at a 1:1000 dilution prepared in PBST. 
Folin’s reagent: Folin & Ciocalteaus reagent (BDH) diluted 1:1 in mH2O, stored at 4ºC away 
from light. 
Formaldehyde: Formaldehyde (37% w/v) was purchased from Sigma and used at a final 
concentration of 0.4% (w/v). 
Frozen Storage Buffer (FSB) (per litre):  
Manganese (II) chloride 4-hydrate (MnCl2.4H2O) (BDH) 8.91 g (45 mM) 
Calcium chloride dihydrate (CaCl2.2H2O) (BDH)  1.47 g (10 mM) 
Potassium chloride (KCl) (Ajax)     7.46 g (10 mM) 
Hexamine cobalt chloride (Sigma-Aldrich)   0.80 g (100 mM) 
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Glycerol (BDH)       100 mL (10%) 
Potassium acetate (KOAC) (Sigma-Aldrich)   10 mL (10 mM) 
The above reagents were combined and mH2O was added to approximately 800 mL.  The pH 
was adjusted to 6.4 with 0.1 M HCL and mH2O was added to a final volume of 1 L. 
Glycerol: 100%, 50% (v/v) glycerol (BDH). 
Haemolysin liquid assay buffer x10 (HLAB): 250 mM Tris, pH 7.4, 100 mM CaCl2, 
100 µM ZnCl2 (BDH) 8.5% NaCl. 
Hydrochloric acid: 32% (w/v) (Ajax Chemicals Ltd., Australia). 
Hydrogen peroxide (H202): 30% (w/v) H2O2 (BDH). 
Imidazole: A 5 M imidazole stock solution (Sigma-Aldrich) was prepared and filtered 
through a 0.45 µm filter. 
Isopropanol: Propan-2-ol (BDH). 
Isopropyl-β-D-thiogalactopyranoside (IPTG) 1 M stock: 0.2 g/mL IPTG (Astral), filter-
sterilised.  One millilitre aliquots were stored at -20°C.  
Lowry reagent A: 2% (w/v) Sodium carbonate (BDH), 0.4% (w/v) sodium hydroxide 
(BDH), 0.16% (w/v) sodium potassium tartrate (Sigma-Aldrich) and 1% (w/v) SDS. 
Lowry reagent B: Copper sulphate, 4% (w/v)  (Ajax, Australia) 
Magnesium chloride: BDH Chemicals, UK 
Methanol: 100% (v/v) (BDH). 
Native PAGE running buffer (10x): 0.25 M Tris, 1.92 M glycine (Sigma-Aldrich). 
Native PAGE sample buffer (5x): 312.5 mM Tris (pH 6.8), 50% (v/v) glycerol (BDH), 
0.05% (w/v) bromophenol blue (Sigma-Aldrich). 
Native PAGE separating gel (x%): 
1.5 M Tris pH 8.8   2.5 mL 
Bis/Acrylamide (40%)  x/4 
H2O     7.5-x/4 mL 
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Ammonium persulphate (10%) 50 µL 
TEMED    5 µL 
Native PAGE stacking gel (5%): 
0.5 M Tris pH 6.8   1.0 mL 
Bis/Acrylamide   0.67 mL 
Ammonium persulphate (10%) 30 µL 
TEMED     5 µL 
H2O     2.3 mL 
Newborn Calf Serum (NCS): NCS (Cytosystems Pty Ltd, Australia) was dipsensed into 
10 mL aliquots and heated to 65ºC for 15 min to inactive serum proteins.  NCS was stored at -
20ºC until required.  
Nickel Sulphate (0.2 M): Nickel sulphate (2.6 g) (BDH) was dissolved in 50 mL of mH2O. 
Penicillin/Streptomycin: A stock of 5 mg/mL was purchased from Trace, and used at a final 
concentration of 5 µg/mL for tissue culture cell line maintenance.  
Phenol (saturated): Supplied by Astral Scientific. 
Phenol/chloroform-isoamyl: A ratio of 25:24:1 (BDH) of phenol, chloroform and isoamyl 
alcohol. 
Phosphate-buffered saline (PBS): 1 tablet  Dulbecco’s ‘A’ PBS (Oxoid) in 100 mL mH2O 
(sodium chloride 0.8%, potassium chloride 0.02%, disodium hydrogen phosphate 0.115%, 
potassium dihydrogen phosphate 0.02%). 
PBST: PBS and 0.05% (v/v) Tween 20 (polyoxyethylene sorbitan monolaurate, Sigma-
Aldrich). 
Plasmid isolation solution I: 50 mM Glucose (Sigma-Aldrich), 10 mM EDTA (BDH), 25 
mM Tris-HCl (pH 8.0, Amresco).  Lysozyme (BM) (4 mg/mL) was added immediately prior 
to use. 
Plasmid isolation solution II: 1% (w/v) SDS (BDH), 0.2 M NaOH (BDH). 
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Plasmid isolation solution III: 60 mL of 5 M potassium acetate (BDH) (final concentration 3 
M), 11.5 mL glacial acetic acid (BDH) (final concentration 5 M) and 28.5 mL mH2O. 
Protein lysis buffer 1: 25 mM Tris, pH 8.0, 0.5 M NaCl, 60 mM imidazole.  Lysozyme (1 
mg/mL) was added to the solution just before use. 
Protein lysis buffer 2: 50 mM Tris, pH 8.0, 100 mM NaCl. Lysozyme (1 mg/mL) was added 
just before use. 
RPMI/NCS: RPMI solution was purchased from Sigma. It was supplemented with 2 mM 
glutamine and 5% NCS prior to use. 
Saline: 0.85% sodium chloride (BDH). 
SDS loading buffer (5x): 60 mM Tris (pH 6.8), 25% (v/v) glycerol (BDH), 2% (w/v) SDS 
(BDH), 14.4 mM β-mercaptoethanol (Bio-Rad, Aust.), 0.1% (w/v) bromophenol blue (Sigma-
Aldrich). 
SDS-PAGE Separating gel (x%) 
1.5 M Tris pH 8.8   2.5 mL 
10% SDS    100 µl 
Bis/Acrylamide (40%)  x/4 mL 
H2O     6.5-(x/4) mL 
Ammonium persulphate (10%) 50 µL 
TEMED    10 µl 
SDS-PAGE stacking gel (4%) 
0.5 M Tris pH 6.8   1.0 mL 
10% SDS    40 µL 
Bis/Acrylamide (40%)  375 µL 
H2O     2.585 mL 
Ammonium persulphate (10%) 20 µl 
TEMED    5 µL 
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SDS running buffer stock (10x): 0.25 M Tris, 1.92 M glycine (BDH), 1% (w/v) SDS 
(BDH). The pH was adjusted to 8.3. 
Skim milk: Bonlac Foods Limited, Australia. 
Sodium acetate: 3 M (BDH), pH 4.6. 
Sodium chloride: 5 M Stock solution of sodium chloride. 
Sodium dodecyl sulphate (SDS): 10% (w/v) SDS (BDH). 
Sodium hydroxide (NaOH): 10 M Stock solution (BDH). 
Sucrose buffer I: 25% (w/v) Sucrose (BDH), 50 mM Tris (BM), pH 8.3.  This solution was 
sterilised at 109ºC for 30 min. 
Sucrose buffer II: 20% Sucrose (BDH), 0.1 mM EDTA, 30 mM Tris, pH 8.0, filter sterilised. 
Sulphuric acid (H2SO4) (TMB stop solution): 1.0 M Sulphuric acid (BDH). 
Transfer buffer: 25 mM Tris (Amresco), 192 mM glycine (BDH), 20% (v/v) methanol 
(BDH). 
TE buffer x10: 100 mM Tris (BM), 10 mM EDTA (Amresco), pH 8.0. 
TEMED (N,N,N’,N’-tetramethylethylenediamine): Electrophoresis purity (Biorad). 
Tetramethylbenzidine (TMB): TMB substrate reagent A (BD Biosciences, USA) and TMB 
substrate reagent B (BD Biosciences) were mixed in a ratio of 1:1 and used within 10 min. 
Tris (hydroxymethyl) aminomethane (Tris): 2 M Stock solution (BM) 
Tris-Acetate buffer (TAE) x 50: 2 M Tris, 1 M acetic acid, 0.1 M EDTA. 
Tris buffered saline (TBS): 25 mM Tris, 0.18 M sodium chloride, pH 7.4. 
Trypan Blue stain: Purchased from Sigma (0.4%) (w/v). 
Trypsin - EDTA: Diluted by 50% in sterile PBS prior to use (Trace Biosciences, Australia. 
Tryptone: Oxoid. 
TST: 10 mM Tris (pH 7.4), 150 mM NaCl (BDH) and 0.05% (v/v) Tween 20 
(polyoxyethylene sorbitan monolaurate, Sigma-Aldrich). 
Urea: 6 M Stock (BDH). 
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Wash Buffer: 25 mM Tris, pH 8.0, 0.5 M NaCl, 60 mM imidazole. 
Western blot substrate solution: Chloro-1-naphthol (30 mg) (Sigma-Aldrich) was dissolved 
in 10 mL methanol (BDH), brought up to 50 mL with TBS, mixed with 30 µl hydrogen 
peroxide (H2O2) and used immediately for the development of Western blots probed with 
horseradish peroxidase (HRP) conjugates.  
Whole cell lysis buffer: 0.1 M Tris, 2% (v/v) SDS and 15% (v/v) glycerol, pH 6.8. 
Zinc chloride (ZnCl2): 1 M Stock solution (BDH), filter sterilised. 
 
2.2.3.1 Enzymes 
All enzymes were used with their supplied buffer according to manufacturer’s instructions, 
and were stored at -20ºC unless otherwise stated. 
DNA polymerase, Expand Long Template PCR system:  5U/µL (Roche, Germany). 
DNA polymerase, Pfu: 3U/µL (Promega, USA). 
DNA polymerase, AmpliTaq: 5U/µL (Perkin-Elmer, USA) 
Restriction enzymes: See Table 2.4 
Calf intestinal phosphatase (CIP): 10U/µL (Roche, Germany), stored at 4ºC. 
Polynucleotide kinase (PNK): 10U/µL (Promega, USA) 
Pronase solution: 10 mg/mL (BM). 
DNase I bovine pancreas: A stock of 10U/µL was prepared from a lyophilised vial of DNase 
(Sigma-Aldrich). 
RNase solution: 10 mg/mL ribonuclease 1A bovine pancreas (Pharmacia).  For DNase free 
RNase, the RNase solution was boiled for 30 min. 
Lysozyme solution 1: 20 mg/mL lysozyme (BM) in EDTA buffer, prepared fresh. 
DNA Ligase (T4): 10U/µL (Boehringer Mannheim, Germany). 
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2.2.3.2 Antibodies 
Horse anti-α-toxin polyclonal antisera  
(gas-gangrene antisera):    CSL, Australia 
Rabbit anti-horse IgG (H+L)-HRP:  ICN, USA 
Goat anti-mouse IgG-HRP:    ICN, USA 
Rat anti-mouse IFN-γ (capture antibody):  Abcam, UK 
Rat anti-mouse IL-4 monoclonal antibody: Abcam 
Biotin rat anti-mouse IFN-γ :   Abcam 
Biotin rat anti-mouse IL-4 monoclonal antibody: Abcam 
 
2.3 Microbiological methods 
2.3.1 Bacterial strains, plasmids and recombinant proteins developed 
throughout the study 
The description of all the bacterial strains and plasmids used throughout this study is listed in 
Tables 2.1. and 2.2.  A description of all the recombinant proteins developed throughout the 
study is listed in Table 2.3. 
 
2.3.2 Bacterial storage 
E. coli and Salmonella strains were stored at -70oC in 50% glycerol.  C. perfringens strains were 
stored at -70oC in a solution containing 10% skim milk, 1% tryptone, and 10 mM Tris, pH 7.5. 
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Table 2.1: Bacterial strains used in this study 
Bacterial strain Genotype/Description Source 
Clostridium perfringens   
61 Type A Necrotic enteritis (NE) 
isolate from a chicken 
60 Type A NE isolate from a chicken 
   
Escherichia coli Genotype/Description Source 
TOP10F’ F´{lacIq, Tn10(TetR)} mcrA 
∆ (mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 
araD139 ∆(ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
BL21 F- ompT hsdSB(rB
-mB
-) gal dcm 
(DE3) 
Invitrogen 
BL21 (DE3)pLysS  F- ompT hsdSB(rB
-mB
-) gal dcm 
(DE3) pLysS (CamR) 
Invitrogen 
DH5α supE ∆lacU169 (φ80 
lacZ∆M15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 
(Hanahan, 1983) 
Salmonella 
Typhimurium 
Genotype/Description Source 
LT2-9121 leu hsdL trpD2 rpsL120 ilv52 
metE551 metA22 hsdA hsdB 
Prof. P. Reeves, Department 
of Microbiology, The 
University of Sydney 
STM-1 ∆aroA- ∆serc- RMIT University 
Salmonella Typhimurium 
82/6915 
Wild type Inv+ (Alderton et al., 1991) 
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Table 2.2: Vectors used in this study 
Plasmid Description/Genotype Source/Reference 
pCR2.1 3.9 kb PCR cloning plasmid, AmpR, KmR, lacZ  Invitrogen 
pRplc10F Complete plc lacking the first 84 nucleotides from 
the start codon (coding for the signal sequence of the 
mature α-toxin) cloned into PstI and EcoRI sites of 
pRSETA 
Chapter 3 
pCplc3 1.24 kb amplified fragment from C. perfringens 
strain 61 containing the complete plc with a 6xCAT 
(coding for 6xHis) at the 5’ end, cloned into pCR2.1 
using TA cloning 
Chapter 3 
pCplcInv3 Inverse amplified and self-ligated pCplc3 (with 
nucleotides 250-309 of plc deleted) 
Chapter 3 
pRSETA 2.9 kb protein expression plasmid: AmpR, N-terminal 
6xHis, T7 promoter 
Invitrogen 
pRplc14 Complete plc cloned into the PstI and EcoRI sites of 
pRSETA using primers AllPstI and PlcEcoRev 
Chapter 5 
pRplcInv9 Inverse amplified and self-ligated pRplc14 (with 
nucleotides 250-309 of plc deleted) 
Chapter 5 
pRplc316 Nucleotides 246 (from ATG) to 1243 of the plc from 
C. perfringens strain 61 cloned into PstI and EcoRI 
sites of pRSETA 
Chapter 3 
pRplc204 Nucleotides 582-1243 (from ATG) of the plc from 
C. perfringens cloned into the PstI and EcoRI sites of 
pRSETA 
Chapter 3 
pRplc104 DNA sequence coding for the C-terminus of plc 
(nucleotides 882-1243) cloned into the PstI and 
EcoRI sites of pRSETA 
Chapter 3 
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Table 2.2 Cont. 
Plasmid Description/Genotype Source/Reference 
pBluescript SKII 2.96 kb phagemid: AmpR, lacZ, ColE1 origin of 
replication 
Stratagene, USA 
pGEX4T-1 4.969 kb protein expression vector: AmpR, LacIq, 
N-terminal glutathione-S-transferase fusion, tac 
promoter (Ptac), pBR322 origin of replication 
Amersham-
Biosciences, Sweden 
pBTac3 Ptac amplified from pGEX4T-1 inserted into 
pBluescript via blunt end ligation at EcoRV site 
Chapter 5 
pBPAGC21 PagC promoter (PpagC) from Salmonella 
Enteritidis inserted into EcoRV site of 
pBluescript via blunt ended ligation 
(Moutafis, 2002) 
pBTCαInv Amplified αInv from pRplcInv9 cloned into the 
BglII and NotI sites of pBTac3 
Chapter 5 
pBTCα104 Amplified α104 from pRplc104 cloned into the 
BglII and NotI sites of pBTac3 
Chapter 5 
pBPCαInv Amplified αInv from pRplcInv9 and cloned into 
pBPAGC21 via BglII and NotI sites 
Chapter 5 
pBPCα104 Amplified α104 from pRplc104 and cloned into 
pBPAGC21 via BglII and NotI sites 
Chapter 5 
pBHAαInv Amplified htrA promoter (PhtrA) ligated to αInv 
through BglII sites and cloned into pBluescript 
SKII- via XbaI and NotI sites. 
Chapter 5 
pBHAα104 Amplified PhtrA ligated to α104 through BglII 
sites and cloned into pBluescript via XbaI and 
NotI sites. 
Chapter 5 
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Table 2.3: Description of the α-toxin recombinant proteins developed throughout this 
study. 
Expression vector Protein Description Affinity his-tag 
pCplc3 plc3 Mature α-toxin (370 aa) C-terminal 
pCplcInv3 plcInv3 Plc3 with an internal deletion of amino 
acid (aa) residues 56-75 which 
encompassing two zinc binding domains 
essential for phospholipase C activity 
C-terminal 
pRplc316 plc316 The α-toxin with the deletion of the first 
55 N-terminal aa residues encompassing 
the first three α-helical domains 
N-terminal 
pRplc204 plc204 Deletion of the first 166 N-terminal aa’s 
of α-toxin encompassing 7 α-helices  
N-terminal 
pRplc104 plc104 Deletion of the first 266 N-terminal aa’s 
of α-toxin encompassing the complete α-
helical N-terminal domain and the first 
β-sheet. 
N-terminal 
Numerous* αInv Amino acid sequence identical to plcInv3 
but without the affinity C-His tag 
Not present 
Numerous α104 Amino acid sequence identical to plc104 
but without the affinity N-His tag 
Not present 
*The numerous expression vectors used to express αInv and α104 were developed for use 
within STM1 and included plasmids pBHAαInv, pBHAα104, pBTCαInv, PBTCα104 and 
pBPCαInv, pBPCα104 (Table 2.2). 
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2.3.3 Culture conditions 
All E. coli and Salmonella strains were grown on solid microbiological media under aerobic 
conditions at 37°C for 16 h.  In instances where broth cultures were used, the strains were 
grown aerobically at 37°C for 16-20 h on a Ratek orbital shaker set at 120 rotations per min. 
 
All Clostridia grown on solid agar were placed in airtight jars and anaerobiosis was 
maintained with an Anaerogen gas pack containing ascorbic acid as the active component 
(Oxoid).  Clostridia were grown at 37ºC for 16-20 h.  
 
Broths for clostridial cultivation were used immediately, once cooled from sterilisation.  If not 
fresh, broths were boiled for ten minutes prior to C. perfringens inoculation to remove any 
dissolved oxygen. 
 
2.4 Methods of DNA analysis 
2.4.1 Chromosomal DNA extraction  
Genomic DNA from C. perfringens was prepared by following the method described in 
“Current protocols in molecular biology” (Ausubel et al., 1994) with a few modifications.  
Bacteria were grown on HBA plates overnight.  Bacteria were harvested with 3 mL sucrose 
buffer and washed and pelleted twice in the same buffer by centrifugation at 16,000 x g.  The 
pellet was resuspended in 2 mL sucrose buffer and 500 µL of lysozyme solution was added, 
followed by 500 µL of 10% SDS.  This was incubated at 37ºC for 30 min.  Thirty microlitres 
of RNase solution and 200 µL of pronase solution was then added, and the incubation allowed 
to continue for a further 45 min.  The NaCl concentration of the solution was increased to 0.8 
M by the addition of 640 µL of 5 M NaCl and 130 µL of Tris-EDTA buffer (TE).  The 
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solution was thoroughly mixed and 0.1 volumes of CTAB/NaCl were added.  The solution 
was mixed and incubated in a 65oC water bath for 10 min.  An equal volume of PCI was 
added and the tube mixed by inversion.  The phases were separated by centrifugation at 
10,000 x g for 5 min and the upper phase was collected, mixed with an equal volume of PCI 
and re-spun in a centrifuge at 10,000 x g for 5 min.  The supernatant was collected and an 
equal volume of isopropanol added.  The solution was mixed by inversion until the DNA 
precipitated out of solution.  The DNA was then fished out using a pasteur pipette, transferred 
to a 1.5 mL tube and washed in 70% ethanol.  The DNA was resuspended in 100 µL TE. 
 
Salmonella Typhimurium chromosomal DNA was extracted following the method of 
Ausubel, et al., 1994. 
 
2.4.2 Alkaline lysis plasmid extraction (miniprep) 
Plasmids used in restriction digests were purified by using the alkaline lysis method described 
in “Current protocols in molecular biology” (Ausubel et al., 1994). 
 
One and a half millilitres of an overnight culture was placed in a microfuge tube and pelleted 
in a centrifuge at 16,000 x g for 2 min.  The pellet was resuspended in 100 µL of plasmid 
isolation solution I and left at room temperature for 5 min followed by cell lysis using 200 µl 
of plasmid isolation solution II.  The solution was placed on ice for 5 min followed by the 
addition of 150 µL ice cold plasmid isolation solution III to precipitate chromosomal DNA 
and protein.  The precipitate was pelleted by centrifugation at 16,000 x g for 10 min at 4oC 
and the supernatant transferred to a new microfuge tube.  Fifty microlitres of PCI was added 
to the tube, mixed by vortex and centrifuged for 2 min at 16,000 x g.  The upper aqueous 
phase was collected and mixed with 50 µL of CI.  The solution was mixed by vortex and 
Chapter 2. General materials and methods 
 79
pelleted by centrifugation as above.  The aqueous phase was collected and 2 volumes of 96% 
ethanol added to precipitate the plasmid DNA.  Plasmid DNA was pelleted by centrifugation 
at 16,000 x g for 5 min, the supernatant decanted and the pellet air-dried before the addition of 
40 µL 10 mM Tris, pH 8.0 and stored at -20ºC. 
 
2.4.3 Plasmid extraction for DNA sequencing  
Plasmid DNA required for sequencing was purified using the QIAprep® spin miniprep kit as 
per the manufacturer’s instructions. 
 
2.4.4 Extraction of DNA from agarose 
DNA was excised from the agarose gel and extracted using the GeneClean® kit according to 
the manufacturer’s instructions. 
 
2.4.5 Purification of DNA from PCR 
Amplified DNA fragments were desalted by use of the Wizard® PCR prep DNA purification 
kit according to the manufacturer’s instructions. 
 
2.5 Agarose gel electrophoresis 
Ten microlitres of PCR or extracted DNA product and 2.0 µL of 11x DNA loading buffer 
were combined and separated on a 1-2% DNA grade agarose gel in a minigel or midigel unit 
filled with 1xTAE buffer.  A current of 100 V was applied to the gel, and the DNA fragments 
separated for 1 h. The gel was then stained in a 3 µL/mg EtBr bath for 5 min, followed by a 
20 min destaining period in running tap water. 
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The DNA products were visualized with an UV illuminator and photographed using the 
Geldoc imaging system (Biorad).  Sizes of DNA fragments were estimated by the addition of 
lambda (λ) DNA previously digested with PstI (λ-PstI) to the gel prior to electrophoresis.  A 
diagram of the λ-DNA sizes is located in Appendix 2. 
 
2.6 Quantitation of DNA 
A number of methods were used in the quantitation of DNA.  For the exact quantitation of 
well-purified DNA, a spectrophotometer was used, and for approximate quantitation of DNA, 
an ethidium bromide plate was used or DNA was separated on an agarose gel and compared 
along known standards of λ-PstI. 
 
2.6.1 Spectrophotometric quantitation of DNA 
The Shimadzu UV-160 Spectrophotometer was used to determine the optical density (OD) of 
a solution of DNA at a wavelength of 260 nm, which is the optimal wavelength for nucleic 
acids.  Protein contamination was detected by an OD reading at 280 nm.  An OD ratio of 
DNA/protein was then used to measure the quality of the DNA.  Ratios of 1.8-2.0 indicated 
good quality DNA (Sambrook and Russell, 2001).  An OD of 1 corresponded to 50 µg/mL 
double stranded DNA and the amount of DNA present was determined using this standard. 
 
2.6.2 Ethidium bromide plates for the quantitation of DNA 
Ethidium bromide (EtBr) plates were used for the quantitation of samples containing between 
1-250 ng of DNA.  One percent DNA grade agarose (Progen) in TAE buffer was dissolved in 
a microwave.  After cooling slightly, the agarose was poured into a petri dish and EtBr to the 
Chapter 2. General materials and methods 
 81
final concentration of 0.5 µg/mL was added.  The plates were swirled to evenly distribute the 
EtBr and covered with aluminium foil to cool.  The plates were stored at 4°C away from light 
until required. Plates were dried at 37ºC prior to use.  One microliltres quantities of varying λ 
DNA concentrations were placed on the EtBr plates, 1.0 µL of sample DNA was added and 
quantified by comparing with the λ standards under a UV illuminator. 
 
2.6.3 DNA gel electrophoresis quantitation of DNA 
Lambda-DNA previously digested with PstI was separated on an agarose gel along with 
sample DNA fragments.  The quantity of DNA within each digested fragment of λ-DNA is 
listed in Appendix 2 and was compared with intensities of unknown DNA samples. 
 
2.7 DNA manipulation 
2.7.1 Restriction enzymes 
The restriction enzymes used throughout the study are listed in Table 2.4.  
 
Approximately 1 µg of plasmid DNA was digested with 1U of enzyme containing 1x buffer 
in a total volume of 10-20 µL at 37oC for 2 h.  Enzymes were heat inactivated at 65ºC for 15 
min when DNA was to be used in cloning experiments.  All restriction enzymes were 
purchased from Promega, USA. 
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Table 2.4: List of restriction enzymes (RE) used in this study 
Restriction enzyme Recognition sequence 
BamHI G⇓GATCC 
BglII A⇓GATCT 
DpnI GA⇓TC 
EcoRI G⇓AATTC 
EcoRV GAT⇓ATC 
NotI GC⇓GGCCGC 
PstI CTGCA⇓G 
SacI GAGCT⇓C 
XbaI T⇓CTAGA 
XhoI C⇓TCGAG 
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2.7.2 Amplification of DNA 
2.7.2.1 Primers 
Primers were designed with the aid of the software program Sci Ed Central for Windows 95.  
Primers were designed to have a guanine/cytosine (GC) content between 40-60% with a 
melting temperature (TmºC) in the range of 50-80ºC where possible.  Primers were obtained 
as lyophilised samples from a number of companies (Table 2.5).   
 
2.7.2.2 Polymerase chain reaction (PCR) 
General PCR was performed according to the polymerase manufacturer’s instructions.  The 
general reaction mix and programs used are listed in Table 2.6, 2.7 and 2.8.  The annealing 
temperature is specified in the relevant chapters.  PCR products for cloning purposes were 
amplified using Pfu polymerase (Promega, USA) or Expand Long template PCR system 
(Roche, Germany) to reduce errors.  PCR for general detection of fragments was prepared 
with AmpliTaq polymerase.  
 
The reagents were prepared in the sterility of a Biological Safety Cabinet, Class II.  A Perkin-
Elmer DNA Thermal Cycler or a ThermoHybaid gradient cycler was used to amplify the 
DNA.  Approximately 10 and 100 ng of template DNA was used from plasmid and 
chromosomal DNA respectively.  Reactions were prepared in a final volume of 25 µL, when a 
high amount of amplified DNA was required the reaction was prepared in a final volume of 
50 µL. 
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Table 2.5: List of primers used throughout this study 
Primer name Sequence Description TmºC* 
ALLPstI TAACGCTGCAGATAAAAAATGAAAAGAAAGA Forward primer for plc 55 
253PLCf GGTTCCTGCAGTCCAGATTATGATAAGAACG Starts at base pair (bp) 253 of plc 62 
590PLCf AATCTGCAGAGCAGGTTGCAAAACTAATGAGGA Starts at bp 590 of plc 62 
Pst891F CAACCTGCAGTGAAAAAGATGCTGGAAC Starts at bp 891 of plc 60 
PlcEcoREV GCTTTGAATTCGTAAATACCACCAAAACC Reverse primer for complete plc 57 
plcHisEcoREV CGCGAATTCTTAATGATGATGATGATGATGTTTT
ATATTATAAGTTGA 
Reverse primer for the introduction of a 
6xCAT at the 3’ of plc. 
 
Inv1 AATAATTTCTCAAAGGATAATAGTTGG Forward primer for inverse PCR of plc 
starting at bp 310 and ending at bp 336 
51 
Inv2 TGGATAAGTAGAACCTAATTGAAGCTC Reverse primer for inverse PCR of plc 
starting at bp 249 and ending at bp 223 
55 
Fpst2 AGTCTGCAGTTGGGATGGAAAGATTGATGGA Amplification of plc without signal sequence   
pRSETNotI CTTCGCGGCCGCCTTTGTTAGCAGCCGGATCAA Reverse primer for the amplification of plc 
truncates from vector pRSETA for cloning 
into pBluescript 
86.7 
890BglII TCAAGATCTGGTGAAAAAGATGCTGGAACAGAT Forward primer for the amplification of 
plc104 from pRplc104 for cloning into 
pBluescript 
74.6 
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Primer name Sequence Description TmºC* 
plcBglII TAAAGATCTAAAAGAAAGATTTGTA Forward primer for the amplification of 
plcInv9 from pRplcInv9 for cloning into 
pBluescript 
65.0 
TacR GTATAGATCTCATGAATACTGTTTCCTGTGT Reverse primer for tac promoter  64.2 
TacF GTTTCTAGATGCACGGTGCACCAATGCTT Forward primer for tac promoter  75.5 
HtrAF AAGTCTAGAGCTTAACGACTTTCGCGA Forward primer for htrA promoter  68.6 
HtrAR TGGTAGATCTCATGTGTTTCAATCTCGATTA Reverse primer for htrA promoter  69.3 
pRSET Rev TAGTTATTGCTCAGCGGTGG Sequencing frompRSETA 52 
T7 Promoter TAATACGACTCACTATAGGG Sequencing from for pRSETA 48 
M13 -20 GTAAAACGACGGCCAG Sequencing from pBluescript, pCR2.1 45.8 
M13 Reverse CAGGAAACAGCTATGAC Sequencing from pBluescript, pCR2.1 44.5 
*Calculated by company of synthesis  
Bases highlighted are enzyme recognition sites with: 
Pink sequence indicating a PstI 
Green sequence indicating an EcoRI 
Blue sequence indicating a BamHI 
Red sequence indicating a NotI 
Orange sequence indicating a BglII 
Purple sequence indicating an XbaI 
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Table 2.6: Standard reaction conditions for amplification of DNA by PCR 
PCR reagent Final concentration 
DNA template 10-100 ng 
dNTP 0.2 mM 
Primer A 0.2 µM 
Primer B 0.2 µM 
10 x PCR buffer (supplied with polymerase) 1 x 
MgCl2 (AmpliTaq only) 2.5 mM 
Polymerase: 
pfu 
AmpliTaq 
Expand Long range 
 
1.5U/50 µL 
1.0U/50 µL 
2.5U/50 µL 
 
 
 
Table 2.7: Standard amplification conditions of PCR with Taq and Expand Long range 
polymerase. 
Temperature (oC) Time (s) Cycles 
94 60 1 
94 10  
Specific Annealing ºC 30  
72 Taq 60/kbp  
68 Expand 60/kbp 
35 
72 10 min 1 
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Table 2.8: Standard amplification conditions with pfu polymerase. 
Temperature (oC) Time (s) Cycles 
94 60 1 
94 45  
Specific Annealing ºC 45 35 
72 120/kbp  
72 10 min 1 
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2.7.3 Phosphatase treatment of vector DNA 
Plasmids were treated with alkaline phosphatase by incubating 4-6 µg of restriction-digested 
plasmid DNA with 0.06U of calf-intestinal alkaline phosphatase in the supplied buffer for 1-2 
h in a total volume of 30 µL.  The hydroxylated plasmid DNA was then purified using the 
Geneclean® kit according to the manufacturer’s instructions. 
 
2.7.4 Kinase treatment of PCR products 
Prior to self-ligation, 150-250 ng of PCR amplified DNA was incubated with 10U of T4 
polynucleotide kinase (PNK), 10 µM ATP, 1x PNK buffer in a total volume of 50 µL.  The 
reaction was incubated at 37oC for 2 h and then heat inactivated at 70oC for 10 min.  
 
2.7.5 Ligation 
Ligations were performed with purified digested DNA at a ratio of 1 vector molecule to 3 
molecules of insert with the addition of 2U T4 ligase and buffer in a total volume of 10-20 
µL.  The reaction was incubated at 14-16oC overnight.  In some instances digested DNA was 
ligated without further purification.  In these cases the volume of digested DNA never 
exceeded 1/3 the total reaction volume.  The ligated DNA was then purified prior to 
transformation via electroporation, or used directly for transformation with chemically 
competent cells. 
 
2.7.5.1 Purification of DNA from ligation for electroporation 
DNA ligations were precipitated from their buffers in order to prevent arcing during 
electrotransformation.  This was done by the addition of 0.1 vol of 3 M sodium acetate, 2.5 
vol of 100% ethanol, and 1 µL dextran (of a 10 µg/µL stock) directly into the ligation.  The 
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reaction was mixed by vortex and left on ice for 10 min.  The DNA was then precipitated by 
centrifugation at 16,000 x g for 5 min.  The sample was washed in 70% ethanol and the 
centrifugation process repeated.  The DNA was resuspended in 10 µL water and transformed 
via electro-transformation as described below. 
 
2.7.6 Electro-competent cell preparation 
Bacterial cells were prepared for electro-transformation by the method supplied with the Gene 
Pulser apparatus user’s manual (BioRad).  Briefly, 200 mL of Luria-Bertani broth (LB) was 
inoculated with 1/100 volume of an overnight bacterial culture.  The cells were grown with 
vigorous shaking at 37ºC to an OD600 of 0.5-0.7 (early to mid-log phase).  The culture was 
chilled on ice for 15 to 30 min and the culture pelleted by centrifugation in 50 mL tubes at 
5,445 x g for 15 min at 4ºC.  The supernatant was drained and the pellet resuspended in an 
equal volume of ice-cold mH2O.  The centrifuge process was repeated and the cells 
resuspended in a total volume of 100 mL of ice-cold mH2O.  The cells were pelleted as above 
and resuspended in 4 mL ice-cold 10% glycerol.  The cells were pelleted once again and 
resuspended with 10% glycerol in a final volume of 400 µL.  Aliquots of 40 µL were 
distributed to 1.5 mL tubes and stored at -70ºC until required. 
 
2.7.7 Electro-transformation 
The method supplied with the Gene Pulser apparatus user’s manual (BioRad) was employed 
for the high efficiency electro-transformation of E. coli and S. Typhimurium.  Frozen electro-
competent cells were thawed on ice for 15 min and mixed with up to 2 µL of unpurified 
DNA, or 10 µL of purified DNA and transferred to an ice-cold electrocuvette with a 0.2 cm 
gap.  The pulse settings used to deliver DNA into the cells were 2.5 kV, 25 µF and 200 Ω.  
After the pulse, LB was immediately added to the cells to a total volume of 1 mL and were 
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incubated at 37°C for 1 h.  One hundred microlitres of transformed culture was plated out 
onto Luria-Bertani agar (LA) containing the appropriate selective agents.  In some instances 
the remaining contents of the transformation mixture were concentrated by centrifuging at 
5,455 x g for 5 min and also plated onto LA containing the appropriate selective agents. 
 
2.7.8 Preparation of chemically competent cells 
Bacteria were grown overnight on LA plates and 4-5 isolated colonies were selected and used 
to inoculate a 100 mL flask of LB.  The cells were incubated at 37ºC with vigorous shaking 
and when mid-log growth reached were placed in 50 mL tubes and allowed to cool on ice for 
10 min.  The cells were pelleted by centrifugation at 5,445 x g for 10 min at 4ºC.  The 
supernatant was drained and the cells resuspended in 20 mL of frozen storage buffer (FSB).  
The cells were pelleted once again and resuspended in 1 mL of FSB.  One to two hundred 
microlitre aliquots were prepared in 1.5 mL tubes and stored at -70ºC until required for 
transformation. 
 
2.7.9 Chemical transformation 
Up to 10 µL of a ligation (5% of the total competent cell volume) was added to the chemically 
competent cells.  This was incubated on ice for 30 min.  The cells were then heat shocked in a 
42ºC water bath for exactly 90 s, followed by incubation on ice for 1-2 min.  LB broth was 
added to a final volume of 1 mL and the cells incubated at 37ºC for 1 h.  Ten to 100 µL of the 
transformed cells were plated onto LA plates containing appropriate selective agents. 
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2.7.10  Sequencing 
DNA was amplified using the ABI Prism BigDye Terminator Cycle Sequencing Ready 
Reaction kit (Perkin-Elmer).  DNA from pRSETA was amplified using primers pRSETRev or 
T7promoter, and DNA from plasmids pBluescript and pCR2.1 was amplified using primers 
M13-20 or M13reverse.  The amplified DNA was then precipitated with 2.5 vol of absolute 
ethanol and 0.1 vol of 3 M sodium acetate as described in the manufacturer’s protocol and 
was sequenced using the ABI Prism 377 DNA Sequencer with XL Upgrade (Perkin-Elmer) at 
Monash University (Clayton Campus), Victoria, Australia. 
 
2.8 Protein methods 
2.8.1 Preparation of whole cell lysates 
Samples of E. coli and Salmonella from broth cultures were pelleted by centrifugation at 
16,000 x g for 2 min.  The pellet was resuspended in 0.1 vol of whole cell lysis buffer and the 
sample boiled for 5 min.  Debris was pelleted by centrifugation and the protein content of the 
supernatant was determined using the Lowry method. 
 
2.8.2 Protein determination 
2.8.2.1 Bradford assay 
Protein content determination in samples containing no traces of detergent was performed 
using the Bradford method (Bradford, 1976; Bollag and Edelstein, 1991).  
 
One millilitre of Bradford reagent was added to 100 µL of sample, or standard, mixed by 
inversion and left to stand for 2 min.  Where required samples and standards were diluted in 
0.15 M NaCl.  Bovine serum albumin fraction V (BSA) was used as the standard protein 
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solution.  Two hundred microlitres of processed sample was added to the wells of a 96-well 
microtitre plate.  The OD of samples was determined with a Dynatech ELISA plate reader at 
600 nm (OD600), and a standard curve constructed by plotting the concentrations of the bovine 
serum albumin standards (µg) versus absorbance was used to determine the protein content of 
unknowns. 
 
2.8.2.2 Lowry assay 
The Lowry assay was performed on samples containing the detergent SDS.  Lowry reagent A 
and Lowry reagent B were mixed in a ratio of 100:1 to produce Lowry reagent C.  Six 
hundred microlitres of reagent C was mixed with 200 µL of bacterial cell lysate (or BSA 
protein standards) then incubated at room temperature for 20 min.  Sixty microlitres of Folin’s 
reagent (Folin-Ciocalteau reagent diluted 1:1 in water) was added then mixed rapidly and left 
to stand for 30 min.  Two hundred microlitres of the mixture was dispensed into wells of a 96-
well microtitre tray and the OD600 was determined.  A standard curve was constructed by 
plotting the concentrations of the bovine serum albumin standards (µg) versus absorbance, 
and the concentration of unknown samples determined. 
 
2.8.3 SDS-PAGE 
SDS-PAGE was performed using a discontinuous buffer system (Bollag and Edelstein, 1991).  
The gels were prepared using SDS stacking gel buffer and SDS separating gel buffer.  
Proteins were mixed with SDS loading buffer and heated to 100ºC in a dry heating block for 5 
min.  The proteins were separated by electrophoresis at 80 V for 30 min and then at 200 V for 
35 min in an electrophoresis unit (Biorad) containing SDS running buffer.  Two gels were run 
at the same time in this system.  Gels that were not transferred onto nitrocellulose membranes 
for immunoblotting were stained with Coomassie blue.  The SeeBlue protein marker was 
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separated along side protein samples and used for the determination of protein size (Appendix 
3). 
 
2.8.4 Native PAGE 
Native PAGE was prepared according to the methods in Bollag and Edelstein (1991).  Native 
PAGE gel stacking buffer and native PAGE gel separating buffer was used to prepare the 
polyacrylamide gel.  Proteins were mixed with native PAGE sample buffer, loaded onto the 
gel and separated by electrophoresis for up to 3 h at 120 V at 4ºC in native PAGE running 
buffer.  Gels were then stained by Coomassie blue. 
 
2.8.5 Coomassie staining 
SDS PAGE gels were stained in Coomassie blue staining solution for 30 min.  Gels were 
rinsed under dH2O and destained in the Coomassie destain solution for up to 2 h.  A tissue 
was folded and placed into the destaining solution to hasten the destaining of the gels. 
 
2.8.6 Immunoblotting 
2.8.6.1 Adsorption of antisera to E. coli. 
Four millilitres of TE buffer were used to flood an agar plate of E. coli grown for 18 h at 
37ºC.  The cells were harvested and pelleted by centrifugation for 10 min at 5,445 x g.  The 
cells were washed in TE buffer and sonicated using 6 x 20 s bursts with a 30 s cooling off 
period between each sonication.  Insoluble matter was pelleted by centrifugation at 14,000 x g 
for 5 min and the supernatant filtered through a 0.45 µm filter.  Two millilitres of the 
supernatant was used to adsorb 15 µL of anti-α-toxin antisera (anti-gas-gangrene) (CSL, 
Australia) previously diluted in 1 mL TST.  This was left shaking at room temperature for 4 h 
Chapter 2. General materials and methods 
 94
or at 4oC for 24 h.  The adsorbed antisera was diluted to 25 mL in Tris buffered saline (TBS) 
and 1% skim milk and stored at -20oC until required. 
 
2.8.6.2 Protein electrophoretic transfer and immunoblotting 
Proteins resolved by SDS-PAGE gels were transferred by electrophoresis onto a nitrocellulose 
membrane padded with 4 sheets of Whatman chromatography paper and a scotch-brite pad on 
both sides of the cassette.  Transfer buffer was added to the tank and the electrophoretic 
transfer was carried out at 70 V for 1.5 h.  A container of ice was placed in the buffer to 
maintain a cool temperature to prevent overheating of sample transfer. 
 
After electrophoretic transfer, the nitrocellulose membrane was blocked by incubation with 
5% (w/v) skim milk in TBS for 1 h on a rotary shaker.  The skim milk solution was removed 
and the membrane washed twice by gentle agitation in TBS for 2 min.  The membrane was 
then incubated overnight at 4°C on a rotary shaker with 25 mL of TST containing adsorbed 
antiserum.  The membrane was then washed 2 times in TBS buffer for 5 min.  Horseradish 
peroxidase-conjugated (HRP) antibodies diluted 1:5000 in TBS containing 1% skim milk 
were used as the secondary antibodies and were incubated with the membrane for 1 h shaking 
at 22ºC.  The membranes were washed 3 times in TBS for a total of 5 min and the bound 
peroxidase was visualised by incubating in the Western blot substrate solution for about 5–15 
min.  The reaction was stopped by washing the blot in dH2O. 
 
2.8.7 Enzyme-Linked Immunosorbent Assay 
Ninety-six well flat bottomed sterile plates (Greiner, Germany) were coated with 100 µL of 
3 µg/mL purified protein or 10 µg/mL of a mixed protein sample diluted in PBS and 
incubated for 1 h at 37ºC or 4ºC overnight.  Unbound protein was removed with 3 washes in 
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PBS/Tween20 and the plate coated with 200 µL of blocking buffer.  After a further hour 
incubation at 37ºC, plates were washed as above, patted dry on absorbent paper towelling, and 
100 µL of primary antibody two-fold serially diluted in diluent (1% skim milk, PBST) was 
added.  Plates were incubated at 37ºC with vigorous shaking on an ELISA shaker platform for 
2 h.  The solution was discarded, wells washed 4 times in PBST and patted dry.  Secondary 
antibody conjugated to HRP was diluted 1:5000 in PBST (1% skim milk) and 100 µL added 
to the wells of the ELISA plate.  Following a 1 h incubation at 37ºC on a shaking platform, 
the plates were washed 4 times in PBST followed by a wash in dH2O and then patted dry on 
absorbent paper.  Tetramethylbenzidine (TMB) substrate was prepared and 100 µL added to 
all wells.  The development of the reaction was allowed to proceed for up 30 min and the 
reaction was stopped with 50 µL of 1 M sulphuric acid.  The OD450 of the wells was 
determined in a Dynatech ELISA microplate reader.  The endpoint was determined as the 
dilution at which the OD450 was 3 times the background level (OD≥0.2).  All samples were 
tested in duplicate. 
 
2.9 Tissue culture techniques 
The Chinese hamster ovary (CHO) cell line was purchased from CSL, Australia.  
 
2.9.1 Maintenance and storage of cell lines 
Cell lines were maintained in Dulbecco’s Modified Eagles Medium (DMEM) with 10% (v/v) 
newborn calf serum (NCS) and 5 µg/mL penicillin and streptomycin (P/S) (Trace) in a tissue 
culture incubator containing 5% CO2, 95% air at 37ºC.  Upon reaching cell confluence, the 
tissue culture medium was discarded and the cells washed twice with sterile PBS.  Cells were 
then treated with 50% trypsin/EDTA (Trace Biosciences, Aust.) for 5 min.  Cells were 
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harvested from flasks by vigorous pipetting and transferred to 10 mL tubes.  Cells were 
pelleted by centrifugation at 1,800 x g for 5 min and resuspended in 1 mL DMEM with 10% 
(v/v) NCS.  The cell suspensions were used for subculture, or long term storage (with 10% 
(v/v) methyl sulphoxide) in liquid nitrogen.  
 
2.10  Animal studies 
Prior to the commencement of any animal studies, animal ethics approval was gained via the 
RMIT Animal Ethics Committee under apporval numbers AEC 0243 and AEC 0404. 
 
Specific pathogen free (SPF) six to eight week old female BALB/c mice were purchased from 
the Animal Resource Centre, Canningvale, Western Austalia.  Mice were acclimatised for a 
minimum of 1 week prior to the start of any experimentation. 
 
Mice were bled from the retro-orbital vein using a capillary tube coated with heparin.  Blood 
samples were pelleted by centrifugation at 6,000 x g for10 min and the sera was collected and 
stored at -20ºC until required for assays. 
 
2.11 Bioinformatics 
All the Bioinformatics programs used in this investigation were located at the Australian 
National Genomic Information Service (ANGIS) within WebANGIS and BioManager 
(www.angis.org.au).  The program Sci Ed Central was used for the design of primers and 
vectors.  
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 Chapter 3 
Cloning, mutation and characterisation of the alpha-toxin 
 
3.1 Introduction 
The C. perfringens α-toxin is a co-catalytic zinc binding enzyme present in all C. perfringens 
type-strains (Kurioka and Matsuda, 1976; Rood and Cole, 1991; Vallee and Auld, 1993b).  It 
is the major toxin responsible for the production of gas-gangrene in humans and is intimately 
involved in the production of a number of veterinary diseases (Awad et al., 1995; Songer, 
1996; Songer, 1998; Awad et al., 2001). 
 
The α-toxin is composed of 398 amino acids, of which the first 28 N-terminal residues are 
cleaved upon translocation and release of the toxin into the extracellular environment (Leslie 
et al., 1989; Saint-Joanis et al., 1989; Tso and Siebel, 1989).  The mature 43 kDa α-toxin is 
highly toxic, and the administration of as little as 100 ng intravenously and 1 µg 
intraperitoneally is lethal to mice (Fujii et al., 1986; Tso and Siebel, 1989; Ginter et al., 
1996).  
 
The α-toxin is a phospholipase C (plc) enzyme, but unlike many other bacterial plc’s it is 
highly toxic (MacFarlane and Knight, 1941; Leslie et al., 1989; Tso and Siebel, 1989; Tsutsui 
et al., 1995).  Its toxicity is attributed to its ability to attack biological membranes from cells 
such as erythrocytes, platelets, leukocytes and sphingomyelin rich membranes (MacFarlane 
and Knight, 1941; McDonel, 1980; Krug and Kent, 1984; Saint-Joanis et al., 1989).  Its 
indirect effects include the activation of the arachidonic acid cascade leading to unmitigated 
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host inflammatory responses (Gustafson and Tagesson, 1989; Ninomiya et al., 1994; Bunting 
et al., 1997; Ellemor et al., 1999; Titball et al., 1999). 
 
The precise nature of the receptor targeted by α-toxin remains unknown, although the nature 
of the phospholipid moiety is integral to recognition by α-toxin and is influenced by 
cholesterol content, saturation of phospholipids and membrane fluidity (Nagahama et al., 
1996; Naylor et al., 1998). 
 
X-ray crystallography of the C. perfringens α-toxin has revealed that it is composed of two 
domains, an α-helical N-terminal domain (residues 1-249) containing nine helices, and an 
eight-stranded β-sandwich C-terminal domain (residues 256-370), linked together by a 
number of highly mobile residues (247-255) (Figure 3.1) (Naylor et al., 1998).  The N-
terminal domain contains the catalytic site whilst the C-terminal consists of the phospholipid 
membrane binding domain (Titball et al., 1991; Titball et al., 1993; Nagahama et al., 1998).  
The catalytic site is maintained by the presence of two zinc molecules.  A third exchangeable 
ion which can accommodate zinc or another divalent cation such as cobalt is liganded to a 
third site within the active site cleft  (Krug and Kent, 1984; Nagahama et al., 1995).  The 
membrane binding domain of the C-terminal region requires Ca2+ for activation and binding 
to phospholipids (Fujii et al., 1986; Guillouard et al., 1997).  The N-terminal domain retains 
phospholipase activity when separated from its C-terminal domain, but is devoid of its 
sphingomyelinase, haemolytic, cytotoxic, myotoxic and lethal properties (Titball et al., 1991; 
Titball et al., 1993; Nagahama et al., 1998; Jepson et al., 1999).  
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Figure 3.1: Cartoon representation of the α-toxin. The N-terminal α-helical domain is 
shaded purple and the C-terminal β-sandwich is shaded green. The flexible linker joining the 
two regions is shaded red (Naylor et al., 1998).  
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The α-toxin is found in two conformational states, a closed inactive state, and an open active 
state.  Activation of the α-toxin relies on communication between the N- and C-terminal 
domains (Eaton et al., 2002).  Calcium mediated binding of the C-terminal domain to 
phospholipids may trigger the transition of α-toxin from the closed inactive state to the open 
active state by the movement of two loops encompassing amino acid (aa) residues 50-90 and 
135-150.  In the closed form of α-toxin, loop 50-90 is thought to keep the active site away 
from the membrane binding plane, while loop 135-150 prevents residues H-148 and His-136 
from forming the third zinc binding domain (Naylor et al., 1998; Naylor et al., 1999; Eaton et 
al., 2002).   
 
Inactivation of the α-toxin has been achieved via site-directed mutagenesis of aa residues 
essential to membrane binding, and catalytic activity of the toxin.  Five of the nine histidines 
within the toxin are required for zinc binding (His-11, His-68, His-126, His-136, His-148) 
(Nagahama et al., 1995; Guillouard et al., 1996) whilst a number of residues located on 
protruding loops between β-sheets are required for calcium binding and membrane 
recognition (Naylor et al., 1998; Naylor et al., 1999; Walker et al., 2000; Jepson et al., 2001). 
 
Separation of the two domains reveals that the C-terminal domain, although non-toxic is able 
to protect against the lethal effects of the α-toxin (Titball et al., 1991; Titball et al., 1993; 
Williamson and Titball, 1993; Stevens et al., 2004).  Therefore the presence of the C-terminal 
domain is essential for the development of protection against the effects of α-toxin. 
 
This study aims to develop a number of truncated α-toxin structures, via graduated deletion 
from the catalytic N-terminal domain, or via a deletion of a region required for substrate 
binding in order to remove cytotoxic properties and evaluate the truncates as potential vaccine 
candidates.  A protein based on cpa247-370 previously developed by Titball et al., (1993) will 
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also be created although this protein will have an additional deletion at the C-terminal domain 
in order to determine what, if any, changes in immunological and structural properties occur.  
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3.2 Materials and methods 
3.2.1 Analysis of plc sequences 
Primers for the amplification of the full plc were designed from plc sequences published in 
the ANGIS database and are listed in Table 2.5. 
 
Multiple plc sequences were aligned and analysed using the program ClustalW (Thompson et 
al., 1994)(obtained within BioManager by ANGIS) and areas of homology were chosen for 
primer design.  Primers developed for the truncation of the plc were designed from the cloned 
and sequenced plc gene in this study. 
 
3.2.2 Cloning of plc 
The plasmids developed for the cloning and truncation of the α-toxin gene are outlined in 
Table 3.1. 
3.2.2.1 PCR of the plc gene (pRSETA) 
The forward primers Fpst2, 253PLCf, Pst891F and 590PLCf were used in conjunction with 
the reverse primer PLCecoREV to create nested deletions from the 5’ terminus of plc.  The 
plc gene from the chromosomal DNA of C. perfringens 61 (chromosomal DNA extraction 
method in Chapter 2.4.1 was amplified using pfu polymerase (Promega, USA) according to 
the methods described in Chapter 2.7.2.2.  The annealing and elongation conditions for each 
amplification were as follows: 
Fpst2, annealing at 52ºC, elongation of 2 min; 
253PLCf, annealing at 62ºC, elongation of 2 min; 
590PLCf, annealing at 55ºC, elongation of 1.5 min; and 
891PLCf, annealing at 60ºC, elongation of 1 min.
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Table 3.1: Description of vectors used to clone and mutate the α-toxin gene of 
C. perfringens. 
 
Vector Description Source/Reference 
pCR2.1 AmpR, KanR, lacZ Invitrogen 
pCplc3 1.24 kb amplified fragment from 
C. perfringens strain 61 containing the 
complete plc with a 6xCAT (coding for 
6xHis) at the 5’ end, cloned into pCR2.1 
using TA cloning 
This study 
pCplcInv3 Inverse amplified self-ligated pCplc3 (with 
nucleotides 250-309 of  plc deleted) 
This study 
pRSETA 2.9 kbp protein expression plasmid: AmpR, 
N-terminal 6xHis, PT7 
Invitrogen 
pRplc316 Nucleotides 246 (from ATG) to 1243 of the 
plc from C. perfringens strain 61 cloned into 
PstI and EcoRI sites of pRSETA 
This study 
pRplc204 Nucleotides 582-1243 (from ATG) of the plc 
from C. perfringens cloned into the PstI and 
EcoRI sites of pRSETA 
This study 
pRplc104 DNA sequence coding for the C-terminus of 
plc (nucleotides 882-1243) cloned into the 
PstI and EcoRI sites of pRSETA 
This study 
pR10plc2F Complete plc lacking the first 84 nucleotides 
from the start codon (coding for the signal 
sequence of the mature α-toxin) cloned into 
PstI and EcoRI sites of pRSETA 
This study 
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Ten microlitres of each amplified product was analysed on a 1% agarose gel, and the 
remaining PCR product desalted using the Wizard PCR prep DNA purification kit (Promega, 
USA).  The purified DNA was digested overnight with EcoRI and PstI.  pRSETA previously 
isolated from E. coli BL21, was also digested with the aforementioned enzymes.  The two 
were heat inactivated and then ligated overnight without further purification.  Following the 
purification of the ligation, 10 µl was transformed via electroporation into electrocompetent 
E. coli BL21 pLysS.  When electro-cuvettes were unavailable, the chemical transformation of 
E. coli followed the ligation (Chapter 2.7.9).  One millilitre of LB was added and the 
transformation further incubated at 37ºC for 1 h.  One hundred microliters were plated out 
onto LA plates and SBA plates supplemented with 100 µg/mL ampicillin (from now on 
referred to as LA100 and SBA100 respectively).  Colonies surrounded by a distinct zone of 
haemolysis (presence and expression of complete plc) or 10-20 randomly selected colonies 
(truncated plc) were selected and screened for the presence of plc using the alkaline lysis 
miniprep method as outlined in Chapter 2.4.2.  Plasmid inserts were screened with a number 
of enzymes including SacI, BamHI or double digested with XhoI and EcoRV and the presence 
of plc and its truncates was confirmed by DNA sequence characterisation. 
 
3.2.2.2 TA cloning of plc  
Primers ALLPstI and PlcHisecoREV (Table 2.5) were used to amplify plc from 
C. perfringens strain #61.  The Expand long range polymerase (Roche, Germany) was used 
and the conditions used to amplify the sequence were as described in Chapter 2.7.2.2.with an 
annealing temperature of 48ºC for 30 s and an elongation time of 2 min.  The concentration of 
primer PlcHisecoRev was increased to 0.6 µM. 
 
The PCR product was analysed on a 1% agarose gel, and the PCR product was cloned directly 
into the TA cloning vector pCR2.1 according to the manufacturer’s instructions (Invitrogen).  
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Briefly, 30 ng of PCR product was mixed with 50 ng of pCR2.1 vector along with 4U of T4 
DNA ligase and ligase buffer.  This was incubated overnight in a 14ºC waterbath.  Two 
microlitres of the ligation product was then transformed into chemically competent E. coli 
TOP10F’ cells, supplied with the TA cloning kit.  One hundred microlitres of the transformed 
cells were plated onto SBA100 and LA100 previously spread with 40 µL of 40 mg/mL 
isopropyl-β-D-thiogalactopyranoside (IPTG) and 40 µL of 40 mg/mL 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-Gal).  Clones with a distinct zone of haemolysis were 
selected for further analysis.   
 
3.2.2.3 Inverse PCR of plc: 
Primers Inv1 and Inv2 were used for inverse PCR of plc.  The vector pCR2.1 carrying plc was 
used as a template for the inverse PCR.  Pfu polymerase was used in the PCR to allow for the 
direct blunt-ended self-ligation of the vector.  The pCR2.1 vector carrying the plc insert was 
amplified with an annealing temperature of 50ºC for 30 s followed by an elongation of 11 
min. 
 
Amplification of the vector was confirmed by gel electrophoresis and the remaining PCR 
product was digested with DpnI to degrade any template DNA present.  Forty microlitres of 
PCR product was digested with 20U of DpnI with its corresponding buffer in a total volume 
of 100 µL.  The digestion was stopped after a 2 h incubation at 37°C by heat inactivation of 
DpnI at 65ºC for 15 min.  The PCR product was purified using the Wizard® PCR prep DNA 
purification kit and resuspended in a final volume of 25 µL of mH2O and the DNA 
concentration determined with a spectrophotometer. 
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Prior to self-ligation, phosphate groups were added to the 5’ end of the PCR product by 
incubation with T4 polynucleotide kinase as described in Chapter 2.7.4.  The ligation was 
performed directly on the kinase treated PCR product without further purification.  To 
determine the optimum intramolecular ligating conditions, two concentrations of DNA were 
used in the self-ligation.  Fifty and 100 ng of DNA were used along with 2U of T4 ligase and 
buffer in a total volume of 20 µL.  The ligation was incubated at room temperature (about 
22ºC) overnight.  The self-ligated vector was transformed into TOP10F’ cells as described in 
the TA cloning Kit manual.  Transformants were grown on SBA100 and colonies lacking a 
zone of haemolysis were selected for plasmid analysis.  Clones were screened using the 
alkaline lysis miniprep method followed by digestion with the restriction enzyme BamHI. 
 
3.2.3 Characterisation of plc clones 
3.2.3.1 Expression of α-toxin and α-toxin truncates 
One percent (v/v) of an overnight culture of E. coli harbouring plc or its truncates was used to 
inoculate 10 mL LB100.  The broth was incubated at 37ºC with vigorous shaking until mid-
log phase of growth was reached (an OD600 of between 0.4-0.6).  IPTG to a final 
concentration of 1 mM was added to the culture and the culture incubated for a further 16 h.  
One millilitre hourly samples of culture were taken pre and post induction, pelleted by 
centrifugation and lysed using the whole cell lysis method (Chapter 2.7.1). Fifteen to thirty 
micrograms of lysed cell supernatant was analysed using SDS-PAGE and immunoblotting 
(Chapter 2.7.3) 
 
3.2.3.2 Isolation and localisation of foreign protein 
Periplasmic fractions were isolated by osmotic shock.  Pelleted bacteria were resuspended in 
1/20 the original volume of sucrose buffer II.  This suspension was left on ice for 10 min and 
the cells resuspended every few minutes by flicking the tube.  The cells were then pelleted by 
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centrifugation at 17,200 x g for 10 min at 4ºC.  The supernatant was discarded and the pellet 
resuspended in 1/10 the original culture volume of ice cold 0.1 mM MgCl2.  The suspension 
was continually resuspended by flicking the tube every few minutes while keeping it at 4ºC 
for 10 minutes.  The cells were pelleted by centrifugation as before and the supernatant 
(containing the periplasmic fractions) was collected. 
 
The remaining spheroplasts were resuspended in 1/10 the original culture volume of 0.1 M 
Tris, pH 8.0 containing 1 mg/mL lysozyme.  The spheroplasts were lysed by up to four 
freeze/thaw cycles.  This consisted of freezing the sample in a liquid nitrogen bath, followed 
by thawing the sample at 42ºC.  In the final thaw cycle 5U of DNase was added.  The 
cytoplasmic fractions were collected following centrifugation, and the insoluble matter 
resuspended in the same volume of 1x SDS PAGE sample buffer.  Equal volumes of each 
fraction were loaded onto an SDS-PAGE and separated by electrophoresis. Separated protein 
samples were stained using Coomassie blue reagent or transferred onto a nitrocellulose 
membrane and detected via an immunoblot (Chapter 2.7.3). 
 
3.2.3.3 Isolation of inclusion bodies 
A bacterial culture grown and induced as described in Chapter 3.2.3.1 was used as the starting 
point for inclusion body isolation.  The bacteria were pelleted by centrifugation at 14,000 x g 
for 5 min.  The pellet was resuspended in 3 mL of protein lysis buffer II per gram of E. coli 
and left shaking on a rotating platform for 20 min.  Ten millimolar benzamidine and 10 
µg/mL leupeptin were added followed by 4 mg of deoxycholic acid per gram of E. coli and 
the suspension incubated at 37ºC for a further 20 min on a rotating platform.  The solution 
was frozen in liquid nitrogen and thawed at 42ºC.  Upon thawing DNase was added to the 
suspension to a final concentration of 5 µg/mL and incubated at 37ºC until the solution was 
no longer viscous.  The freeze/thaw process was repeated once again.  The sample was 
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pelleted by centrifugation at 16,000 x g for 15 minutes at 4ºC.  The supernatant was collected 
for further analysis on an SDS-PAGE and the pellet resuspended in 1 mL mH2O/gram E. coli.  
One hundred microlitre aliquots of the solution were dispensed into 1 mL tubes and pelleted 
by centrifugation as above.  The supernatant was discarded and the pellets resuspended in 0.1 
M Tris, pH 8.5 containing different concentrations of urea ranging from 0.5 to 5 M.  Insoluble 
debris was once again pelleted as above and the supernatant of each different concentration of 
urea analysed by SDS-PAGE and immunoblots.  
 
3.2.4 Protein purification 
3.2.4.1 Isolation of soluble proteins 
One percent of an overnight culture (v/v) was used to inoculate 100-500 mL fresh LB.  The 
culture was grown until an OD600 of 0.4-0.6 was reached and protein expression induced with 
1 mM IPTG.  The culture was incubated for a further 3 h and then pelleted by centrifugation.  
The bacteria were resuspended in 1/25 the volume of protein lysis buffer I and incubated at 
4ºC for 30 min on a rocking platform.  The bacteria were then treated with a repeated 
freeze/thaw cycle up to 4 times, with the addition of 5U of DNase following the first thaw 
cycle.  Debris was pelleted by centrifugation at 5,445 x g for 40 min at 4ºC.  The supernatant 
was filter sterilised through a 0.2 µm membrane and loaded onto an immobilised metal 
affinity chromatography (IMAC) gravity flow column. 
 
3.2.4.2 Immobilised Metal Affinity Chromatography (IMAC)  
Chelating sepharose fast flow was prepared according to the manufacturer’s instructions 
(Amersham Biosciences) using 1 and 5 mL gravity flow columns (QIAGEN).  Once packed 
and washed with H2O, the column was charged using half a column volume (CV) of a 0.2 M 
solution of the transitional metal nickel sulphate (NiSO4) (BDH).  The column was washed 
with at least 5 CV of 0.45 µm filtered mH2O and equilibrated with 5 CV of binding buffer.  
Chapter 3. Cloning, mutation and characterisation of the α-toxin                                                                            
 109
Up to 60 mL of supernatant containing his-tagged protein was applied to the column.  The 
column was washed with 10 CV of wash buffer containing 80 mM imidazole, or 60 mM 
imidazole for plcInv3, following protein binding and eluted with 10 CV of elution buffer.  
One millilitre fractions were collected during the elution step, and analysed using SDS-
PAGE. The flow through from the column was then placed into a second 1 mL IMAC column 
and the process repeated. 
 
3.2.4.3 On-column refolding of urea-solubilised inclusion bodies 
Proteins resolubilised with urea were filtered through a 0.2 µm filter and loaded onto an 
IMAC column previously charged with NiSO4 and washed with 5 M urea in refolding buffer 
(25 mM Tris, pH 8.0, 25% glycerol, 0.5 M NaCl).  Once bound, his-tagged proteins were 
subjected to a reducing gradient of urea concentrations in refolding buffer from 5 M to 0 M in 
1 M decrements to aid in refolding of the protein.  The column was washed in refolding buffer 
containing 60 mM imidazole and his-tagged protein eluted with refolding buffer containing 
200 mM imidazole.  
 
3.2.4.4 Cleaning in place and regeneration of column 
Gravity flow columns were re-used up to 5 times and cleaned between each use to remove 
hydrophobic and ionic bound contaminants.  Cleaning in place involved the application of 10 
CV of 2 M NaCl, followed by 10 CV of 1 M NaOH, and finished with 10 CV of 70% ethanol 
(v/v).  Columns were washed with H2O between each solution and Ni
2+ was stripped with 2 
CV 0.05 M EDTA, 0.5 M NaCl, pH 7.0.  A 20% ethanol solution was added to the sepharose 
when stored for later use. 
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3.2.4.5 Buffer exchange of proteins 
Eluted proteins were concentrated using Centricon centrifugal devices (Millipore) of cut-off 
pore size 3 kDa and 10 kDa according to the manufacturer’s instructions.  Buffer exchange of 
proteins was also done in the Centricon devices.  Salts and metals were removed by continual 
concentration and dilution of the protein sample in the new buffer.  
 
3.2.5 Alpha-toxin assays 
3.2.5.1 EYA reaction 
Wells were bored into Nagler plates using a 5 mm metal borer.  Plates were warmed and dried 
at 37ºC and 20 µL volumes of protein were added to the wells.  Twenty-five millimolar Tris, 
pH 7.4 was used as a control.  The plates were incubated at 37ºC and the diameter of the zone 
of turbidity developed was measured every half hour (in mm).  Samples with no observable 
signs of hydrolysis were left at 37ºC for up to 24 hours. 
 
3.2.5.2 Haemolysin assay 
SBA was prepared as described in Chapter 2.2.2.1 with the addition of 100 µg/mL of 
ampicillin to the molten agar.  Fifty microlitres from a stock solution of 100 mM IPTG was 
spread onto the SBA plates and E. coli colonies transformed with vector containing plc or 
truncates were streaked onto the agar and incubated for 18 h at 37ºC.  Plates were then 
incubated at 4ºC for 2 h prior to determining the presence of incomplete haemolysis 
surrounding the colonies. 
 
3.2.5.3 Haemolysin liquid assay (HLA) 
Five millilitres of a sheep red blood cell (SRBC) suspension was pelleted by centrifugation at 
3,000 x g for 10 min.  The SRBC were washed and pelleted repeatedly in HLA buffer until 
Chapter 3. Cloning, mutation and characterisation of the α-toxin                                                                            
 111
the supernatant was clear of lysed blood cells.  A 1% solution (v/v) of SRBC was prepared in 
HLA buffer. 
Alpha toxin (100 µL) was diluted two-fold in HLA buffer along the wells of a 96-well 
microtitre plate.  One hundred microlitres of H2O or HLA buffer were used as the positive 
and negative controls respectively.  One hundred microlitres of the 1% SRBC suspension was 
added to each well and the plate incubated at 37ºC on a shaking platform for 2 h.  Following a 
further 1 h incubation at 4°C the plate was spun in a centrifuge at 3,000 x g for 15 min at 4ºC 
and 100 µL of the supernatant dispensed into a new 96-well plate.  The optical density was 
determined at a wavelength of 550 nm in a Dynatech ELISA plate reader.  The percent of cell 
lysis was determined using the following equation: 
 
 (OD test well /mean OD positive well) X 100  
 
The number of haemolytic units (HU50) was expressed as the reciprocal of the dilution of 
toxin required to cause 50% haemolysis. The specific haemolytic activity of the protein was 
defined as the amount of protein in nanograms required to cause 50% haemolysis. 
 
3.2.5.4 MTT cytotoxicity assay 
The CHO cell line was cultured in 25cm2 tissue culture flasks in DMEM supplemented with 
10% (v/v) NCS and 5 µg/mL penicillin/streptomycin at 37oC in air with 5% CO2 until 
confluent.  Cells were harvested by trypsin-EDTA treatment and counted using a 
haemocytometer cell counting chamber (Chapter 2.9.1).  Trypan blue was added to the cells 
to distinguish viable from dead cells.  
 
Ninety-six well tissue culture plates were seeded with 2 x 104 CHO cells in 100 µL DMEM/10% 
NCS and incubated overnight to form a monolayer.  One hundred microlitres of protein in two-
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fold serial dilutions (made with 25 mM Tris, pH 7.4) was added to the wells.  One hundred 
microliltres of 25 mM Tris pH 7.4 was added to control wells.  Test fractions were performed in 
duplicate.  After 18 h incubation, the percentage of cell death was determined using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). 
 
Twenty microlitres of 5 mg/mL MTT in 10 mM Tris-Cl, pH 8.0, was added to each well and 
incubated at 37oC for 4 h.  The overlaying medium was carefully removed using a 
multichannel pipette, and 100 µL of 0.04 M HCl in dimethylsulphoxide (DMSO) was added 
to dissolve the formazan product.  The plates were placed on a shaking platform for 5-15 min 
(until all products were solubilised) and then placed in a Dynatech ELISA plate reader to 
determine the absorbance at a wavelength of 600 nm.  One hundred microlitres of 0.04 M HCl 
in DMSO was used as a blank.  The percentage of cell death was calculated using the 
following equation. 
 
OD600 of test well 
                     % cell death = (1 –   
OD600 of negative control well 
) X 100 
 
The cytotoxicity was expressed as the tissue culture dose 50 (TCD50).  A TCD50 was defined 
as the dilution of toxin that caused death in 50% of the cells at the chosen time point.  The 
inverted value of this dilution gave the titre - the number of TCD50 units in the stock solution 
of the toxin, or as specific toxicity, which was defined as the amount of the toxic fraction, in 
nanograms of protein, required to cause 50% cell death. 
 
In order to determine the cytotoxic effects of the truncated α-toxin proteins on CHO cells, 
100 µg/mL of each protein was assayed in the MTT assay, along with 50 µg/mL of α-toxin, a 
level which results in approximately 80% cell death. 
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3.2.5.5 p-NPPC assay 
The activity of α-toxin on the substrate para-nitrophenylphosphorylcholine (p-NPPC) was 
determined using the method of Kurioka and Matsuda (1976) with a few modifications.  
Briefly, a reaction mix (200 µL) consisting of 10 mM p-NPPC substrate (Sigma), 10 µM 
ZnCl2, 60% glycerol, 50 mM Tris, pH 7.2 and toxin was dispensed in a 96-well plate and 
incubated in a fluoSTAR OPTIMA plate reader (BMG Labtechnologies) at 37°C.  The plate 
was shaken for 1 min prior to each reading.  The absorbance was determined every 5 min and 
the concentration of p-nitrophenol liberated determined using a standard curve of various 
p-nitrophenol concentrations in the same reaction buffer.  One Unit was defined as the 
hydrolysis of 1 nanomole of p-nitrophenol per min under the specified conditions.   
 
3.2.5.6 Gel mobility assay 
Tris buffered saline (20µL) containing 0.15 µg/µL of α-toxin or truncated α-toxin proteins 
was incubated with 20 mM CaCl2 and 10 mM EDTA, or EDTA alone at 22ºC for 5 min.  
Native PAGE sample buffer was added and the samples loaded onto an 8.5% (α-toxin and 
plcInv3) or 12.5% (plc104) native-PAGE gel and separated by electrophoresis at 120 V for 
3 h at 4ºC.  The gels were stained in Coomassie blue dye followed by destaining solution. 
 
3.2.5.7 Erythrocyte binding assays: 
Qualitative assay: 
This assay was adapted from Nagahama et al., (1995).  Membranes were prepared by 
pelleting 2 mL of sheep red blood cells in a centrifuge for 5 min at 5,445 x g and 
resuspending them in 10 mL of 5 mM Tris, pH 8.0.  The membranes were pelleted at 14,000 x 
g and washed twice more with a final resuspension in 5 mL of TBS.  The protein content of 
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the membranes was determined using the Bradford assay, and the suspension was adjusted to 
100 µg/mL with TBS. 
 
One hundred microlitres of the 100 µg/mL erythrocytic membrane suspension was mixed 
with 1 µg of protein.  Each protein sample was assayed in the presence and absence of 5 mM 
CaCl2.  Following a 30 min incubation at 37°C on a orbital shaker, the membranes were 
pelleted by centrifugation at 14,000 x g for 20 minutes at 4°C.  The supernatants were 
collected for analysis and the membranes washed in TBS and pelleted as above.  This wash 
was repeated three times and the membranes were finally resuspended in 100 µL SDS loading 
buffer.  Thirty microlitres of supernatant and membrane suspension was analysed via SDS-
PAGE followed by an immunoblot using horse polyclonal anti-alpha toxin antisera.  
 
Quantitative assay: 
Membranes were prepared as above and 100 µL of the 100 µg/mL membrane suspension was 
used to coat a 96-well microtitre plate.  All following incubations were completed at 37ºC for 
1 h and microtitre plates were washed three times in TBS between each step.  After a 1 h 
incubation, the wells of the plate were washed and unbound sites blocked with 200 µL of TBS 
containing 5% skim milk (v/v).  Following incubation and washing, 100 µL of a 10 µg/mL 
protein sample (α-toxin or truncated α-toxin protein) diluted in TBS and 1% skim milk was 
added to the wells of the plate in the presence or absence of 10 mM CaCl2.  The plate was 
incubated at 37ºC on a rotating platform.  Following washing, mouse anti-α-toxin sera diluted 
1:2,000 in TBS(1% skim milk) was prepared and 100 µL added to the wells.  After incubation 
and washing, wells were incubated with 100 µL of a 1:5000 dilution of goat anti-mouse IgG-
HRP.  Plates were washed four times in TBS and 100 µL of TMB substrate added to each 
well.  Following a 15 min incubation at room temperature 50 µL of 1 M sulphuric acid was 
added and the absorbance of the wells at an OD450 was determined using a Dynatek plate 
Chapter 3. Cloning, mutation and characterisation of the α-toxin                                                                            
 115
reader.  Three wells were treated the same as the test wells except that no α-toxin was added, 
and these were used as the background reading for the assay and were automatically 
subtracted by the Dynatek plate reader.  All test samples and controls were performed in 
triplicate.   
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3.3 Results 
3.3.1 Cloning of the plc gene 
A number of plc sequences have been published in the Genbank database and were obtained 
through the ANGIS website.  These sequences were used to design primers for the 
amplification of plc.  Two strategies were developed for the cloning and expression of plc.  
One primer, Fpst2, was designed to bind 84 base pairs downstream of the plc start codon in 
order to avoid amplifying the signal sequence of plc usually required for the secretion of the 
α-toxin into the extracellular environment of C. perfringens.  The amplified plc was 
directionally cloned into pRSETA and transformed into E. coli BL21pLysS to create clone 
BL21pLysS(pR10plc2f) (Figure 3.2 B,C).  Sequencing of the clone confirmed that plc was in 
frame with the vector start codon and produced a product of 412 aa’s which equated to a 
theoretical size of approximately 47.5 kDa.  Its size was estimated at 57 kDa when calculated 
from its migration on a SDS-PAGE, approximately 10 kDa higher than the theoretical weight.  
The expressed α-toxin was designated 10plc2f and contained a 5 kDa region upstream of its 
N-terminus which included the His x 6 sequence required for downstream processing and was 
recognised by horse polyclonal anti-α-toxin antibodies (Figure 3.3).   
 
The second strategy of cloning and expressing the complete plc gene involved engineering a 6 
x CAT sequence (to code for the protein His x 6) to the reverse plc primer (primer 
PlcHisEcoRev) in order to purify the α-toxin using IMAC from a C-terminal His-tag (C-His 
tag) as opposed to the N-terminal His-tag (N-His tag) as for 10plc2f.  The plc was amplified 
and cloned into pCR2.1 using the TA cloning strategy and transformed into E. coli TOP10F’ 
cells (Figure 3.4).   
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Figure 3.2: The development of α-toxin expression systems using the commercial vector 
pRSETA (Invitrogen). (A) PCR of truncated plc. Lane 1, λ-PstI; Lane 2+3, PCR of plc316; 
Lane 4+5, PCR of plc204; Lane 6+7, PCR of plc104. (B) Cloning of plc and truncated plc 
genes into pRSETA expression vector. Lane 1, pR10plc2f; Lane 2, pRplc316; Lane 3, 
pRplc204; Lane 4, pRplc104; Lane 5, λ-PstI. Lanes 1-4 digested with PstI and EcoRI, Lane 5 
digested with PstI. (C) Restriction map of pR10plc2F. The 10plc2F gene was cloned into the 
PstI and EcoRI sites of pRSETA to create pR10plc2F. The same methodology was used for 
the cloning of the other three truncated plc genes into pRSETA. 
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Figure 3.3: Expression of α-toxin from BL21pLyS(pR10plc2f) as detected by an 
immunoblot using horse anti-α-toxin antibodies. Lane 1, 3 h insoluble pellet of 
BL21pLysS(pR10plc2f); Lane 2, 3 h cytoplasmic fraction of BL21pLysS(pR10plc2f); Lane 3, 
6 h insoluble pellet of BL21pLysS containing empty vector; Lane 4, 6 h cytoplasmic fraction 
of BL21pLysS containing empty vector; Lane 5, 4 h insoluble pellet of 
BL21pLysS(pR10plc2f); Lane 6, 4 h cytoplasmic fraction of BL21pLysS(pR10plc2f); Lane 7, 
Seeblue protein marker; Lane 8, 6 h insoluble pellet of BL21pLysS(pR10plc2f); Lane 9, 6 h 
cytoplasmic fraction of BL21pLysS(pR10plc2f).  
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Figure 3.4: The development of the plc expression vector pCplc3. (A) PCR of plc using 
reverse primer containing internal CAT x 6 sequence. Lane 1, λ-PstI; Lane 2+3, PCR of plc at 
a 45°C and 50°C annealing temperature respectively. (B) Haemolytic transformants following 
ligation of pCR2.1 and plc. Distinct zone of incomplete haemolysis observed around colonies 
which have acquired the complete plc sequence. (C) Cloning of plc into pCR2.1 vector. Lane 
1, λ-PstI; Lane 2-4, clone 1 (pCplc1), clone 2 (pCplc2) and clone 3 (pCplc3) digested with 
BamHI. (D) Restriction map of vector pCplc3 with the plc insert. The plc was cloned directly 
into the vector by the use of the TA cloning strategy. 
(A) (B) 
(D) 
1.24 kb 
4.79 kb 
0.353 kb 
   1      2     3      4  
  1     2     3  
(C) 
pCplc3 
5148 
1000 
2000 3000 
4000 
5000 
PstI 
BamHI 
XmnI 
EcoRV 
PstI 
EcoRV 
NotI 
PstI 
XmnI 
ScaI 
HindIII 
BamHI 
plc 
6xHis 
KanamycinR 
AmpR 
ColE1 
LacZ' 
BglII 
1.15 
1.7 
1.09 
0.8 
kbp 
11.5 
5.07 
2.8 
1.7 
kbp 
Chapter 3. Cloning, mutation and characterisation of the α-toxin                                                                            
 120
Transformants were grown overnight on HBA100 and IPTG, and haemolytic colonies (Figure 
3.4) were isolated for further analysis by restriction enzyme digests (Figure 3.4).  Clone 
TOP10F’(pCplc3) was sequenced (Appendix 3) and used for the expression and purification 
of the α-toxin, named plc3.  Sequencing results showed that plc cloned into the pCR2.1 
vector was not in frame with the upstream lacZ gene and hence its expression was void of any 
β-galactosidase amino acids.  The initiation codon of plc was 95 bp downstream of the lacZ 
initiation codon, and there was no identifiable consensus Shine-Dalgarno (S-D) 8-13 bp 
upstream of the plc initiation site.  The theoretical molecular weight (MW) of the expressed 
mature plc3 was calculated as 43.4 kDa, and after its migration on an SDS-PAGE was 
calculated as 47 kDa. 
Expression of α-toxin from BL21pLysS(pR10plc2f) and TOP10F’(pCplc3) clones revealed 
that 10plc2f was predominantly expressed and localised to the cytoplasm in the form of 
inclusion bodies (Figure 3.3) rather than soluble cytoplasmic protein, whereas plc3 was 
expressed and secreted into the periplasmic space of E. coli (Figure 3.5).  Furthermore 
attempts to purify the soluble component of 10plc2f were unsuccessful.  The protein did not 
bind very well to Ni2+ charged IMAC and was constantly eluted in the wash buffer in the 
presence of low levels (10 mM) of imidazole.  Clone TOP10F’(pCplc3) expressed α-toxin in 
a soluble form.  The C-His tag of plc3 was used to purify the protein from the cell lysate via 
IMAC (Figure 3.6).  Concentration of up to 80 mM imidazole did not affect the affinity of 
plc3 to the Ni2+ column, and the protein was eluted with 200 mM imidazole.  Approximately 
3.5 mg of plc3 was obtained per litre of E. coli following IMAC purification. 
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Figure 3.5: Location of plc3 3 h post-induction as analysed on an SDS-PAGE. (A) 
Coomassie blue stained gel (B) Following an immunoblot using anti-α-toxin horse polyclonal 
antisera. Lane 1, resolubilised pellet of TOP10F’ cells (negative control); Lane 2, cytoplasmic 
fraction of TOP10F’cells; Lane 3, periplasmic fraction of TOP10F’ cells; Lane 4, 
resolubilised pellet of TOP10F’(pCplc3); Lane 5, cytoplasmic fraction of TOP10F’(pCplc3); 
Lane 6, periplasmic fraction of TOP10F’(pCplc3); Lane 7, empty well; Lane 8, SeeBlue 
protein marker. 
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Figure 3.6: IMAC purification of alpha-toxin (plc3) eluted with 200 mM imidazole. Lane 
1, pre-column whole cell lysate; Lane 2-6, elution 1-5 respectively; Lane 7, SeeBlue protein 
standard. 
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3.3.2 Cloning of plc truncated genes 
The truncation of plc was based on two strategies; nested deletions occurring at the 5’ end of 
the plc, or as an internal deletion of plc.  Three products were created by the amplification of 
nested deletions, a 1.01 kb, 0.67 kb and 0.37 kb product (Figure 3.2 A) which were all 
digested with PstI and EcoRI and directionally cloned into expression vector pRSETA, and 
following transformation into BL21pLysS produced clones BL21pLysS(pRplc316), 
BL21pLysS(pRplc204) and BL21pLysS(pRplc104) (Figure 3.2 B, C) respectively.  The 
number in each vector name is representative of the number of α-toxin amino acids present in 
the expressed sequence.   
 
Deletion of an internal fragment of plc was achieved via inverse PCR of plasmid pCplc3.  
Primers Inv1 and Inv2 bound within the plc region 60 base pairs apart amplifying a fragment 
of 5.088 kb in size.  This fragment was then self-ligated, transformed into TOP10F’ cells and 
grown on SBA100.  Non-haemolytic colonies were selected, and their plasmids screened via 
RE digestion for the absence of a second BamHI site deleted during inverse PCR (Figure 
3.7).  One such clone, TOP10F’(pCplcInv3) was selected for protein expression of the 
truncated α-toxin, plcInv3.   
 
The amino acid alignment in Figure 3.8 illustrates the amino acids deleted within the α-toxin 
from each construct with reference to the complete mature α-toxin.  The properties of each 
construct are described in Table 3.2.  The 3-dimensional structure of the α-toxin has been 
solved by Naylor et al., (1998) and its structure is presented in Figure 3.1 with the N-terminal 
and C-terminal domains outlined.  Proteins plc316, plc204 and plc104 were developed with 
deletions from the N-terminal domain of the α-toxin, with plc104 composed only of the C-
terminal β-sheets.   
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Figure 3.7: The development of vector pCplcInv3. (A) Restriction map of pCplc3. Outward 
facing black arrows indicate point of primer binding for inverse PCR. Open box indicates 
region deleted via PCR which includes a BamHI site. (B) Restriction map of pCplcInv3. The 
BamHI site is no longer present. (C) Clones of transformants carrying the pCplcInv3 self-
ligated vector. Lane 1, pCplcInv2; Lane 2, pCplcInv3; Lane 3, λ -PstI. All clones were 
digested with BamHI.  
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1  WDGKIDGTGT HAMIVTQGVS ILENDLSKNE PESVRKNLEI LKENMHELQL  
1  WDGKIDGTGT HAMIVTQGVS ILENDLSKNE PESVRKNLEI LKENMHELQL  
 
51  GSTYPDYDKN AYDLYQDHFW DPDTDNNFSK DNSWYLAYSI PDTGESQIRK  
51  GSTYP                      NNFSK DNSWYLAYSI PDTGESQIRK  
51      PDYDKN AYDLYQDHFW DPDTDNNFSK DNSWYLAYSI PDTGESQIRK  
 
101 FSALARYEWQ RGNYKQATFY LGEAMHYFGD IDTPYHPANV TAVDSAGHVK  
101 FSALARYEWQ RGNYKQATFY LGEAMHYFGD IDTPYHPANV TAVDSAGHVK  
101 FSALARYEWQ RGNYKQATFY LGEAMHYFGD IDTPYHPANV TAVDSAGHVK  
 
151 FETFAEERKE QYKINTAGCK TNEDFYADIL KNKDFNAWSK EYARGFAKTG  
151 FETFAEERKE QYKINTAGCK TNEDFYADIL KNKDFNAWSK EYARGFAKTG  
151 FETFAEERKE QYKINTAGCK TNEDFYADIL KNKDFNAWSK EYARGFAKTG  
151                  AGCK TNEDFYADIL KNKDFNAWSK EYARGFAKTG  
 
201 KSIYYSHASM SHSWDDWDYA AKVTLANSQK GTAGYIYRFL HDVSEGNDPS  
201 KSIYYSHASM SHSWDDWDYA AKVTLANSQK GTAGYIYRFL HDVSEGNDPS  
201 KSIYYSHASM SHSWDDWDYA AKVTLANSQK GTAGYIYRFL HDVSEGNDPS  
201 KSIYYSHASM SHSWDDWDYA AKVTLANSQK GTAGYIYRFL HDVSEGNDPS  
 
251 VGKNVKELVA YISTSGEKDA GTDDYMYFGI KTKDGKTQEW EMDNPGNDFM  
251 VGKNVKELVA YISTSGEKDA GTDDYMYFGI KTKDGKTQEW EMDNPGNDFM  
251 VGKNVKELVA YISTSGEKDA GTDDYMYFGI KTKDGKTQEW EMDNPGNDFM  
251 VGKNVKELVA YISTSGEKDA GTDDYMYFGI KTKDGKTQEW EMDNPGNDFM  
251                  EKDA GTDDYMYFGI KTKDGKTQEW EMDNPGNDFM  
 
301 TGSKDTYTFK LKDENLKIDD IQNMWIRKRK YTAFPDAYKP ENIKIIANGK  
301 TGSKDTYTFK LKDENLKIDD IQNMWIRKRK YTAFPDAYKP ENIKIIANGK  
301 TGSKDTYTFK LKDENLKIDD IQNMWIRKRK YTAFPDAYKP ENIKIIANGK  
301 TGSKDTYTFK LKDENLKIDD IQNMWIRKRK YTAFPDAYKP ENIKIIANGK  
301 TGSKDTYTFK LKDENLKIDD IQNMWIRKRK YTAFPDAYKP ENIKIIANGK  
 
351 VVVDKDINEW ISGNSTYNIK  
351 VVVDKDINEW ISGNSTYNIK  
351 VVVDKDINEW ISGNSTYNIK  
351 VVVDKDINEW ISGNSTYNIK  
351 VVVDKDINEW ISGNSTYNIK  
 
Figure 3.8: Amino acid sequence of mature α-toxin. Region shaded grey represents N-
terminal α-helical domain and open boxed region represents C-terminal β-sheet domain. Each 
truncated α-toxin created in this study is represented by a different colour: Black; plc3, 
plum; plcInv3, blue; plc316, orange; plc204, green; plc104. 
Amino acids highlighted pink are important for zinc binding at active site. 
Amino acids highlighted teal are important for calcium binding. 
Amino acids highlighted green are important for binding of active site to membranes.  
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Table 3.2: Description of α-toxin gene products 
Expression 
vector 
Protein No. of aa 
in proteina 
Deletion(∆)b Purification 
(mg/L of 
culture) 
Calculated MW 
(kDa) 
pR10plc2f 10plc2f 370 Signal sequence -c 57.9+/-0.602 
pCplc3 plc3 370 - 3.5 46.9+/-0.478 
pCplcInv3 plcInv3 350 56-75 (∆ of 2 zinc 
binding domains) 
1.5 44.0+/-1.08 
pRplc316 plc316 316 1-55 (∆ of the first 3 α-
helices from N-
terminus) 
1.4 47.3+/-0.434 
pRplc204 plc204 204 1-166 (∆ of the first 7 
α-helices from N-
terminus) 
2.0 30.6+/-0.331 
pRplc104 plc104 104 1-266 (∆ of complete 
α-helical N-domain 
and the first β-sheet) 
3.0 18.3+/-1.01 
 
a His tag region not included 
b Amino acid (aa) position number of mature α-toxin 
c Not determined 
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PlcInv3 has an internal deletion at the N-terminal domain within the catalytic cleft of the α-
toxin. 
 
All four truncated α-toxins were successfully expressed from E. coli and recognised by anti-
α-toxin horse polyclonal antisera (Figure 3.9).  Protein plc316 was expressed at a high level 
but the majority of the protein was isolated as inclusion bodies (Figure 3.10).  Protein plc204 
was slightly more soluble, but again the majority of it was isolated as inclusion bodies (Figure 
3.11).  Protein plc104 was highly soluble and isolated in both the cytoplasm and as inclusion 
bodies (Figure 3.12).  Protein plcInv3 was not expressed as inclusion bodies to a high degree 
and like its parent protein plc3, was translocated to the periplasmic space of E. coli (Figure 
3.13).  Protein plcInv3 IMAC purification required a milder wash of 60 mM imidazole as 80 
mM imidazole eluted the protein from the column.  TOP10F’ cells harbouring pCplcInv3 also 
grew much slower than cells harbouring pCplc3 even prior to induction.  It took 
approximately 3 hours for TOP10F’(pCplc3), and 5 hours for TOP10F’(pCplcInv3) cells to 
reach the mid-log phase of growth (as determined by an OD600 of 0.5)  
 
As plc316 and plc204 were isolated in an insoluble form, 5 M urea was required to solubilise 
them.  The proteins were purified via their N-His tag using IMAC.  Removal of urea and 
refolding of plc316 and plc204 was achieved during IMAC via on-column refolding using a 
gradient reduction of urea, and then finally eluted with 200 mM imidazole (Figure 3.14).  
Protein plc104 required no such treatment and was much simpler and quicker to purify.  In 
general, about 1.4, 1.5, 2, and 3 mg of protein per litre of E. coli was purified from 
BL21pLysS(pRplc316), TOP10F’(pCplcInv3), BL21pLysS(pRplc204) and 
BL21pLysS(pRplc104) respectively (Table 3.2). 
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Figure 3.9: Expression of α-toxin truncates plc316, plc204, plc104 and plcInv3 as 
assessed by SDS-PAGE and immunoblotting using E. coli adsorbed horse anti-α-toxin 
antisera. (A) Lane 1, uninduced cell lysate of BL21pLysS(pRplc316); Lane 2, 3 h post-
induced lysate of BL21pLysS(pRplc316); Lane 3, uninduced cell lysate of 
BL21pLysS(pRplc204); Lane 4, 3 h post-induced lysate of BL21pLysS(pRplc204); Lane 5, 
Seeblue protein marker; Lane 6, uninduced cell lysate of BL21pLysS(pRplc104); Lane 7, 3 h 
post-induced lysate of BL21pLysS(pRplc104). (B) Whole cell lysate of TOP10F’(pCplcInv3) 
3 h post-induction with IPTG. Lane 1, TOP10F’(pCplcInv3); Lane 2, SeeBlue protein marker. 
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Figure 3.10: The localisation of plc316 expressed from BL21pLysS(pRplc316). (A) 
Immunoblot using anti-α-toxin horse polyclonal antisera to detect the expression of plc316 at 
0, 1, 2 and 3 h post-induction in the insoluble matter (Lanes 1-4) or in the cytoplasm of the 
cell lysate (lanes 6-9). (B) Solubilisation of BL21pLysS(plc316) with; standard protein lysis 
buffer (Lane 2); deoxycholate (Lane 3); 5 M urea (Lane 4). (C) Immunoblot of 
BL21pLysS(plc316) with anti-α-toxin polyclonal antisera after solubilisation in 5 M urea. 
Lane 1, SeeBlue protein marker; Lane 2, deoxycholate in protein lysis buffer; Lane 3, 5 M 
urea. 
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Figure 3.11: The localisation of plc204 expressed from BL21pLysS(pRplc204). (A) 
Solubilisation of BL21pLysS(plc204). Lane 1, standard protein lysis buffer; Lane 2, 
deoxycholate in protein lysis buffer; Lane 3, SeeBlue protein marker; Lane 4, 5 M urea. (B) 
Immunoblot probed with anti-α-toxin polyclonal antisera after solubilisation in 5 M urea. 
Lane 1, SeeBlue protein marker; Lane 2, deoxycholate in protein lysis buffer; Lane 3, 5 M 
urea. 
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Figure 3.12: The localisation of plc104 expressed from BL21pLysS(pRplc104). The 
detection of plc104 using horse anti-α-toxin polyclonal antisera as the primary antibody in the 
(A) periplasm (Lanes 2-4) or cytoplasm (Lanes 5-7) and (B) cytoplasm (Lanes 2 & 3) or 
inclusion bodies solubilised in 5 M urea (Lane 4).  
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Figure 3.13: The localisation of plcInv3 from TOP10F’(pCplcInv3). (A) Immunoblot of 
periplasmic fractions (Lanes 1, 2 & 4), or cytoplasmic fractions (Lanes 5-7); Lane 3, SeeBlue 
protein marker; (B) Immunoblot of cytoplasmic and solubilised inclusion bodies of 
TOP10F’(pCplcInv3). Lane 1, cytoplasmic fraction pre-induction; Lane 2, insoluble fraction 
preinduction; Lane 3, SeeBlue protein marker; Lane 4, cytoplasmic fraction 1 h post-
induction; Lane 5, insoluble fraction 1 h post-induction.  
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Figure 3.14: IMAC purification of α-toxin truncates. Cell lysates were loaded onto a 
nickel-charged 1 mL sepharose column, washed with 80 mM imidazole (60 mM when using 
TOP10F’(pCplcInv3) cell lysate) and eluted with 200 mM imidazole. About 1-2 µg were 
loaded onto a SDS-PAGE, separated and stained with Coomassie blue. (A) Protein plc316 (B) 
Protein plc204 (C) Protein plc104 (D) Protein plcInv3. SeeBlue protein marker (Labelled M) 
loaded with samples. 
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Once purified from the cell lysates, imidazole was removed from the proteins by buffer 
exchange with 25 mM Tris using Centricon centrifugal filter units.  The proteins were 
concentrated using the same devices.  Concentration of refolded plc316 and plc204 in this 
manner resulted in the formation of protein aggregates.  This lead to a decrease in protein 
solubility by 12 and 7 fold in the case of plc316 and plc204 respectively.  Protein plc104 was 
concentrated to a higher degree without protein aggregation, but upon storage in 30% 
glycerol, 25 mM Tris at -20ºC, the protein began to aggregate over time.  Samples of plc104 
prepared in SDS loading buffer and stored at -20ºC for a couple of weeks were found to form 
aggregates of varying sizes on subsequent SDS-PAGE separation (Figure 3.15).  Three 
distinct bands were observed of approximately 56.6, 39.3 and 18.5 kDa in size.  Protein plc3 
and plcInv3 were soluble during concentration and buffer exchange and were stored at 
concentrations of up to 4 mg/mL. 
 
3.3.3 Properties and activities of α-toxin (plc3) and truncated proteins 
The activities of the cloned α-toxin were assessed with a number of assays.  Haemolytic, 
cytotoxic, and phospholipase activities were assessed using the HLA, MTT and p-NPPC/EYA 
assays respectively.  The assays were optimised to maximise the α-toxin activity and also 
used to assess the activities of the truncated α-toxin proteins. 
 
The rate of activity of plc3 on the hydrolysis of egg yolk was determined to be 1.07 mm/h 
when a 100 µg/mL solution of plc3 was dispensed into wells of an EYA plate.  When 
phospholipase activity of the truncated α-toxins on EYA was assessed, no activity was 
observed at concentrations up to 100 µg/mL of protein, or when clones carrying the vectors 
were streaked onto EYA plates and incubated overnight in the presence of IPTG. 
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Figure 3.15: Oligomerisation of plc104 following heating (5 min, 100ºC) and cooling in 
SDS sample buffer. 
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The haemolytic activity of the α-toxin and truncated proteins was assessed with the 
haemolysin liquid assay (HLA).  On optimisation of the assay using plc3, ZnCl2 alone 
between 1 µM and 1 mM had no effect on haemolysis of sheep erythrocytes and 10 mM 
CaCl2 alone resulted in minimal activity (Figure 3.16), whereas the addition of 10 µM ZnCl2 
to the reaction containing 10 mM CaCl2 resulted in a 12-fold increase in activity.  The 
combination of 10 µM ZnCl2 and 10 mM CaCl2 was taken as 100% activity and all other 
determinations were made from a comparison to this reference.  An increase to 100 µM ZnCl2 
in the presence of 10 mM CaCl2 again enhanced α-toxin activity by 2.6 times the reference 
activity.  Zinc chloride at levels of 1 mM were found to be inhibitory to the assay, and when a 
control sample of erythrocytes prepared in TBS was lysed in water in the presence of 1 mM 
ZnCl2 haemolysis was not observed. 
 
All α-toxin truncates were unable to lyse erythrocytes when concentrations of up to 100 
µg/mL were tested.  Whereas as little as 0.6 µg/mL of α-toxin was able to cause the lysis of 
50% (HU50) of the erythrocytes in the assay. 
 
Another assay used to determine the effects of calcium and zinc on α-toxin activity was the p-
NPPC assay first developed by Kurioka and Matsuda (1976).  In this assay, α-toxin in the 
presence of calcium was not effective at causing any p-NPPC hydrolysis at any concentration 
tested (between 0.1-10 mM) but zinc was most effective between 1 and 10 µM with α-toxin 
activity decreasing significantly (p<0.05) in the presence of 1 mM ZnCl2 (Figure 3.17). 
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Figure 3.16: The effects of zinc and calcium ions on the haemolysin activity of the alpha-
toxin (plc3). The percent haemolytic activity was defined as a percentage of the ratio of the 
test HU50 over HU50 of plc3 in the presence of 10 mM CaCl2 and 10 µM ZnCl2 (shaded 
green). HU50 was defined as the reciprocal of the toxin dilution required to lyse 50% of the 
sheep red blood cells under the experimental conditions. The starting dilution for all reactions 
was 50 µg/mL. 
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Figure 3.17: The effect of zinc on the rate of p-NPPC hydrolysis by α-toxin (plc3). A 
reaction mix of 200 µL was prepared containing 25 mM Tris, 0.15 M NaCl, 60% glycerol, 20 
mM p-NPPC, and 50 µg/mL plc3. Samples were incubated for an hour at 37ºC and the units 
of activity were calculated as the number of nmol of nitrophenol liberated per minute under 
the experimental conditions. 
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The cytotoxic effects of the α-toxin and its mutants were assessed via the MTT tissue culture 
assay.  The TCD50 for α-toxin was found to be 48.2 ng (or 0.24 µg/mL), whereas all α-toxin 
truncated proteins (plcInv3, plc316, plc204 and plc104) were unable to cause any cytotoxic 
effects in the CHO cell line when tested at concentrations up to 30 µg/mL. 
 
3.3.4 Further studies of plc104 and plcInv3 
The two soluble proteins, plcInv3 and plc104, were further characterised.  Their calcium and 
membrane binding abilities were examined in a number of assays.  Gel mobility assays of the 
α-toxin in the presence of calcium showed that both plc3 and plcInv3 bound calcium as 
observed by their reduced mobility through an 8.5% native PAGE gel (Figure 3.18).  Mobility 
of plc104 was harder to examine due to its small size and on a 12.5% native PAGE gel, no 
differential migration was observed.   
 
The binding of the toxins to erythrocytic membranes was analysed by two methods, a 
qualitative method involving α-toxin binding to a suspension of erythrocytic membranes in 
the presence or absence of Ca2+, followed by thorough washing and SDS-PAGE separation of 
the membrane suspension, and a quantitative method whereby the erythrocytic membranes 
were fixed onto a plastic support, followed by the addition of α-toxin, plcInv3 or plc104, in 
the presence or absence of calcium ions and the quantitation of binding assessed using an 
ELISA.   
 
The results of the qualitative calcium binding assay revealed that binding of plc3 and plcInv3 
was enhanced in the presence of Ca2+, whereas plc104 was isolated in the wash solution 
(Figure 3.19).  Its presence associated with erythrocytic membranes could not be seen in the 
presence or absence of Ca2+.  
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Figure 3.18: Gel mobility of α-toxin (plc3), plcInv3 and plc104 in the presence or 
absence of Ca
2+
. (A) Native PAGE of α-toxin. Lane 1 & 6, SeeBlue protein marker; Lane 2 
& 4, α-toxin + 20 mM CaCl2 + 10 mM EDTA; Lane 3 & 5, α-toxin + 10 mM EDTA. (B) 
Native PAGE of plcInv3. Lane 1 & 4, SeeBlue protein marker; Lane 2, PlcInv3+ 10 mM 
EDTA; Lane 3, PlcInv3 + 20 mM CaCl2 + 10 mM EDTA (C) Native PAGE of plc104. Lane 
1, Plc104 + 10 mM EDTA; Lane 2, Plc104 + 20 mM CaCl2 + 10 mM EDTA. 
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Figure 3.19: Erythrocyte membrane qualitative binding assay of α-toxin, plcInv3 and 
plc104. Proteins were incubated in an erythrocytic membrane suspension in the presence or 
absence of Ca2+ followed by thorough washing of the suspension and analysis by SDS-PAGE. 
Following transfer to a nitrocellulose membrane bound proteins were detected using horse 
anti-α-toxin polyclonal antisera. (A) Plc3 in the pelleted membranes. Lanes 1, 2, and 4, 
erythrocytic membranes with plc3 and Ca2+; Lanes 5, 6, and 7, membranes and plc3 without 
Ca2+; Lane 3, SeeBlue protein marker. (B) PlcInv3 in the pelleted membranes. Lanes 1, 3, and 
4, membranes and plcInv3 with Ca2+; Lanes 5, 6, and 7, membranes and plcInv3 without 
Ca2+; Lane 2, SeeBlue protein marker. (C) Plc104 in the supernatant of pelleted membranes. 
Lanes 2, 3 and 4, supernatant of membranes with Ca2+; Lane 1, SeeBlue protein marker. 
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To confirm the binding of plcInv3 to membranes and the absence of binding of plc104, the 
quantitative ELISA was done.  The results of the assay are displayed in Figure 3.20.  Binding 
of plc3 and plcInv3 to membranes was significantly enhanced (p<0.05) in the presence of 
Ca2+, whereas binding of plc104 to membranes was not enhanced in the presence of Ca2+. 
 
The results of membrane binding between protein samples could not be directly compared as 
polyclonal, and not monoclonal antibodies were used in the ELISA, which would result in 
misconstrued data for protein plc104 as this protein likely lacks a number of epitopes 
recognised by the horse polyclonal anti-α-toxin antisera.  Therefore the difference in binding 
within a protein sample in the presence and absence of Ca2+ was determined, and the 
difference obtained compared to the other protein samples.  Binding properties of plc3 and 
plcInv3 did not differ significantly, but the binding of plc104 was significantly less (p<0.05) 
compared to both plc3 and plcInv3 suggesting that this protein has lost its ability to bind to 
erythrocytic membranes. 
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Figure 3.20: Quantitative erythrocyte-membrane binding assay. Binding of proteins to 
membranes was assessed in the presence and absence of Ca2+ and detected using an ELISA 
assay with mouse polyclonal anti-α-toxin antisera. (A) Binding of proteins to membranes 
with and without Ca2+. (B) Calculated binding differences within each sample for direct 
comparison between proteins. The OD450 result from within a sample containing Ca
2+ was 
subtracted from the OD450 reading of the same sample without Ca
2. Plc3 and plcInv3 were not 
significantly different in their binding capacities. *Binding to erythrocytic membranes by 
plc104 was significantly lower than both plc3 and plcInv3 (p<0.05). 
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3.4 Discussion 
Cloning of plc has previously been achieved by a number of researchers (Leslie et al., 1989; 
Saint-Joanis et al., 1989; Titball et al., 1989; Tso and Siebel, 1989).  In this study, the plc of 
C. perfringens was cloned and expressed in E. coli, as a first step in creating non-toxic 
variants, for potential use as vaccines.  Expression and purification of the complete plc was 
aided by the presence of a 6xHis-tag located either at the N- (10plc2f) or C- (plc3) terminus 
of the α-toxin.   
 
The first of these proteins, 10plc2f, with the N-His tag, was isolated in inclusion bodies within 
the cytoplasm of the host.  This could suggest that the over-expression of α-toxin led to 
misfolding of the protein, but based on the literature of the structure of α-toxin, it is more 
likely that the integrity of the amino-terminus was compromised by the addition of the amino-
terminus His-tag (including the 36 vector coded aa’s) that replaced the α-toxin signal 
sequence.   
 
The binding of Zn2+ to the active site of α-toxin involves a number of residues scattered 
throughout different regions of the toxin (Nagahama et al., 1995; Guillouard et al., 1996; 
Naylor et al., 1998).  One of these residues, tryptophan 1 (Trp-1), is responsible for liganding 
one zinc molecule in the active site (Naylor et al., 1998) and in the mature toxin is buried 
within the molecule protected from attack by aminopeptidases (Nagahama et al., 1994).  The 
spatial position and not the nature of the side chain of Trp-1 is crucial for binding of the toxin 
to the zinc ion (Nagahama et al., 2000) and this spatial arrangement could have been 
disrupted by the addition of 36 vector encoded amino acids (which also included the 6xHis) to 
the N-terminus of Trp-1.  Trp-1 is localised to a hydrophobic pocket within the active site 
(Guillouard et al., 1996), and hindrance of Trp-1 to this position may have exposed the 
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hydrophobic active site to solvent leading to the formation of insoluble aggregates.  
Nagahama et al. (2000) examined the effects of the addition of two amino acid residues 
preceding Trp-1 (glycine and isoleucine) and although the protein remained soluble, a marked 
reduction in phospholipase C activities and the abolishment of haemolytic activities was 
observed.  In the current study, the addition of 36 instead of 2 aa’s may have lead to a more 
pronounced effect on toxin structure and stability. 
 
As can occur during high levels of expression of heterologous proteins in E. coli, a small 
proportion of the toxin remained soluble during expression (Fahnert et al., 2004) and was 
isolated in the cytoplasm.  This fraction was no longer able to bind to the IMAC column even 
at relatively low imidazole concentrations.  Lack of binding to the column may have been due 
to cleavage of the N-His tag by proteases.  As soluble protein expression from vector 
pR10plc2f was very low, further characterisation of α-toxin was obtained from protein plc3. 
 
Expression of plc3 was successfully achieved from E. coli TOP10F’cells harbouring pCplc3, 
a plasmid based on the TA cloning vector.  This vector is not an ideal vector for protein 
expression, as its lacZ promoter is not as efficient as other systems at over-expressing 
recombinant proteins (Amann et al., 1983; de Boer et al., 1983).  On analysis of the cloned 
plc sequence, a consensus Shine-Dalgarno sequence (S-D) such as GGAGG, GGAG, GAGG, 
AGGA 8-12 bp upstream of the initiation of translation codon was not present (Appendix 4).  
The lack of an S-D suggests that ribosomal RNA (rRNA) was able to bind directly to the plc 
initiation codon and begin translation.  This has been noted in a number of research articles, 
and what is becoming clear is that the S-D sequence is not obligatory for the successful 
expression of genes (Nakamoto, 2006), rather, accessibility of rRNA to the initiation codon is 
more important than the presence of a S-D sequence (Van Etten and Janssen, 1998).  The low 
level of purification (3 mg/L) of plc3 achieved in this study may have resulted from the low 
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level of translation achieved, on the other hand, the low level of translation may have 
prevented the formation of inclusion bodies as is so commonly seen in high-level expression 
systems where the dynamics of protein folding cannot keep up with the 
transcription/translation efficiency of the cell (Ellis, 1997).  The incorporation of a S-D 
sequence 8-12 bp upstream of the plc initiation codon could be used to determine if its 
presence alters expression levels. 
 
3.4.1 Alpha-toxin activities 
The haemolytic activity of α-toxin provides a strong indication of its toxicity in living 
organisms (Jepson et al., 1999) therefore a haemolytic assay was established to determine the 
presence of residual toxicity of the truncated α-toxins.  On optimisation of this assay using 
plc3, Ca2+ in the form of CaCl2 at a level of 10 mM was required for efficient lysis of sheep 
red blood cells in the presence of 100 µM Zn2+.  Calcium is required at much higher levels 
than Zn2+ as it binds to α-toxin with a very low affinity (Guillouard et al., 1997; Naylor et al., 
1999).  On the other hand excess Zn2+ at levels of 1 mM was inhibitory to the assay.  On 
closer examination of this inhibitory effect, it was found that 1 mM Zn2+ inhibited the osmotic 
lysis of a 1% suspension of sheep red blood cells prepared in TBS, therefore this inhibition 
was unrelated to the α-toxin activity and was a consequence of reversible binding of zinc to 
the erythrocyte cells (Avigad and Bernheimer, 1976).  Osmotic lysis of erythrocytes is not 
suppressed by high levels of Zn2+ when only in the presence of water (Avigad and 
Bernheimer, 1976) but the presence of Tris (>10 mM) precipitates released hemoglobin 
(Takeda et al., 1977) projecting the illusion of inhibited lysis. 
 
As inhibition of haemolysis by α-toxin in the presence of Zn2+ was found to be unrelated to 
the inhibition of α-toxin activity, hydrolysis of p-NPPC was used to assess the effects of Zn2+ 
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and Ca2+on the α-toxin (Kurioka and Matsuda, 1976).  Calcium ions had no effect on the 
hydrolysis of p-NPPC as would be expected as Ca2+ is only necessary for the binding of α-
toxin to membrane packed and not mono-dispersed phospholipids (Titball et al., 1991).  Zinc 
was very effective at increasing the rate of p-NPPC hydrolysis between 1 and 10 µM, and 
there was a significant decrease in the rate of p-NPPC hydrolysis when 1 mM Zn2+ was added 
to the assay (as ZnCl2). 
 
It appears from the results that Zn2+ are stimulatory at low concentrations but inhibitory at 
high concentrations in the p-NPPC assay.  A possible explanation for this involves the 
activation of the active site.  Two molecules of zinc are tightly bound to the active site of α-
toxin (Krug and Kent, 1984; Nagahama et al., 1995; Nagahama and Sakurai, 1996).  A third 
molecule of zinc is also regularly found liganded to the toxin, but this site is a loosely bound 
interchangeable region that can accommodate the binding of other divalent cations such as 
cobalt or manganese (Nagahama et al., 1995; Nagahama and Sakurai, 1996).  This third 
loosely bound cation is necessary for activity of the toxin (Nagahama et al., 1995; Nagahama 
et al., 1997).  Closed and open forms of α-toxin have been observed using crystallography 
and each contains two and three atoms of zinc respectively (Naylor et al., 1998; Titball et al., 
2000; Eaton et al., 2002).  Catalysis of substrate may require continual exchange between the 
two forms for efficient hydrolysis, and the presence of excess zinc may hinder the efficient 
catalysis of p-NPPC (a mode of direct inhibition) by saturating the cocatalytic sites.   
 
Similar findings of zinc inhibition at high Zn2+ concentrations have been reported for some 
mono-zinc metalloenzymes such as thermolysin, carboxypeptidase and endopeptidase 
(Holmquist and Vallee, 1974; Kerr and Kenny, 1974; Mallya and Van Wart, 1989; Gomez-
Ortiz et al., 1997). 
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Further enzyme studies are required to determine the kinetics of the inhibition observed in the 
p-NPPC assay. 
 
3.4.2 Characterising deletions 
Truncation of the plc was based on two strategies.  Deletion of bases from the 5’ end (N-
terminal end of translated protein) and the truncation of areas within the plc known to be 
important for the catalytic activity of the expressed mature enzyme.   
 
Deletion of the first 54 or 166 amino acids of α-toxin resulted in the production of proteins 
plc316 and plc204 respectively.  Expression of both these proteins led to inclusion body 
formation within the cytoplasm of BL21pLysS cells.  pRSETA is a strong expression vector 
and it is likely that inclusion bodies formed due to the high expression levels of the vector.  
Inclusion body formation of recombinant proteins from high expression vector systems is 
very common and occurs due to a highly unfavourable protein-folding environment caused by 
the high macromolecular crowding of recombinant protein (Ellis, 1997; Sorensen and 
Mortensen, 2005).  The level of translation far exceeds the process of protein folding leading 
to aggregation of intermediates with surface exposed hydrophobic patches normally buried 
within the interior of the protein molecule (Ellis, 1997; Fahnert et al., 2004).  Methods to 
decrease inclusion body formation include reducing the growth temperature of the 
recombinant bacterium and reducing the induction process, both of which were attempted in 
this study but to no avail.  The co-expression of chaperones has had some success in 
increasing the rate of soluble protein present in a cell, and this could be further examined in 
the future (Ellis, 1997; Sorensen and Mortensen, 2005). 
 
The formation of inclusion bodies does have its benefits, such as ease of purification, high 
level of production, and resistance to protease cleavage (Fahnert et al., 2004) and both 
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proteins were isolated from inclusion bodies and solubilised in urea to a relatively high level.  
The disadvantage of isolating and purifying proteins from inclusion bodies is that a relatively 
low yield is obtained following refolding of protein in non-denaturing solutions.  Refolding of 
urea-solubilised plc316 and plc204 was attempted whilst bound to a Ni2+ charged resin 
column.  Refolding of the proteins by this manner was successful but over time both proteins 
began to aggregate whilst in storage and during buffer exchange with the Centricon 
centrifugal devices.  The cause for the re-aggregation of both proteins is uncertain, but it may 
be that the deletions of α-helices from the N-terminus of α-toxin which are also involved in 
the stability of the catalytic domain of the toxin led to the destabilisation of the toxin moiety, 
with the exposure of the hydrophobic pocket, eventually leading to aggregation of monomers 
with exposed hydrophobic residues (Nagahama et al., 1995; Guillouard et al., 1996; 
Nagahama et al., 1997; Naylor et al., 1998).   
 
The third truncate, plc104 is composed of the C-terminal β-barrel domain.  Truncates 
composed entirely of the C-terminal domain (cpa247-370) have previously been shown to retain 
their ability to bind membranes, but lack any detectable enzymic activities (Titball et al., 
1993; Nagahama et al., 1998; Naylor et al., 1998).  Truncate plc104 is smaller than these 
previously expressed truncates in that it is only composed of 7 of the 8 β-sheets, as the first β-
sheet comprising aa’s 256-265 has been deleted (Titball et al., 1993).   
 
One major difference between plc104 and the previously cloned and characterised C-terminal 
domain is the inability of plc104 to bind calcium.  Gel mobility assays of plc104 exhibited no 
observable differential migration in the presence and absence of Ca2+.  Calcium ions bind to 
α-toxin with a low affinity, but in association with phospholipids, this affinity can be 
enhanced 1000-fold (Rizo and Sudhof, 1998; Naylor et al., 1999), therefore a number of 
membrane binding assays were attempted. 
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Membrane binding of α-toxin can only occur in the presence of Ca2+ , and the presence or 
absence of Ca2+ in membrane binding assays with plc104 did not lead to enhanced membrane 
binding abilities suggesting that plc104 has lost its ability to bind Ca2+ and phospholipid 
membranes.  Lack of membrane binding can be attributed to the deletion of the first β-sheet 
encountered in the C-terminal domain, β1.  The β-sandwich sheets of the C-domain are 
structured to resemble a scaffold which allows the emergence of variable loops at the top and 
bottom of the domain (Rizo and Sudhof, 1998).  These loops are involved in calcium binding 
and determine the functional specificity of the domain (Naylor et al., 1998; Rizo and Sudhof, 
1998; Naylor et al., 1999).  Residues required for calcium binding are located on loop-β1/β2 
(located between sheets β1 and β2), loop-β3/β4 (between sheets β3 and β4) and loop-β5/β6 
(between sheets β5 and β6) (Guillouard et al., 1997; Naylor et al., 1998; Naylor et al., 1999; 
Walker et al., 2000; Jepson et al., 2001) and all loops are found in a cluster at one end of the 
structure, held together by the β-sheets.  Loop-β1/β2 is involved in the liganding of two Ca2+, 
the highest affinity calcium binding site Ca1, and the lower affinity Ca3 site (Guillouard et 
al., 1997; Naylor et al., 1998; Naylor et al., 1999; Jepson et al., 2001).  The deletion of β1 in 
the development of plc104 may have disorganised the structure of this loop, creating a linear 
rather than a loop topology, leading to the disruption of calcium liganding at the two sites, 
possibly three if the tertiary structure of truncate has been compromised.  Probe studies with 
monoclonal antibodies could be used to determine the degree of structural change in plc104. 
 
One other consequence of deleting β1 may have been the destabilisation of the protein.  
Polymers of plc104 were observed after native and SDS-PAGE analysis of the sample (Figure 
3.15).  The three bands observed on the gel equate to dimers and trimers of the plc104.  
Deletion of β1 may expose non-polar residues of β2 which include methionine, phenylalanine 
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and isoleucine to solvent (Naylor et al., 1998).  Over time, clustering of plc104 molecules 
may occur in these regions, leading to the oligomer formation observed after gel analysis.   
 
Despite the lack of membrane binding and slight insolubility developed over time, plc104 
retained epitopes recognised by polyclonal antisera against the α-toxin, whilst remaining non-
haemolytic and non-cytotoxic.   
 
The final truncate, plcInv3 was created from an internal deletion of plc previously cloned into 
vector pCR2.1.  Unlike plc316 and plc204, where the deletion of the N-terminus resulted in 
misfolding of the toxin, a deletion of an internal region of the N-terminus important in the 
functioning of the activity of the α-toxin did not result in an insoluble mass, and retained its 
structural integrity.  Evidence to support this includes the recognition of plcInv3 by 
polyclonal antisera against the α-toxin, the ability to bind calcium and migrate differentially 
on a native gel and the ability to bind erythrocytes in the presence of excess Ca2+.  All these 
features were present in the absence of enzymic activity and hence toxicity.  The use of 
monoclonal antibodies to confirm the integrity of epitopes could also be done to further assess 
the conformational differences between plc3 and plcInv3. 
 
PlcInv3 lacks aa residues 56-75 of the mature α-toxin.  This region forms part of a mobile 
loop encompassing aa residues 55-90 and is important for communicating between the N- and 
C-terminal domains (Eaton et al., 2002).  In the closed form of the α-toxin this loop region 
folds into an α-helix not present in the open form.  Aspartate (Asp)-71 is hydrogen bonded to 
lysine-201, and a salt bridge is formed between the side chains of aspartate-75 and arginie-99.  
These interactions hold the loop in place away from the membrane binding plane and stabilise 
the newly created α-helix composed of aa’s 73-80 (Eaton et al., 2002) in order to obstruct the 
active site.  On binding of the C-terminal domain to membranes a conformational shift 
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triggers the collapse of the α-helix, the reformation of the complete loop, which then exposes 
the active site to the membrane.  The alignment and insertion of the active site cleft into the 
phospholipid membrane occurs via polar residues followed by the cleavage of the 
phospholipid tail (Nagahama and Sakurai, 1996; Eaton et al., 2002; Nagahama et al., 2006).  
Upon cleavage, α-toxin is released, and returns to its closed conformation (Eaton et al., 
2002). 
 
Protein plcInv3 lacks part of this flexible loop, and the shortened loop present may be unable 
to alternate between the open and closed forms of the toxin rendering the toxin inactive.  The 
absence of the essential residues, tyrosine-57, tyrosine-65 , phenylalanine-69, threonine-74 
(highlighted in Figure 3.8) would prevent binding and insertion of α-toxin into biological 
membranes (Guillouard et al., 1996; Nagahama and Sakurai, 1996; Nagahama et al., 1997; 
Nagahama et al., 2006).  The deletion of histidine-68 and aspartate-56 would also alter the 
binding efficiency of at least 2 zinc molecules (Nagahama et al., 1995; Nagahama et al., 
1997; Eaton et al., 2002; Nagahama et al., 2006). 
 
Indirect evidence that plcInv3 binds less (if any at all) Zn2+ is seen during the washing steps 
of IMAC.  The reduced ability of plcInv3 to bind Ni2+ on the IMAC reflects the reduction in 
the number of zinc binding domains present.  The exact number of Zn2+ ions able to bind 
plcInv3 was not calculated, and could be determined in the future with the use of atomic 
absorption spectrophotometry. 
 
As plcInv3 mimics the binding properties of α-toxin, it may have potential use as a probe to 
further determine the nature of the α-toxin receptor on biological membranes, without the 
lytic and toxic side-effects.  
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One interesting feature of TOP10F’ cells harbouring vector pCplcInv3 was the difference in 
growth rate observed when compared to pCplc3, its parent vector.  Apart from a 60 bp 
deletion within plc, cells harbouring pCplc3 and pCplcInv3 were identical, yet the latter 
transformant constantly took almost twice as long to grow to mid-log phase, and produced 
much less protein than pCplc3 harbouring cells (1.5 mg/mL vs. 3.5 mg/mL).   
 
Usually an impaired growth rate is observed in response to high levels of heterologous protein 
expression within E. coli (Hoffmann and Rinas, 2004).  This is a direct response to the high-
energy requirements induced by recombinant protein synthesis, leading to the synthesis of 
stress proteins and elevated respiration rates (Hoffmann and Rinas, 2004).  High levels of 
plcInv3 expression were not observed following induction, and strict control of expression 
was not maintained due to the expression system used, therefore the reduced growth rate 
observed with cells harbouring plcInv3 can not be attributed to high levels of protein 
expression, but is more likely due to the characteristic properties of protein plcInv3 taking 
effect during leaky expression.  
 
PlcInv3 may be much more unstable than plc3, leading to increased protease activity by the 
E. coli host, in effect leading to enhanced respiration and the observed decrease in growth rate 
(Schmidt et al., 1999; Rozkov and Enfors, 2004).  The complete degradation of plcInv3 did 
not occur as the protein was evident during induction and growth phases of bacteria, unlike 
the protein degradation observed by Schmidt et al., (1999) where protein was not evident in 
an immunoblot after an hour induction with IPTG.  Future studies such as pulse labelling 
experiments could be used to show whether the majority of plcInv3 is degraded upon its 
expression (Viaplana et al., 1997).  Another cause for the up-regulation of stress-responses 
leading to increased respiration could be due to the interaction of plcInv3 with the host cell 
membranes.  During its translocation into the periplasm, plcInv3 may interact with the 
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membranes in a way that more energy is required for maintenance of the membrane potential 
of the host, leading to increased protease activity and degradation of the protein (Viaplana et 
al., 1997). 
 
Reduced plcInv3 expression levels could also be caused at the translational level by the 
formation of secondary mRNA structures that obstruct rRNA binding to the initiation codon 
of plcInv3.  This would reduce translation efficiency resulting in lowered plcInv3 expression 
levels (Wikstrom et al., 1992).   
 
Analysis of the host gene expression pattern via its transcriptome or proteome could be used 
to identify changes in synthesis of host cell proteins during the recombinant protein 
production phase (Hoffmann and Rinas, 2004; Schweder and Hecker, 2004).  This knowledge 
could then lead to determining what and where this recombinant expression-specific host 
stress response is occurring. 
 
In conclusion, an active form of α-toxin engineered with a C-His tag was created and 
successfully purified from E. coli.  The α-toxin, named plc3 retained all of its enzymic 
properties and was recognised by polyclonal antisera against the α-toxin.  A number of α-
toxin mutants were also successfully cloned and purified from E. coli.  The level of solubility 
of the concentrated proteins varied somewhat, but none of them retained any haemolytic, 
cytotoxic or phospholipase C activities whilst still being recognised by polyclonal antisera.  
The immunogenicity of these proteins will be further assessed in animal studies as a first step 
in determining their potential as vaccine candidates. 
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 Chapter 4 
Immunogenicity of α-toxin mutants and their potential as 
protective vaccines 
 
4.1 Introduction 
The α-toxin of C. perfringens is a major contributing factor in the development of necrotic 
enteritis (NE) in avian species (Al-Sheikhly and Truscott, 1977b; Al-Sheikhly and Truscott, 
1977c; Fukata et al., 1988; Lovland et al., 2003; McCourt et al., 2005).  It acts by arresting 
the migration of neutrophils and platelets to the site of infection by promoting their 
aggregation adjacent to but not at the infectious site (Bunting et al., 1997; Bryant et al., 
2000a; Bryant et al., 2000b), and reduces sodium dependant glucose absorption from the gut 
contributing to the diarrhoea observed in cases of NE (Rehman et al., 2006).  Antibodies 
developed against the cells of C. perfringens alone do not afford protection against a 
C. perfringens infection (Traub et al., 1991) and antibodies directed towards the toxins, in 
particular α-toxin, are necessary (Traub et al., 1991).  Therefore prevention of NE and other 
diseases of C. perfringens would require vaccination against the exoenzymes it produces. 
 
Retrospective immunological analysis of commercial poultry flocks reveals a significant 
association between the occurrence of C. perfringens associated hepatitis (CPH) or sub-
clinical NE at slaughter and the increased presence of a specific antibody response to α-toxin 
(Lovland et al., 2003).  The presence of higher anti-α-toxin antibodies also results in less 
mortality (Heier et al., 2001).  Protection from the lethal effects of the α-toxin have also been 
demonstrated in birds administered anti-α-toxin antibodies prior to challenge with 
C. perfringens (Fukata et al., 1988).  These studies demonstrate the ability of birds to develop 
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an antitoxin response against the α-toxin and the presence of these anti-α-toxin antibodies 
results in a decreased mortality rate.  The development of vaccines targeting the α-toxin could 
reduce the risks of NE in chickens, and save thousands of dollars in revenue lost from this 
disease (van der Sluis, 2000).   
 
Experimental reproduction of NE in chickens is quite complex and involves a number of 
predisposing factors, which even when present cannot guarantee the reproduction of the 
disease (explored in Chapter 1.6.3.3) (Cowen et al., 1987; Elwinger et al., 1992; Kaldhusdal 
et al., 1999), therefore, another model to determine the effectiveness of an α-toxin vaccine is 
necessary.  One such model is the gas-gangrene model in mice.  Studies have shown that α-
toxin is the major contributing factor in the disease, and therefore this model could be used to 
examine the efficacy of recombinant α-toxin proteins as potential vaccine candidates 
(Ninomiya et al., 1994; Awad et al., 1995; Awad et al., 2000) . 
 
Gas-gangrene is characterised by the production of gas within the tissues as a result of 
C. perfringens metabolism, accompanied by the production of numerous toxins (Shimizu et 
al., 2002a).  The toxins act by reducing the oxygen tension in the infected area, allowing the 
proliferation of C. perfringens, and also as a spreading factor, degrading tissues and allowing 
for the migration of the bacterium throughout the body (Shimizu et al., 2002a).  The α-toxin 
causes intravascular coagulation (Barzaghi et al., 1988; Ninomiya et al., 1994; Bunting et al., 
1997; Ellemor et al., 1999), reduced perfusion and the development of thrombosis, all of 
which lead to a reduced oxygen flow to the infected area (Bryant et al., 2000a; Bryant et al., 
2000b).  Cyanosis ensues followed by the necrosis of deoxygenated tissues, leaving the area 
swollen, necrotic and black.  The synergistic activity of the toxins decreases the viscosity of 
ground substances in connective tissue and allows the migration of C. perfringens into deeper 
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tissues, where the continuous production of α-toxin eventually leads to shock and death 
(Stevens and Bryant, 1997; Shimizu et al., 2002a). 
 
A number of truncated α-toxin proteins have been developed (Chapter 3) and their residual 
toxin activity determined to be non-existent making them ideal candidates for immunisation 
and challenge trials in mice.  This chapter explores their potential for use as vaccines targeted 
against the α-toxin of C. perfringens using a Murine gas-gangrene model. 
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4.2 Materials and methods 
4.2.1 Protein preparation 
Proteins plc3 (α-toxin), plcInv3, plc316, plc204 and plc104 developed in Chapter 3 (Table 
4.1) were purified to homogeneity as described in Chapter 3.2.4.  Tris was removed from 
protein samples by buffer exchange with PBS using Centricon centrifugal devices and the 
proteins were concentrated using the same devices. 
 
4.2.2 Toxoid preparation  
Formaldehyde (Sigma-Aldrich) was added directly to a solution of plc3 (prepared in PBS at a 
concentration of 1 mg/mL) to give a final concentration of 0.4% (v/v) formaldehyde.  The 
mixture was incubated at 37ºC overnight on a rotating platform.  Toxin inactivation was 
confirmed by the addition of 40 µL of formaldehyde treated sample to wells bored into a 
Nagler and SBA plate in the presence of 10 mM CaCl2.  Residual formaldehyde was removed 
by buffer exchange with PBS in Centricon centrifugal filters and the protein content of the 
solution was reconfirmed by the Bradford method, as protein losses during buffer exchange 
could be quite high. 
 
4.2.3 Adjuvant preparation 
Prior to vaccinations, inactivated plc3 (toxoid) and truncated α-toxin proteins plcInv3, plc316, 
plc204 and plc104 were prepared in an equal volume of Freund’s incomplete adjuvant (FIA) 
(Sigma) following the protocol outlined in Ausubel, (1994). 
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Table 4.1: Description of the α-toxin truncated proteins used in this study as potential 
vaccine antigens for the development of immune responses targeted against the α-toxin. 
Protein Description Location of His tag 
plc3 The complete α-toxin of C. perfringens. C-terminus 
plcInv3 Plc3 with an internal deletion of aa residues 
56-75 which encompass two zinc binding 
residues essential for phospholipase C activity. 
C-terminus 
plc316 The α-toxin with the deletion of the first 55 
aa’s of the mature toxin (deletion of the first 
three α-helices of the N-terminal domain). 
N-terminus 
plc204 The α-toxin with a deletion of the first 166 aa’s 
of the mature toxin (deletion of the first 7 α-
helices of the N-terminal domain).  
N-terminus 
plc104 The α-toxin with the deletion of the first 266 
aa’s of the mature toxin (deletion of the 
complete N-terminal α-helical domain and the 
first β-sheet of the C-terminal domain) 
N-terminus 
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In brief, an emulsion was prepared by drawing up and expelling equivalent volumes of protein 
and FIA through a 21 gauge needle in a 3 mL glass syringe until the fluidic suspension 
increased markedly in viscosity and was no longer able to disperse when a drop was placed in 
a  glass beaker of cold water.  Vaccines prepared in adjuvant were used within 6 h of 
preparation. 
 
4.2.4 Mouse immunogenicity trial 
Six groups, each containing seven female BALB/c mice (6-8 week old) were vaccinated via 
the intraperitoneal route using a 1 mL syringe and 21 gauge needle with 50 µL of 
protein:adjuvant emulsion.  The groups consisted of a PBS:FIA control, toxoid(plc3):FIA, 
plcInv3:FIA, plc316:FIA, plc204:FIA and plc104:FIA.  Mice were vaccinated on days 1, 15, 
and 37 with 5, 25, and 50 µg of protein respectively.  Mice were bled prior to each 
vaccination and thrice more following the final vaccination at intervals between 14-20 days. 
 
4.2.4.1 ELISA 
Antibody responses of vaccinated mice were measured using the ELISA as outlined in 
Chapter 2.8.8 with a few modifications.  Wells were coated with 3 µg/mL of purified α-toxin 
(plc3).  Doubling dilutions of sera obtained from vaccinated mice were used as the primary 
antibody, and goat anti mouse IgG-HRP (diluted 1:5000 in PBST/1% skim milk) was used as 
the secondary conjugated antibody.  Following the addition of the substrate TMB, plates were 
incubated for 15 min before the addition of 50 µL of a 1 M solution of sulphuric acid.  The 
endpoint was determined as the dilution at which the optical density (OD) at a wavelength of 
450 (OD450), was 3 times the background level (determined as an approximate OD of 0.2).   
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4.2.5 Antibody purification 
One millilitre gravity flow columns were packed with a combination of 250 µL of Protein G 
Sepharose 4 Fast Flow (Amersham Biosciences) and 250 µL of Protein A Sepharose 4 Fast 
Flow (Amersham Biosciences).  The columns were washed with PBS prior to loading of 
serum samples.  Sera obtained from mice within the same group were pooled and diluted by 
half with 2 x PBS.  Diluted sera were loaded on the column, unbound protein was washed out 
with 10 column volumes (CV) of PBS and antibodies were eluted with 0.1 M glycine, pH 3.0.  
Eluted antibody was collected in 500 µL lots into 1 mL tubes containing 50 µL 1 M Tris, pH 
9.0 to neutralise the effects of the acidic elution buffer.  The sepharose was regenerated by 
washing with an additional 3-4 CV of elution buffer followed by re-equilibration with 3-4 CV 
of PBS.  Strongly bound hydrophobic proteins, lipoproteins and lipid were removed by 
cleaning in place procedures which included washing the sepharose column with 2 CV of 50 
mM NaOH in 1.0 M NaCl and 2 CV of 70 % ethanol.  Five CV of PBS was added between 
the two cleaning steps. 
 
Removal of glycine from immunoglobulins isolated by this procedure was achieved by buffer 
exchange with 25 mM Tris, pH 7.4, in VivaSpin 0.5 mL 10 kDa cut-off concentrators 
(Satorius group) according to the manufacturer’s instructions.  Protein content of the 
immunoglobulins was determined using the Bradford assay (Chapter 2.8.2.1) 
 
4.2.6 Toxin neutralisation assays 
The MTT cytotoxicity assay (Chapter 3.2.5.4) was used to test the α-toxin neutralising 
abilities of the antisera obtained from vaccinated mice.  Antiserum (50 µL lots containing 
0.15 mg/mL to 20 mg/mL protein) was heat inactivated at 56ºC for 30 min prior to use and 
then mixed with 50 µL of α-toxin (20 µg/mL).  After 30 min at 37ºC the 100 µL samples 
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were dispensed into wells of a 96-well plate previously seeded with 2 x 104 CHO cells.  The 
MTT assay was performed as described in Chapter 3.2.5.4. 
 
The assay was unsuccessful (see Section 4.3.2) and therefore the neutralising effects of the 
antiserum was assessed using the p-NPPC assay described in Chapter 3.2.5.5.  Serum (40-160 
µg) inactivated at 56ºC for 30 min or purified polyclonal antibodies (49-114 ng) were mixed 
with 2 µg (for serum samples) or 4 µg (for purified immunoglobulins) of α-toxin (plc3), in a 
final volume of 20 µL, for 30 min at 37ºC.  Following the incubation, the toxin activity was 
assessed with the p-NPPC assay in a fluoSTAR OPTIMA plate reader set to 37ºC with a 
shaking interval of 1 minute prior to each 5 min reading.  Samples were repeated in triplicate 
for the unpurified sera and quadruplicate for the purified immunoglobulins.  One unit was 
equivalent to the hydrolysis of 1 nmol of p-NPPC in 1 min under the specified conditions. 
 
4.2.7 Mouse challenge trials 
4.2.7.1 Vaccination regime 
Groups of seven BALB/c female mice (6-8 week old) were vaccinated on days 1, 14 and 28 
with 14, 25, and 50 µg of a protein:FIA emulsion in a total volume of 100 µL via the 
intraperitoneal route.  Proteins plcInv3 and plc104 (developed in Chapter 3) were used as the 
test vaccines, and plc3 toxoid was used as a positive control.  A fourth group consisting of 
vaccination with an unrelated bacterium (S. Typhimurium aroA-) was used as the negative 
control throughout this study.  The control group was previously vaccinated with 109 
attenuated S. Typhimurium (STMI) cells via the oral route using a gavage needle (Alderton et 
al., 1991).  Mice were challenged with either α-toxin or C. perfringens two weeks following 
the final vaccination as described below. 
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4.2.7.2 Toxin challenge 
Mice vaccinated as in Section 4.2.7.1 were administered five times the lethal dose (5 µg) of 
purified α-toxin (plc3) via the intraperitoneal route in a total volume of 100 µL (Williamson 
and Titball, 1993; Schoepe et al., 1997; Jepson et al., 1999).  Mice were observed 
continuously for the first 4 h, hourly for the next 6, and twice daily thereafter.  When three or 
more major signs of toxicity were observed (Table 4.2) mice were sacrificed by cervical 
dislocation.  In most circumstances many of these clinical signs were not observed, therefore 
when mice reached recumbency they were sacrificed immediately and time of death was 
recorded for a comparison to other groups. 
 
4.2.7.3 C. perfringens challenge  
C. perfringens strain 60, a field isolate obtained from a chicken with clinical signs of necrotic 
enteritis was used as the challenge organism (Table 2.1).  One percent (v/v) of an overnight 
culture of C. perfringens 60 grown in thioglycollate broth was used to inoculate bottles 
containing 500 mL of freshly prepared and autoclaved thioglycollate broth.  To avoid oxygen 
exposure to the bacterium, a lid with a rubber septum was used to seal the bottle, and the 1% 
inoculum was injected into the bottles with a syringe.  The rubber septum was first sterilised 
with 80% (v/v) ethanol.  The culture was grown for 4 h at which time approximately 5 x 108 
cfu/mL was reached.   
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Table 4.2: Signs of toxicity observed in mice following intraperitoneal injection of 5 µg 
of α-toxin (plc3). 
 
 Acute clinical signs 
1  Increased respiration (panting) 
2 Impaired eye and pedal reflexes 
3  
 
Pallid mucous membranes or 
ears (paleness) 
4  Recumbency (animals lay limp) 
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The culture was pelleted by centrifugation in sterilised 250 mL autoclave bottles at 10,000 x g 
for 10 min, the supernatant discarded and the pellet washed in sterile saline, repelleted as 
above and resuspended in a final volume of 3 mL saline (including bacterial volume).  Mice 
received 50 µL containing approximately 4 x 109 cells by an intramuscular injection to the left 
thigh.  The right thigh was left unchallenged as an internal control.  Mice were monitored 
closely for the first 4 h, and every 6-8 h for the following 72 h.  Severity of gangrene in the 
mice was determined using an index calculating the severity of infection of challenged mice 
(Table 4.3). Mice were examined and scored according to Table 4.3 every 8 h for the first 48 
h post-challenge and the examination of mice was completed by an individual unaware of the 
vaccination or challenge status of the mice.   
 
4.2.8 Statistical analysis 
All statistical analysis was calculated using the program SPSS v13.0.  The results of all 
ELISA assays for the detection of anti-α-toxin antibodies were transformed by log2 in order 
to produce a data set with an equal variance (Dytham, 2003).  The transformed data of the 
immunogenicity trial (Section 4.2.4) were analysed by an ANOVA and included the Tukey’s 
HSD (Tukey, 1953) post-hoc analysis to determine differences between groups of vaccines. 
 
Independant Student’s t-tests were used to analyse the results of the p-NPPC assays. 
 
Log2 transformed titres obtained from challenge trials (Section 4.2.7) were analysed using the 
independent Student’s t-test ("STUDENT", 1908) and data obtained from mice challenged 
with α-toxin were analysed using the nonparametric Mann-Whitney U rank test (Mann and 
Whitney, 1947) as data could not be transformed to obtain a homogenous variance (Dytham, 
2003).
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Table 4.3: The index used to score mice infected with C. perfringens.  The reduced 
perfusion of vessels and migration of C. perfringens is inadvertently observed via the swelling 
(oedema of infected thigh and gas production by C. perfringens) and blackening (cyanosis) of 
the injection site, and eventual gas-gangrene development towards the foot pad.  
 
Score Clinical signs 
0 Swelling/limping of infected thigh 
1 Cyanosis (blackening) at the 
injection site 
2 Spread of cyanosis to the thigh 
surrounding injection site 
3 Spreading of cyanosis to 
ankle/Swelling of foot pad 
4 Blackening of complete foot pad 
(sacrifice)/mouse found dead 
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4.3 Results 
4.3.1 Immunogenicity of vaccines 
The mouse immunogenicity trials were undertaken to determine the ability of each of the α-
toxin truncates to produce antisera directed towards the α-toxin.  A control vaccination of 
PBS alone was included to confirm the antibody response developed was specific to the 
vaccine in question.  The antibody responses of mice to the different proteins over an 11 week 
period are presented in Figure 4.1.  Levels of IgG were not seen prior to the second 
vaccination with any of the vaccines, including the plc3 toxoid.  Overall, the antibody 
responses to the vaccines peaked between days 46 and 60, with a decline thereafter.  Antibody 
responses at day 60 are shown in Figure 4.2.  The immunogenicity of the different vaccines 
can be separated into two groups, those that stimulate a high antibody production and low 
antibody production.  Proteins plc316 and plc204, showed the lowest production of anti-α-
toxin IgG at a significantly reduced level (p<0.01) when compared to all other vaccines in an 
ANOVA (with Tukey’s HSD post-hoc analysis).  This reduced antibody detection was 
observed at all other time-points as well. 
 
4.3.2 Neutralising activities of antibodies 
Complement inactivated mouse serum from mice immunised with the various α-toxin 
truncated proteins (Table 4.1) was assessed for its α-toxin neutralising effects on the CHO 
cell line using the MTT cytotoxicity assay.  Neutralisation of α-toxin activity was 
unsuccessful when unpurified sera was used in this assay.   
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Figure 4.1: IgG responses of BALB/c mice vaccinated with a number of different alpha-
toxin truncated vaccines. Sera obtained from mice were assessed with an ELISA for the 
production of anti-α-toxin specific IgG.  The titres are representative of the reciprocal dilution 
of the end-point (given as an OD450 of 0.2). Green arrows indicate days of vaccination (Day 1, 
Day 15, and Day 37).  Antibodies were not measurable before day 30. 
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Figure 4.2: Day 60 IgG ELISA results of immunogenicity trial. The titre was calculated as 
the reciprocal (log2) dilution of the end-point (given as an OD450 of 0.2).  Bars with different 
letters are significantly different from each other (p<0.05) when analysed using an ANOVA 
with Tukey’s HSD post-hoc analysis.  Each histogram is the average result and range of titres 
from 6 mice in a group. The control (PBS vaccinated mice) as per Figure 4.1 showed no 
measurable response and is omitted from the graph. 
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The presence of serum components (such as hormones, proteins etc.)  enhanced the growth of 
the cell-line making it impossible to detect any neutralising affects of antiserum from 
vaccinated mice, therefore, the p-NPPC assay was trialled as this assay is specifically 
designed to measure the phospholipase C activity of the α-toxin (Kurioka and Matsuda, 
1976).   
 
When heat inactivated serum from immunised mice was used to neutralise α-toxin in the p-
NPPC assay, a change in the rate of hydrolysis was observed, but in the opposite direction 
from that expected.  The presence of serum components in the p-NPPC assay significantly 
enhanced (p<0.05) the rate of hydrolysis of p-NPPC by α-toxin whether serum from 
vaccinated mice or control serum was used (Figure 4.3).  This effect was seen irrespective of 
whether a smaller (40 µg) or larger (160 µg) serum sample was tested (Figure 4.4). 
 
As serum components were influencing the assay, serum from mice in the same groups were 
pooled, and the immunoglobulins (Ig’s) isolated using Protein A/G columns.  Low levels of 
Ig’s were obtained and assuming the Ig’s were mostly composed of IgG of MW 146,000 Da, 
the total amount of Ig’s obtained was between 150 and 342 ng.  The molar ratio of purified Ig 
to alpha-toxin (plc3) used in the p-NPPC assay was was; 1:109 for plcInv vaccinated mice; 
1:254 for plc104 vaccinated mice; and 1:152 from toxoid vaccinated mice.  Even though there 
were not enough immunoglobulins to saturate and completely neutralise the α-toxin, each 
sample significantly reduced (p<0.001) the rate of p-NPPC hydrolysis over the period tested 
(Figure 4.5) indicating the presence of neutralising immunoglobulins. 
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Figure 4.3: The influence of heat inactivated antisera on α-toxin (plc3) in the hydrolysis 
of p-NPPC. Release of the chromogenic product nitrophenol was detected by an increase in 
absorbance at OD450.  Plc3 (2 µg) was incubated alone (plc3), in the presence of serum 
obtained from mice previously immunised with toxoid (plc3 S), or incubated with serum from 
mice immunised with PBS (plc3 CS). The symbols ‘S’ and ‘CS’ are serum from plc3 and 
PBS immunised mice respectively in the absence of plc3 (control samples).  *A significant 
enhancement of the hydrolysis of p-NPPC in the presence of serum was observed (p<0.05) 
when compared to plc3 alone. 
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Figure 4.4: The influence of various concentrations of heat inactivated antisera on the 
activity of α-toxin (plc3) in the p-NPPC assay. (A) The rate of p-nitrophenol liberation by 
plc3 as determined by an increase in the absorbance at OD450. Plc3 (2 µg) was incubated 
alone (0), or in the presence of 40, 80 and 160 µg of serum obtained from mice immunised 
with toxoid. The “control” consisted of 160 µg of serum from plc3 immunised mice, in the 
absence of plc3. (B) A bar graph representation of the calculated rate of p-NPPC hydrolysis in 
nmol/min of each sample in (A). Results display means and standard errors of triplicate data.  
*A significant reduction in the rate of p-NPPC hydrolysis was observed in the absence of sera 
(p<0.05)  
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Figure 4.5: The neutralisation of the phospholipase C activity of α-toxin by purified 
immunoglobulins (Ig). Alpha-toxin (plc3) (4 µg) was incubated with Ig isolated from mice 
immunised with: plc3 toxoid (82 ng), plc104 (49 ng), and plcInv3 (114 ng) in a final volume 
of 20 µL for 30 min at 37ºC, followed by the p-NPPC reaction.  Rates of p-NPPC hydrolysis 
was calculated (nmol/min) from quadruplicate samples and are displayed as means and 
standard errors. Molar ratio of Ig to plc3 in all samples tested was very low^ (1:270 for 
plc104 Ig) therefore complete inhibition of plc3 activity was not achieved. Although there 
was a highly significant reduction * (p<0.001) in p-NPPC hydrolysis when all Ig isolated 
from plc3 toxoid, plcInv3 and plc104 vaccinated mice incubated with plc3 was compared to 
plc3 activity in the absence of Ig (labelled “no Ig”).  
^ With the assumption that the majority of the Ig’s present are IgG (estimated size of 146 
kDa). 
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4.3.3 Challenge of mice 
The results of the immunogenicity trials outlined in Section 4.2.4 indicated that optimum IgG 
responses were observed 1-3 weeks after final vaccinations (Fig 4.1) and antibody levels 
started to stabilise or decline thereafter, therefore mice were challenged with α-toxin or 
C. perfringens 2-weeks following the final vaccination (Day 43).   
 
4.3.3.1 Toxin challenge 
Prior to challenge, serum was collected from vaccinated mice and was screened to confirm the 
presence of anti-α-toxin antibodies in an ELISA.  All mice vaccinated with plcInv3, plc104 
and toxoid developed significant antibody responses against the α-toxin, whereas anti-α-toxin 
antibodies from sham-immunised mice were undetectable in the ELISA.  Mice vaccinated 
with plcInv3 and plc104 had significantly lower antibody responses when compared to the 
plc3 toxoid vaccinated group (p<0.01) (Figure 4.6). 
 
Signs of toxicity in control mice injected with 5 mouse lethal doses (MLD) (5 µg) of α-toxin 
(plc3) were observed within 2 h of the injection with a mean time to death of 2.1 h (Table 
4.4).  All plc3 toxoid vaccinated mice survived the α-toxin challenge without any observable 
signs of toxicity.  Plc104 and plcInv3 vaccinated mice developed signs of acute toxicity and 
died within 3-4 h of challenge.  One mouse in each group survived the challenge without any 
observable signs of acute toxicity (Table 4.4). 
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Figure 4.6: Anti-α-toxin IgG responses of mice following vaccination with plcInv3, 
plc104 or plc3 toxoid prior to α-toxin challenge. Mice were vaccinated 3 times over a 6 
week period. Each histogram is the average result and range of titres from 7 mice in a group. 
The titre was calculated as the reciprocal (log2) dilution of the end-point (determined as an 
OD450 of 0.2). Bars with different letters were significantly different (p<0.01).  
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Table 4.4: Survival of vaccinated mice following a lethal i.p injection of 5 µg of α-toxin 
(plc3).  Values with different superscript were significantly different from each other 
(p<0.05). 
 
Vaccine No. mice survived/total Mean time to death (h +/- SD) 
plcInv3 1/7 3.083 +/- 0.576a 
plc104 1/7 3.747 +/- 0.295a 
toxoid 7/7 -  
control 0/7 2.108 +/- 0.36b 
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The Levene’s test for homogeneity of variance showed that the variance in time to death of 
groups of mice was not homogenous, and one group, the plcInv3 vaccinated group was not 
normally distributed,  therefore the non-parametric Mann-Whitney test was used to determine 
the differences in time to death of vaccinated mice compared to the control group (mice 
vaccinated with PBS in FIA ).  Plc104 and plcInv3 vaccinated mice survived for a 
significantly longer time when compared to control mice (p<0.05). Differences in time of 
death between plcInv3 and plc104 did not differ significantly (p>0.05).   
 
4.3.3.2 C. perfringens challenge 
Prior to challenge serum collected from vaccinated mice was screened to confirm the presence 
of anti-α-toxin antibodies in an ELISA.  All mice vaccinated with plcInv3, plc104 and toxoid 
developed significant antibody responses against the α-toxin, without any residual signs of 
toxicity, whereas anti-α-toxin antibodies from sham immunised mice were undetectable in the 
ELISA.  Mice vaccinated with plc104 produced an anti-α-toxin response significantly lower 
than plcInv3 and plc3 toxoid immunised mice (p<0.01) (Figure 4.7). 
 
The index of gross pathology of C. perfringens infected mice used in this trial was based on 
previous challenge trials (Awad et al., 2000; Awad et al., 2001) and is outlined in Table 4.3.  
All mice including plc3 toxoid vaccinated mice developed localised swelling and limping in 
the injected thigh muscle, therefore these clinical signs were not included in the scoring 
system.   
 
Retrospective plate counting of the challenge inoculum on SBA revealed that mice were only 
given 4.05 x 106 C. perfringens cells as opposed to the calculated 5 x 108 cells.   
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Figure 4.7: The development of anti-α-toxin IgG antibodies following vaccination of 
mice with plcInv3, plc104 or plc3 toxoid prior to C. perfringens challenge. Mice were 
vaccinated 3 times over a 6 week period. IgG responses were assessed using an ELISA.  Each 
histogram is the average result and range, of titres from 7 mice in a group. The titre was 
calculated as the reciprocal (log2) dilution of the end-point (given as an OD450 of 0.2). Bars 
with different letters were significantly different (p<0.01). 
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Even with the reduced inoculum, all sham-immunised control mice developed severe signs of 
gas-gangrene as described by the development of cyanosis from the site of infection towards 
the footpad, with the death of one mouse between 24 and 32 h after challenge.  When 
gangrene encompassed the footpad mice were sacrificed due to animal welfare considerations 
(Figure 4.8 B). 
 
Toxoid vaccinated mice did not develop any further clinical signs of disease other than 
localised swelling and limping.  All seven plcInv3 vaccinated mice survived equally as well 
as plc3 toxoid vaccinated mice, and other than swelling and limping, the presence or 
progression of gas-gangrene was absent (Figure 4.9).  Three of six mice immunised with 
plc104 succumbed to the clostridial challenge, with gas-gangrene developing around the site 
of injection in two mice, and in a third case progressed towards the ankle.  The 7th mouse died 
prior to the challenge commencing from unrelated causes. 
 
The clinical signs of gas gangrene in both the negative control group and the plc104 
immunised mice became obvious at about 16 h following the C. perfringens challenge and the 
clinical sign became more severe as time progressed (Figure 4.10).   
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Figure 4.8: The clinical signs of gas-gangrene development in mice infected with 
C. perfringens. (A) The spread of gangrene at the ankle and swelling of the foot pad of a 
mouse indicative of a score of 3 according to the index of gross pathology outlined in Table 
4.3. (B) The spread of gas-gangrene to the foot-pad indicative of a score of 4 on the index of 
gross pathology outlined in Table 4.3. (C) Comparisons of left and right thighs of a mouse 
infected with C. perfringens 68 h earlier.  Inflammation and swelling is prominent in the 
infected thigh (left). 
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(C) 
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Figure 4.9: Distribution of infection within immunised groups of mice at 48 hours post 
C. perfringens challenge.  Individual mice were scored according to the severity of the 
clinical signs of gas gangrene; 0 = swelling/limping; 1 = cyanosis at the site of injection; 
2 = spread of cyanosis to the thigh surrounding injection site; 3 = cyanosis spread to the 
ankle/swelling of the foot pad; 4 = blackening of complete foot pad/mouse found dead. 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
Control plcInv3 plc104 Toxoid 
S
c
o
re
 
Chapter 4. Immunogenicity of α-toxin mutants and their potential as protective vaccines 
 182
 
 
 
 
 
 
Figure 4.10: Gross pathology of mice infected with 4.05 x 10
6
 C. perfringens cells 
following vaccination with plcInv3, plc104, plc3 toxoid or an unrelated bacterium 
(control).  A 50 µL dose of C. perfringens cells was administered to the left thigh of mice 
which were then closely observed over a 72 h period for overt signs of disease which included 
swelling and cyanosis of the thigh and footpad. The data reflect the percentage of; the sum of 
scores per group divided by the total possible score. 
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4.4 Discussion 
Four truncated α-toxin proteins developed, expressed and purified as described in Chapter 3, 
were examined for their potential as vaccines targeting the α-toxin of C. perfringens.  Their 
immunogenicity was determined in BALB/c mice when administered i.p with FIA.  All four 
vaccines plcInv3, plc316, plc204, plc104 and the positive control plc3 toxoid produced a 
significant titre of anti-α-toxin IgG.  Mice vaccinated with the proteins plcInv3 and plc104 
responded with the production of a much higher IgG titre than did mice vaccinated with 
plc204 and plc316.  The high level of antibody titre produced against vaccination with plc104 
and plcInv3 as assessed in an ELISA coated with native plc3 indicated that the vaccines were 
strong immunogens that were capable of inducing antibodies that reacted with the holotoxin.  
The reduced antibody responses of plc204 and plc316 vaccinated groups, could be attributed 
to their altered physical states.  Purification and preparation of both proteins resulted in 
decreased solubility (Chapter 3).  The misfolding of the two proteins may have affected 
epitope presentation during vaccination of mice, resulting in reduced production of antibodies 
essential for specific recognition of the α-toxin.  These two vaccine prototypes were omitted 
from further examination, and additional work focussed on the truncated proteins plcInv3 and 
plc104 which were both soluble and highly immunogenic.  
 
The phospholipase C (plc) neutralising abilities of antisera from mice vaccinated with 
plcInv3, plc104 and plc3 toxoid were investigated using the p-NPPC assay.  When antisera 
from PBS vaccinated mice (negative control group) or plc3 toxoid vaccinated mice was 
tested, an enhancement of α-toxin plc activity was observed.  The antiserum was heat treated 
for 30 min at 56ºC to inactivate complement and other heat labile enzymes and was tested in 
the absence of α-toxin to eliminate the possibilities that a component of the antiserum was 
itself hydrolysing the substrate.  When this was done, only a baseline response was observed.  
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The results suggest one of two possibilities, that component(s) of the sera could be enhancing 
the plc activities of the α-toxin or, the effects of the sera could be acting directly on the 
substrate itself by improving the characteristics of the reaction media (Kurioka and Matsuda, 
1976).   
 
Enhanced plc activities of α-toxin have been demonstrated where site-directed mutations or 
the deletion of the complete C-terminal domain have lead to the increased accessibility of the 
active site of α-toxin to p-NPPC (Titball et al., 1991; Walker et al., 2000).  Some proteins in 
eukaryotic cells require activation via regulatory proteins such as calmodulin (Alberts et al., 
2002).  The proteins in the serum could be regulating the α-toxin plc activity in a similar 
regulatory manner, by binding to regions of the α-toxin and enhancing the accessibility of 
substrate to the active site.  If this is found to be true, it has interesting consequences on the 
fate of α-toxin once inside the host, as the hosts own vascular system could be inadvertently 
up-regulating the activity of the α-toxin.  If the latter is found to be true, that serum helps to 
improve the characteristics of the reaction media, future use of the p-NPPC assay could be 
improved by the addition of a small amount of sera to enhance plc activities when only small 
a concentration of α-toxin is available.  Rate limiting effects were not seen at the serum 
concentrations used and further enzyme kinetic studies would be required to further assess the 
behaviour of the mouse serum on α-toxin in the p-NPPC assay.  Studies should also include 
other substrates such as egg yolk and erythrocytes.  
 
Since the antiserum was causing an increase in plc activities, it was necessary to purify the 
immunoglobulins from the antisera.  The neutralising ability of Ig isolated from mice 
vaccinated with plcInv3, plc104 and plc3 toxoid was examined.  All three Ig samples were 
able to reduce the activity of α-toxin in the p-NPPC assay indicating the presence of plc 
neutralising antibodies (Sato et al., 1989; Titball et al., 1991).   
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Protein plc104 does not contain any N-terminal α-helical regions and antibodies produced in 
mice immunised with plc104 would also be devoid of antibodies targeted towards this 
catalytic region, yet these antibodies were able to neutralise the p-NPPC hydrolysing activities 
of the α-toxin.  A mutation in the C-terminal region of α-toxin is most likely to affect the 
binding abilities of the α-toxin and hence haemolytic and cytotoxic, but not phospholipase C 
activities (Titball et al., 1991; Guillouard et al., 1997).  Contrary to this, evidence exists that 
mutations in the C-terminal domain affect the phospholipase C activity of the α-toxin on 
substrates such as p-NPPC which contain no membrane binding surfaces onto which the C-
terminal domain of the α-toxin can anchor (Guillouard et al., 1996; Walker et al., 2000; 
Jepson et al., 2001).   
 
Mutations of residues in the C-terminus alters the active site of the toxin by reducing the 
access of substrate to the active site, reducing binding of the toxin to the phospholipid head 
group of the substrate, altering the structural integrity of the toxin and by interrupting the 
communication between the N-and C-termini which is important for correct catalytic activity 
(Sato et al., 1989; Guillouard et al., 1997; Naylor et al., 1999; Walker et al., 2000; Jepson et 
al., 2001).  Therefore antibodies directed to epitopes in this region would also reduce or 
abolish catalytic activity of the α-toxin via steric hindrance or direct blockage of the active 
site, as was observed in the p-NPPC neutralisation assay. 
 
The positive results of the neutralisation assays suggest that plc activity can be inhibited from 
antibodies produced by vaccination with plc104 and plcInv3, but this does not necessarily 
assume that these antibodies will be protective in vivo as antibodies preventing the binding of 
α-toxin to biological membranes are also necessary for complete protection against the toxin 
Chapter 4. Immunogenicity of α-toxin mutants and their potential as protective vaccines 
 186
(Sato et al., 1989; Williamson and Titball, 1993).  Therefore the vaccines abilities to protect 
mice against a challenge with α-toxin or C. perfringens were assessed.  
 
Mice were vaccinated and challenged with a 5 x mouse lethal dose (MLD) of α-toxin (5µg) 
(Williamson and Titball, 1993; Schoepe et al., 1997; Jepson et al., 1999) or 4 x 106 cfu/mL of 
C. perfringens, a dose large enough to cause gas-gangrene in this study. 
 
Results of the toxin challenge suggest antibodies were produced (Figure 4.6) and did protect 
mice for a longer time than control groups (Table 4.4), although mice did not survive, unlike 
the plc3 toxoid vaccinated group where all mice survived the α-toxin challenge with no 
observable signs of acute toxicity.  However, one mouse from groups plcInv3 and plc104, did 
survive the challenge.  The mice used in the study were inbred Balb/c mice therefore no 
genetic differences would be present amongst the mice.  Although animal to animal variation 
does occur (Moutafis, 2002).  The pre-challenge antibody responses as measured in the 
ELISA showed no reason why these two mice may have survived, in that the antibody 
responses in these mice prior to challenge were not significantly correlated to protection 
against α-toxin challenge.  These two mice may have developed an enhanced immune 
response upon challenge or have been given a slightly smaller dose of toxin which they were 
able to neutralise.  Unfortunately serum from these two mice was not taken post-challenge to 
confirm a boosted immune response occurring. 
 
A publication by Williamson and Titball (1993), suggests that vaccination with the C-terminal 
domain protects mice against α-toxin challenge, whilst the data obtained from the vaccination 
with plcInv3 which contains the complete C-terminus suggests otherwise.  It is difficult to 
compare the survival studies with other authors as in most publications, the quantity of protein 
rather than the unit of activity of α-toxin is mentioned in a challenge trial, and the assays used 
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for unit determination are not standardised.  Therefore even though the protein content is 
similar, the rate of activity may not be.  One other difference between their study and this 
current one is that Williamson and Titball (1993), immunised mice as required until the 
specific antibody titre to α-toxin plateaued or for a maximum of 6 times, therefore the 
antibody levels in their mice may have been much higher during challenge with α-toxin 
which lead to protection against the acute effects of a highly lethal dose of α-toxin, whereas 
this trial was limited to 3 vaccinations.  In the field it would not be realistic to continually 
boost animals as often as required which is why the immunisation regime was kept to a 3 dose 
maximum.  Freund’s complete adjuvant was also omitted because this is not an adjuvant that 
would be used in the veterinary field or in humans.  Indeed it is possible that antibodies 
directed against specifc domains may have been lower in the truncated vaccines. 
 
Even though plcInv3 and plc104 vaccinated mice did not survive the α-toxin challenge, the 
dose administered was much higher than would occur naturally where small pulsed doses 
would be released from actively growing C. perfringens cells.  Therefore a live bacterial 
challenge was administered to determine the overall performance of the proteins as vaccines 
when encountering C. perfringens. 
 
All mice including toxoid vaccinated mice developed swelling and limping.  A high dose of 
bacterial cells, whether dead or alive, particularly into the thigh muscle would induce an acute 
inflammatory response which would include limping and swelling (Awad et al., 2000), 
therefore these clinical signs of disease were omitted during the scoring of challenged mice. 
 
The performance of all three vaccines, plcInv3, plc104 and plc3 toxoid was much better than 
the sham-immunised control group.  
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Some breakthrough in protection was observed in mice vaccinated with plc104.  Antibodies 
against the C-terminal domain are essential for the complete neutralisation of the α-toxin, 
probably by preventing the docking of α-toxin to receptors on phospholipids (Williamson and 
Titball, 1993).  Vaccine plc104 may have a few epitopes missing which are necessary for the 
prevention of anchoring of α-toxin to the membrane surfaces.  The protein itself is no longer 
able to bind erythrocytes (Chapter 3), and the absence of the 1st β-sheet and hence the 
disruption of the 1st loop contains an epitope recognised by monoclonal antibody 9F3A6 
which has some lethal neutralising abilities (Sato et al., 1989; Guillouard et al., 1997).  Its 
absence may have contributed to the breakthrough in protection of C. perfringens infected 
mice.  Protein plc104 is also missing the linear epitope region encompassing residues 192-199 
(ARGFAK).  This linear epitope has shown to be partially protective in α-toxin challenges of 
mice (Logan et al., 1991).  The future production of more plc104 antibodies could be used to 
assess the antisera in other assays such as the haemolysin liquid assay to determine if the 
antibodies present are able to bind to the C-terminal domain of α-toxin, and hence prevent 
cell lysis, which would be indicative of lethality in mice (Schoepe et al., 1997).  From the 
study thus far, it seems that the missing β-sheet is important for the complete protection of 
mice against gas-gangrene. 
 
However even with the deletion of the 1st β-sheet of the C-terminus from α-toxin, mice were 
protected from challenge against live C. perfringens, suggesting other epitopes located in the 
remaining loops are important for protection against infection.   
 
The protection afforded by plcInv3 vaccination was as good as that by plc3 toxoid, which has 
previously been shown to be highly immunogenic and protective in guinea pig trials (Ito, 
1970).  The truncate cpa247-370 developed by Williamson and Titball (1993) also shows 
promising results as a vaccine with only a few mice developing clinical signs of infection 
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when challenged with 3 x 107 to 3 x 109 cfu of C. perfringens (Stevens et al., 2004).  It would 
be interesting to see if both plcInv3 from this study and cpa247-370 from the study by 
Williamson and Titball (1993) would fare just as well as each other in a challenge trial.  
PlcInv3 contains more epitopes targeted against the plc activities of the α-toxin and may 
therefore provide better protection than cpa247-370, as the presence of the non-toxic C-terminal 
region alone, which is responsible for binding receptors, may not protect against an 
overwhelming challenge in the absence of plc neutralising antibodies (Walker, 1992). 
 
The strain of C. perfringens used in this study was a field isolate from a case of NE in a 
chicken.  The strain was able to cause severe gas-gangrene and the death of one mouse when 
administered at doses as low as 4 x 106 cfu.  Other authors (Stevens et al., 1987; O'Brien and 
Melville, 2004) suggest that the inoculum required to cause an observable clinical sign of gas 
gangrene in the Murine model is between 108 and 109 in order to provide enough tissue 
damage and localised blood clotting to bring about ischemia at the site of infection and the 
subsequent development of gangrene.  They suggest that mice are more resistant to the 
development of ischemia than are humans.  It may be that the strain used in this study is more 
pathogenic producing higher levels of α-toxin and other associated toxins. 
 
The overall results of this study describe a new α-toxin vaccine protein, plcInv3, capable of 
protecting mice against the observable clinical signs of gas-gangrene.  Whilst plcInv3 has the 
aa’s 56-75 deleted, the antibodies developed in immunised mice were effective in neutralising 
the plc activity in vitro and protecting mice against a live C. perfringens challenge.  Clearly 
whilst the deleted region has been identified as the active site for plc activity, it is not the only 
region on the α-toxin that can lead to neutralisation of the plc activity (Figure 4.5).  Perhaps 
the binding of antibodies to other epitopes induces a change in folding of α-toxin which leads 
to its neutralisation.  Further protection is provided by the presence of the complete C-
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terminus which leads to the production of antibodies able to prevent the initial binding of the 
α-toxin to eukaryotic membranes. 
 
Vaccine plc104 was also able to protect mice against the major signs of gas-gangrene 
although some breakthrough in protection was observed which may be attributed to the lower 
immune responses observed in these mice or the reduced epitopes present in the vaccine 
which were not enough to provide complete protection.  The neutralisation of plc activity that 
was evident when using immunoglobulins from plc104 immunised mice suggests, as with 
plcInv3, that binding of these immunoglobulins alters the conformation of the α-toxin so that 
it neutralises its plc activity and binding ability and hence leads to reduced pathogenicity with 
a live C. perfringens challenge. 
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 Chapter 5 
Vaccination against the α-toxin of C. perfringens by use of 
the live orally delivered vaccine vector STM1 
5.1 Introduction 
A clostridial vaccine to aid in the prevention of necrotic enteritis (NE) in chickens has yet to 
be developed.  Clostridial vaccines are currently only available for ruminants and these 
consist of toxoid preparations of types C and D C. perfringens bacteria, or a cocktail of 
formalin inactivated β- and ε-toxins (Younan et al., 1995; Kelneric et al., 1996).  NE is a 
multifactorial disease, but the α-toxin of C. perfringens is thought to be a major contributing 
factor to the development of the disease (Chapter 1.6.3).  Vaccination of mice with proteins 
plcInv3 and plc104 (Chapter 3) has shown to protect against the lethal effects of α-toxin 
produced by C. perfringens in a live clostridial challenge (Chapter 4).  These proteins are 
currently administered parenterally in an emulsion of FIA.  The development of these proteins 
into effective veterinary vaccines for chickens would require a system whereby they are easy 
to produce, purify and deliver to the host.  The development of live attenuated bacterial 
vectors that can survive the harsh intragastric environments of the host for use as delivery 
vehicles of foreign antigens meets these criteria.  They are relatively easy to produce, there is 
no need to purify end products, and delivery to chickens can be achieved with mass 
vaccination via the drinking water, feed, or as an aerosol (Coloe et al., 1995).  They also have 
the ability to induce mucosal immune responses (Brown et al., 1987; Maskell et al., 1987; 
Walker et al., 1992; Bullifent et al., 2000), an added benefit in the prevention of diseases of 
the gastrointestinal tract (GIT) such as NE of chickens. 
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One such bacterial vector is the attenuated S. Typhimurium.  It has the potential to be used as 
a combined vaccine due to its known capacity to elicit circulatory and secretory antibodies as 
well as cell mediated immunity (Brown et al., 1987; Dougan et al., 1987; Guzman et al., 
1991; Mastroeni et al., 1992). 
 
Many investigations have often used plasmid-encoded heterologous genes for expression 
within attenuated S. Typhimurium (Poirier et al., 1988; Sadoff et al., 1988; Coulson et al., 
1994a; Londono et al., 1996; Dalla Pozza et al., 1998; Pacheco et al., 2005).  A disadvantage 
of this is the ability of S. Typhimurium to retain the plasmid in the absence of selective agents 
such as antibiotics, as would be found in vivo (Maskell et al., 1987; Dougan et al., 1989; 
Molina and Parker, 1990; Strugnell et al., 1990; Coulson and Titball, 1993).  This plasmid 
instability can lead to the lack of immune responses within the host if the plasmid is removed 
from the system before enough recombinant protein can be accumulated in vivo (Fairweather 
et al., 1990; Dalla Pozza et al., 1998).  One system to overcome plasmid instability is the 
chromosomal integration of the heterologous antigen gene, although the reduced copy number 
of the gene present could also result in a reduced immune response (Strugnell et al., 1992; 
Cardenas and Clements, 1993). 
 
Another system of controlling plasmid stability, while maintaining a relatively high-copy 
number is the use of in vivo inducible promoters.  Such promoters would only induce the 
expression of the recombinant gene under specific environmental conditions (Dunstan et al., 
1999).  This system also alleviates the need for specialised growth conditions and 
supplements in order to induce expression of a foreign antigen (Maskell et al., 1987).  Two of 
the most characterised in vivo inducible promoter systems include the pagC and nirB 
promoters (Chatfield et al., 1992a; Karem et al., 1995; Dunstan et al., 1999; Chen and 
Schifferli, 2000; Chen and Schifferli, 2001; Ruiz-Perez et al., 2002).  Recently the htrA 
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promoter was compared to the nirB and pagC promoters and found to induce a higher 
immune response in addition to protection against challenge  (Roberts et al., 1998; Foynes et 
al., 2003).   
 
In this study the htrA promoter (PhtrA), along with the pagC (PpagC) and the constitutively 
expressed tac promoter (Ptac) were examined for their ability to express the plcInv3 and 
plc104 from within STM1.  Immune responses were documented and the protective capacities 
of the vaccine were examined following a C. perfringens challenge of vaccinated mice.  
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5.2 Materials and methods 
The organisms and vectors used and created in this study is listed in Table 5.1 and 5.2 with a 
detailed description of their construction followed below. 
 
5.2.1 Construction of the vector pBTac3 
The tac promoter (Ptac) was amplified from vector pGEX-4T-1 (Amersham Biosciences, 
Sweden) using primers TacF (forward primer) and TacR (reverse primer) (Table 2.5).  An 
XbaI site was added to primer TacF for ease of determining the orientation of the insert, and a 
BglII site was added to primer TacR for downstream cloning of the α-toxin gene truncates. 
 
Ptac was amplified using pfu polymerase (Table 2.6 and 2.8) with an annealing temperature of 
58ºC and an extension time of 2 min.  The amplification of Ptac was confirmed by gel 
electrophoresis (Chapter 2.5) using a 1.5% agarose gel. 
 
The amplified product was treated with polynucleotide kinase (PNK) (Chapter 2.7.4), in a 
total volume of 30 µL.  The reaction was incubated at 37ºC for 2 h and heat inactivated at 
70ºC for 10 min. 
 
Vector pBluescript (8-10 µg) was digested with EcoRV in a total volume of 10 µL, for 4 h.  
Following heat inactivation, 8 µL of the restriction digested vector was treated with calf 
intestinal phosphatase (CIP) to prevent its self-ligation (Chapter 2.7.3).  The hydroxylated 
vector was then purified using the GeneClean kit (QBIOgene, USA) and resuspended in a 
final volume of 20 µL. 
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Table 5.1: Organisms used in the development of orally delivered vaccines. 
Organism Genotype Source 
E. coli DH5α supE ∆lacU169 (ф80 
lacZ∆M15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 
(Hanahan, 1983) 
Salmonella Typhimurium 
82/6915 
Wild type Inv+ (Alderton et al., 1991) 
Salmonella Typhimurium 
9121 (LT2) 
leu hsdL trpD2 rpsL120 
ilv452 metE551 metA22 
hsdA hsdB 
Prof. P. Reeves, 
Department of 
Microbiology, The 
University of Sydney 
STMI  ∆aroA- ∆serC- (Alderton et al., 1991; 
Coloe et al., 1995) 
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Table 5.2: Plasmids used in the development of STMI orally delivered vaccines. 
Plasmid Description/genotype Source 
pGEX4T-1 4.969 kb protein expression vector: AmpR, 
lacIq, N-terminal glutathione-S-transferase 
fusion, tac promoter (Ptac), pBR322 origin of 
replication 
Amersham 
Biosciences, Sweden 
pBluescript SKII- 2.96 kb phagemid: AmpR, lacZ, ColE1 origin 
of replication 
Stratagene, USA 
genbank #X52330 
pBTac3 Ptac amplified from pGEX4T-1 and inserted 
into pBluescript via blunt end ligation at 
EcoRV site 
This study 
pBPAGC21 PagC promoter (PpagC) from Salmonella 
Enteritidis inserted into EcoRV site of 
pBluescript via blunt ended ligation 
(Moutafis, 2002) 
pRSETA 2.9 kb protein expression plasmid: AmpR, N-
terminal 6 x His, T7 promoter 
Invitrogen 
pRplc14 Complete plc cloned into the PstI and EcoRI 
sites of pRSETA using primers AllPstI and 
PlcEcoRev (Table 2.5) 
This study 
pRplcInv9 Inverse amplified pRplc14 (using primers 
Inv1 and Inv2) self-ligated (nucleotides 250-
309 of plc deleted) 
This study 
pRplc104 DNA sequence coding for the C-terminus of 
plc (nucleotides 882-1243) cloned into the 
PstI and EcoRI sites of pRSETA 
Chapter 3 (3.2.2.1) 
pBTCαInv Amplified αInv from pRplcInv9 cloned into 
the BglII and NotI sites of pBTac3 
This study 
pBTCα104 Amplified α104 from pRplc104 cloned into 
the BglII and NotI sites of pBTac3 
This study 
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Table 5.2 Continued. 
Plasmid Description/genotype source 
pBPCαInv Amplified αInv from pRplcInv9 and 
cloned into pBPAGC21 via BglII and 
NotI sites 
This study 
pBPCα104 Amplified α104 amplified from 
pRplc104 and cloned into pBPAGC21 
via BglII and NotI sites 
This study 
pBHAαInv Amplified htrA promoter (PhtrA) ligated 
to αInv through BglII sites and cloned 
into pBluescript SKII- via XbaI and NotI 
sites. 
This study 
pBHAα104 Amplified PhtrA ligated to α104 through 
BglII sites and cloned into pBluescript 
via XbaI and NotI sites. 
This study 
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The PNK treated amplified Ptac and CIP treated pBluescript were combined in a 3:1 molar 
ratio (as determined by quantisation on an agarose gel) and ligated overnight (Chapter 2.7.5) 
at 22ºC (RT) in a final volume of 20 µL. 
 
The ligated product was precipitated and purified with ethanol and sodium acetate (Chapter 
2.7.5.1) and resuspended in 10 µL of milliQ water followed by electro-transformation into 
DH5α electro-competent cells (Chapter 2.7.6 and 2.7.7).  Following a 1 h incubation at 37ºC, 
10, 50 and 100 µL of the transformation was spread onto LB agar supplemented with 100 
µg/mL ampicillin (LA100), and previously spread with 40 µL of 40 mg/mL IPTG and 40 µL 
of 40 mg/mL X-gal. 
 
Non β-galactosidase producing colonies (white) were selected for further analysis by RE 
digestion following plasmid miniprep extractions (Chapter 2.4.2).  Isolated plasmids were 
digested with XbaI for the confirmation of the Ptac insert and determination of orientation. 
 
5.2.1.1 Expression plasmid pBPAGC21 
Vector pBPAGC21 was kindly provided by G. Moutafis, and contained the pagC promoter 
(PpagC) amplified from S. Enteritidis cloned into the EcoRV site of the pBluescript vector by 
the same procedure as described for the creation of vector pBTac3, except that a BamHI was 
site was incorporated into its 5’ terminus during PCR instead of a XbaI site. 
 
5.2.1.2 Construction of plasmid pRplcInv9 
Construction of the pRplcInv9 vector began with the amplification of the complete plc from 
C. perfringens 61 using primers AllPstI and PlcEcoREV (Table 2.5) and pfu polymerase with 
an annealing temperature of 55ºC and an elongation time of 2 min, followed by PstI and 
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EcoRI digestion and cloning into the PstI and EcoRI sites of pRSETA, creating vector 
pRplc14 (procedures for cloning and transformation essentially as outlined in Chapter 
3.2.2.1).  The pRplcInv9 vector was then constructed using the same methodology as that 
outlined for the construction of pCplcInv3 (Chapter 3.2.2.3), via inverse PCR of pRplc14 
using primers Inv1 and Inv2 (Table 2.5).   
 
5.2.1.3 Amplification of the αInv gene 
Vector pRplcInv9 was used as the template for amplification of αInv, identical to the plcInv3 
(Chapter 3) gene except that the CAT x 6 sequence coding for the His-tag was removed.  
Primers plcBglII and pRSETANotI were used in the PCR.  Expand polymerase (Table 2.6 and 
2.7) was used to amplify the αInv gene with an annealing temperature of 58ºC and an 
extension of 2 min.  Amplification of αInv was confirmed by agarose gel electrophoresis.   
 
5.2.1.4 Amplification of the α104 gene 
Vector pRplc104 (constructed in Chapter 3) was used as the template DNA for amplification 
of the α104 gene.  The forward primer 890BglII and reverse primer pRSETANotI were used 
to amplify α104 using pfu polymerase with an annealing temperature of 58ºC and an 
extension of 2 min.  The α104 gene was identical to the plc104 gene (Chapter 3) except that 
the CAT x 6 sequence coding for the His-tag was removed.  Amplification of α104 was 
confirmed by agarose gel electrophoresis.   
 
5.2.1.5 Cloning of αInv and α104 into pBTac3 and pBPAGC21 
The amplified products, α104 and αInv were purified using the GeneClean kit and along with 
the vectors pBTac3 and pBPagC21 were digested with NotI and BglII for 3-4 h.  After heat 
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inactivation of the digestions, α104 was ligated with pBTac3, in a 3 to 1 molar ratio (Chapter 
2.7.5).  In a separate reaction α104 was ligated to pBPagC21.  The αInv gene was also ligated 
to pBTac3 and pBPAGC21 using the same methodology. 
 
After allowing the fragments to ligate for 18 h at 14-16ºC the products were purified with 
sodium acetate and ethanol (Chapter 2.7.5.1), resuspended in 10 µL of milliQ water, and 
added to electro-competent DH5α cells for electro-transformation (Chapter 2.7.6 and 2.7.7).  
Transformants were grown on LA100, and following 18 h of growth at 37ºC, 10-20 colonies 
were isolated and incubated in 2 mL of LB broth supplemented with Amp100 (LB100) for 18 
h.  Following the incubation, plasmids were isolated (Chapter 2.4.2) and digested with XbaI 
and NotI (pBTac3:α104 inserts) or HindIII (pBPAGC21:α104, pBPAGC21:αInv, and 
pBTac3:αInv inserts) and analysed on an 1.4% agarose gel. 
 
5.2.2 Construction of expression plasmids pBHAαInv and pBHAα104 
Cloning of the αInv and α104 genes into the htrA promoter (PhtrA) was completed prior to the 
cloning of PhtrA into pBluescript.  
 
PhtrA was amplified with primers HtrAF and HtrAR (Table 2.5) using pfu polymerase (Table 
2.6 and 2.8).  A 58ºC annealing temperature was used and the elongation time was kept to 2 
min 50 sec.  Amplification of the αInv and α104 genes was as described in the sections above 
(5.2.1.1 and 5.2.1.2). 
 
The αInv, α104 and PhtrA PCR products were purified using the Wizard PCR Prep DNA 
purification Kit (Promega) and digested with the restriction enzyme BglII.  A sample of each 
digestion was loaded onto an agarose gel to calculate the concentration of each of the 
Chapter 5. Vaccination against the α-toxin of C. perfringens by use of the STM1 delivery vector                
 201
fragments prior to ligation.  Equal concentrations of PhtrA and αInv or PhtrA and α104 were 
added to a reaction mix containing T4 ligase and buffer and incubated for 18 h at 14-16ºC 
(Chapter 2.7.5).  One microliter of each ligation was used in a PCR with primers HtrAF and 
pRSETNotI and pfu polymerase with an annealing temperature of 58ºC and an elongation 
time of 3 min (Table 2.6 and 2.8). 
 
Specific amplification of the ligated fragments PhtrA:αInv or PhtrA:α104 was confirmed by 
separating the samples by electrophoresis on a 1.2% agarose gel.  The PCR products were 
purified from the PCR buffers using the Wizard PCR prep DNA purification Kit and digested 
with the enzymes NotI and XbaI.  Vector pBluescript was also digested with the 
aforementioned enzymes.  The reactions were stopped by heat inactivation of the enzymes 
which was then followed by the ligation of PhtrA:αInv to pBluescript, and PhtrA:α104 to 
pBluescript in a 3 to 1 molar ratio.  Each ligation was purified using sodium acetate and 
ethanol (Chapter 2.7.5) and used in the electro-transformation of DH5α E. coli electro-
competent cells. 
 
Fifty and 100 µL of the transformations was plated onto LA100 and following overnight 
incubation, 10-20 colonies were isolated for plasmid analysis using the restriction enzyme 
HindIII. 
 
5.2.3 Plasmid transformation into vaccine strain STMI 
The vectors pBPAGC21, pBPCαInv, pBPCα104, pBTCαInv, pBTCα104, pBHAαInv and 
pBHAα104 were isolated from their DH5α hosts using the Wizard Miniprep Kit (Promega) 
and electro-transformed into the electro-competent restriction negative modification positive 
S. Typhimurium strain 9121 (LT2) as outlined in Chapter 2.7.6 and 2.7.7. 
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Colonies of S. Typhimurium LT2 harbouring plasmids were isolated, inoculated into LB100 
and following 18 h incubation on an orbital shaker at 37ºC plasmids isolated using the Wizard 
Miniprep Kit.  Plasmids were transformed into electro-competent STMI cells via 
electroporation as above and isolated colonies screened via restriction enzyme digestions for 
the presence of the correct plasmids. 
 
5.2.4 Expression of proteins 
STMI(pBTCαInv) and STMI(pBTCα104) were grown in LB100 at 37ºC on an orbital shaker 
till an OD600 of 0.5 was reached, at which time 1 mL samples were taken, pelleted by 
centrifugation and resuspended in 100 µL of lysis buffer or 1 X SDS loading buffer.  
 
STMI(pBPCαInv) and STMI(pBPCα104) were grown in LB100 in the presence of 100 mM 
MgCl2.  When the cells reached mid-log phase of growth (an approximate OD600 of 0.5) 1 mL 
aliquots were taken, pelleted at 14,000 x g for 5 min and resuspended in fresh LB100 (1 mL 
volumes) containing either 0, 1, 10 or 100 mM MgCl2, and grown for a further 4 h.  The 1 mL 
samples were pelleted and resuspended in 100 µL of whole cell lysis buffer.  Protein content 
was determined using the Lowry protein assay (Chapter 2.8.2.2). 
 
STMI(pBHAαInv) and STMI(pBHAα104) were grown in LB100 at 37ºC on an orbital shaker 
till an OD600 of 0.5 was reached, at which time 1 mL samples were taken and dispensed into 
1.5 mL tubes with the addition of 0, 1 or 10 mM H2O2, or the samples were placed in a 42ºC 
waterbath for a further 2 h.  Following the incubation, the 1 mL samples were pelleted by 
centrifugation and resuspended in 100 µL of 1 X SDS loading buffer.  
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Protein samples were loaded onto an SDS-PAGE and separated by electrophoresis (Chapter 
2.8.3). Following separation, proteins were transferred onto a nitrocellulose membrane 
(Chapter 2.8.7.2), probed with horse anti-α-toxin polyclonal antisera (gas-gangrene antisera) 
(CSL), and then probed with the secondary conjugated rabbit anti-horse IgG-HRP. 
 
5.2.5 Plasmid stability assay 
Stocks of STM1 harbouring the vectors were streak plated onto LA100 to obtain single 
colonies.  Three to four well isolated colonies were selected for plasmid stability assays and 
incubated in 10 mL of LB100 at 37ºC on an orbital shaker for 18 h.  The culture was 10-fold 
diluted from 10-1 to 10-6 in LB and 100 µL of each dilution spread plate onto LA100, in 
duplicate, to determine the initial plate count.  The 10-6 dilution (10 mL) was incubated for 24 
h at 37ºC in the absence of ampicillin.  This culture was again serially 10-fold diluted to 10-6 
and 100 µL of each dilution spread plate onto LA100 and LA, in duplicate.  The 10-6 dilution 
(10 mL) was incubated at 37ºC for 24 h and the process of dilution and spread plating 
repeated. The whole process was repeated for up to 5 days (approximately 100 generations) or 
until less than 0.05-0.002% of the culture retained the plasmid. 
 
5.2.6 Vaccine trials 
5.2.6.1 Preparation of test vaccines 
One percent (v/v) of an overnight culture of STMI harbouring the different plasmid constructs was 
used to inoculate 10-50 mL of freshly prepared LB100. The culture was incubated in an orbital 
shaker at 37ºC until an OD600 of 0.15-0.2 (as determined by adding 200 µL of culture to a 96-well 
plate and measuring the absorbance in a Dynatek plate reader set to a wavelength of 600 nm) was 
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reached.  Cells were concentrated by centrifugation, and using the formula below, resuspended in 
sterile PBS to a final cell concentration of 1.0 x 1010 cfu/mL.   
 
(OD600 x 7.65) – 0.3 = result x 10
9 cfu/mL 
 
1.0 x 109 cfu STM1 were used for oral vaccinations of mice.  This has previously been shown to be 
a safe and effective level with STM1 (Alderton et al., 1991). 
 
5.2.6.2 Delivery of vaccines 
STMI vaccines prepared as above (Section 5.2.6.1) were administered orally to mice using an 
autoclaved gavage needle and a 1 mL syringe.  The vaccine was drawn through the gavage 
needle, which was then dipped in glycerol for a smoother passageway down the mouse 
esophageus.  The needle was rinsed in 80% ethanol (v/v) between the vaccinations of 
different groups of mice.  A dose of 100 µL containing approximately 1 x 109 cells was 
administered orally to each mouse.  The vaccine dose was diluted up to 10-7 in PBS and 
spread plate onto LA100 for retrospective counting of the exact vaccine doses administered. 
 
5.2.7 Immunogenicity assays 
Balb/c mice (5/group) were vaccinated with STM1 harbouring the plasmid construct vaccines, 
or with α-toxin (plc3) toxoid on days 1, 15, and 29.  Cells (between 107-109) were 
administered to all mice, with the exact dose determined following retrospective spread plate 
counting of 10-5, 10-6 and 10-7 diluted cultures on LA100 plates (Table 5.3).  Twenty days 
following final vaccination, mice were sacrificed by cervical dislocation and their spleens 
removed and placed in RPMI/NCS, supplemented with penicillin and streptomycin (5 
µg/mL). 
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Table 5.3: Vaccination of mice via the delivery vector STM1 harbouring plasmids 
containing the various α-toxin truncated genes.   
Vaccine  Dose administered (cfu) 
 Day 1  Day 15  Day 29  
pBPAGC21 2.3 x 108 4.2 x 108 1.5 x 108 
pBPCαInv 2.6 x 10
8 5.6 x 108 3.3 x 108 
pBPCα104 3.2 x 10
8 4.5 x 108 2.61 x 108 
pBHAαInv 2.8 x 10
8 4.4 x 108 2.78 x 108 
pBHAα104 9.24 x 10
7 8.0 x 108 1.3 x 107 
pTCαInv 7.52 x 10
7 3.5 x 108 4.1 x 107 
pBTCα104 8.4 x 10
7 6.0 x 106 1.52 x 108 
Toxoid * 10 µg 25 µg 50 µg 
*Toxoid was administered via the i.p route using a 25 gauge needle and 1 mL syringe. The 
amount stated was administered in a total volume of 100 µL in a 1:1 ratio with FIA (see 
Chapter 4.2.2 for detailed description of toxoid vaccine preparation). 
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5.2.7.1 Splenocyte preparation 
The splenocytes were homogenised by mashing the spleen using the back of a 3 mL syringe.  
The homogenised cells were resuspended in 5 mL of RPMI/NCS and filtered through a cell 
strainer (BD Falcon).  The splenocytes were pelleted by centrifugation at 1,600 x g for 5 min 
at 4ºC, the RPMI/NCS solution decanted and cells resuspended in 5 mL of ACK lysing buffer 
to lyse any erythrocytes present.  Following a 5 min incubation on ice, 5 mL of RPMI/NCS 
was added to the lysing solution and the cells pelleted by centrifugation (1600 x g, 5 min, 
4ºC).  The cells were washed 3 times in RPMI/NCS and resuspended in 1 mL of RPMI/NCS.  
Cell viability was calculated using Trypan Blue exclusion.  Ten microliters of cell suspension, 
10 µL of Trypan blue (Sigma) and 80 µL of PBS were mixed and viable cells counted in a 
haemocytometer chamber using an inverted microscope.  Cell concentration was adjusted to 
106 cells/90µL in RPMI/NCS.  Ninety microliters was dispensed into nitrocellulose backed 
96-well plates previously incubated with anti-cytokine specific antibodies and blocked with 
5%NCS (see Section 5.2.7.2). 
 
5.2.7.2 ELIspot assay 
Preparation of this assay required a sterile work environment.  Multiscreen™-IP Filter 96-
well plates (Millipore) were soaked with 100 µL methanol for 5 min prior to use.  Plates were 
rinsed 3 times with about 200 µL sterile PBS and patted dry with autoclaved paper towelling.  
Wells were then coated with 100 µL of anti-cytokine specific capture antibody diluted in 
coating buffer.  IFN-γ capture antibody was used at a concentration of 1.0 µg/mL  and IL-4 at 
0.5 µg/mL.  Plates were incubated overnight at 4ºC.  Unbound capture antibody was discarded 
and the plates rinsed 3 times in filter sterilised PBST.  Excess liquid was removed from the 
plate by patting the bottom of the plate onto sterilised dry absorbent paper, and wells were 
blocked with 200 µL of 5% NCS (prepared in PBS) for 2 h at room temperature (RT).  Wells 
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were rinsed in PBST (x3) following the blocking step, patted dry and 100 µL of RPMI/NCS 
solution added to each well and incubated in a humidifier for 10 min.  The RPMI/NCS 
solution was discarded, plates were patted dry and 90 µL of splenocytes added to each well 
(containing 106 cells/90 µL).  Wells were seeded in triplicate and a fourth well (for each 
sample tested) served as an internal control (no stimulatory mitogen was added).  An extra 8 
wells were inoculated with spleen cells for use as positive and negative controls.  Four of the 
wells remained unstimulated (negative control) and four wells were stimulated with the 
addition of 10 µL of a stock (10 µg/mL) of concanavalin A (Sigma-Aldrich), a mitogen 
(positive control).  Alpha-toxin (plc3) was prepared in RPMI/NCS at a concentration of 250 
µg/mL and 10 µL added to each well (except positive and negative control wells).  Plates 
were incubated in a humidifier (37ºC, 5%CO2) for 21 h wrapped in aluminium foil.  
Following this incubation, plates no longer required to be kept in a sterile environment.  The 
solution in the wells was decanted and wells washed 8 times with PBST and twice in milliQ 
water.  Biotin rat anti-mouse IFN-γ or IL-4 (Abcam) were prepared at a concentration of 0.5 
µg/mL in PBS containing 1% NCS and 100 µL added to all wells.  The plates were incubated 
at RT for 2 h.  Plates were washed with PBST (4x) and PBS (x2), patted dry and 100 µL of 
EXTRAvidin® (Sigma) diluted 1:1000 in PBS/1% NCS added to each well.  The plates were 
again incubated at RT for 2 h.  The plates were rinsed in PBST (x4) and PBS (x2), patted dry, 
and then 50 µL of alkaline phosphatase conjugate substrate (Biorad) added.  The reaction was 
allowed to proceed until spots began to develop (usually about 10 min) and the reaction 
stopped by rinsing the wells with milliQ water (3x).  The plates were dried and stored in the 
dark (wrapped in aluminium foil) until counting of spots was done.  Spots were enumerated 
using a dissecting microscope. 
 
The independent Student’s t-test was used to determine any statistical differences between 
vaccine groups ("STUDENT", 1908). 
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5.2.7.3 Detection of antibody responses 
5.2.7.3.1 Detection of anti-α-toxin IgG antibodies 
Wells were coated with 3 µg/mL of α-toxin (plc3) antigen.  The ELISA assay was as 
described in Chapter 2.8.8 but following the serial two-fold diluting of sera in the wells, plates 
were incubated at 4ºC for 24 h.  
 
Detection of anti-α-toxin antibodies was also examined in immunoblots.  Two micrograms of 
α-toxin was loaded onto a polyacrylamide gel and the protein separated by electrophoresis 
(Chapter 2.8.3).  The α-toxin was then transferred onto a nitrocellulose membrane (Chapter 
2.8.7.2), blocked with 5% skim milk (in TBS), and probed with pooled mouse sera (overnight, 
4ºC).  The presence of bound anti-α-toxin antibodies was detected by probing with a goat 
anti-mouse IgG-HRP conjugate diluted 1 in 5000 in TBS (1% skim milk).  Bound anti-mouse 
IgG-HRP was visualised with incubation in Western blot substrate solution (Chapter 
5.2.7.3.2). 
 
5.2.7.3.2 Detection of anti-Salmonella IgG antibodies 
S. Typhimurium (82/6915) whole cell antigen was prepared by pelleting a 10 mL overnight 
culture of S. Typhimurium (14,000 x g 5 min) and resuspending it in 5 mL TE buffer.  The 
cells were washed twice in TE buffer and sonicated using 6 x 20 s bursts with a 30 s cooling 
off period between each sonication.  Insoluble matter was pelleted by centrifugation at 14,000 
x g for 5 min and the supernatant filtered through a 0.45 µm filter.  Protein content was 
determined using the Lowry assay (Chapter 2.8.2.2).   
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The wells of 96-well plates were coated with 10 µg/mL of S. Typhimurium whole cell antigen 
and the ELISA protocol for the detection of anti-S. Typhimurium antibodies was as described 
in Chapter 2.8.8.  The primary antibody consisted of pooled sera from each vaccine group. 
 
5.2.8 Mouse challenge trial 
Mice (6/group) were orally vaccinated with 100 µL of STM1 harbouring plasmid constructs 
in PBS, on days 1, 15, and 25 by gavage needle and a 1mL syringe.  Cells (between 107-109) 
were administered to all mice, with the exact dose determined following retrospective spread 
plate counting of 10-5, 10-6 and 10-7 diluted cultures on LA100 plates (Table 5.4).  Toxoid plc3 
was used as a positive control throughout the trial, and this was prepared with FIA in a 1:1 
emulsion and 100 µL administered i.p to each mouse (preparation of toxoid described in 
detail in Chapter 4.2.2).   
 
Mice were bled by retro-orbital puncture prior to challenge (Day 36) and challenged with 5 x 
106 C. perfringens cells in 50 µL saline in the left thigh on day 40 as outlined in Chapter 
4.2.7.3.  Monitoring and scoring of infected mice was as described in Chapter 4.2.7.3. 
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Table 5.4: The vaccination regime for the C. perfringens challenge trial.  Mice were 
vaccinated with the delivery vector STMI harbouring plasmids expressing the various 
α-toxin gene truncates. 
 Dose administered (cfu/100 µL) on day*: 
Vaccine Day 1  Day 15  Day 25  
pBPAGC21 4.4 x 108 2.2 x 108  2.36 x 108 
pBPCαInv 4.4 x 10
8  2.52 x 108  3.0 x 108 
pBPCα104 3.14 x 10
8  2.94 x 108  2.32 x 108 
pBHAαInv 3.5 x 10
8  2.16 x 108  2.48 x 108 
pBHAα104 4.6 x 10
8  8.4 x 107  2.3 x 108 
pBTCαInv 2.76 x 10
8  1.04 x 108  1.32 x 108 
pBTCα104 8.0 x 10
7  2.9 x 108  1.64 x 108 
Toxoid*  20 µg (i.p) 40 µg 50 µg 
 
*Toxoid was administered via the i.p route using a 25 gauge needle and 1 mL syringe. The 
amount stated was administered in a total volume of 100 µL in a 1:1 ratio with FIA. 
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5.3 Results 
5.3.1 Construction of vectors for the inducible expression of the α-toxin 
truncated genes αInv and α104 
Three different promoter systems were developed for the differential expression of α-toxin 
truncated genes using the commercial vector pBluescript SKII as the template.  Vector 
pBPAGC21 was previously created by Moutafis (2002) and contains the pagC promoter 
(PpagC) of S. Enteritidis blunt-end ligated into the EcoRV site of pBluescript SKII in the 
opposite orientation to the lacZ reading frame.  The cloned PpagC region contained the -10 and 
-35 regions, the upstream regulatory binding sites, the Shine-Dalgarno ribosome biding site 
(RBS), and the ATG start signal of pagC.   
 
Two other plasmids with different promoters were also constructed to examine and compare 
their ability to express the α-toxin truncated genes from STM1.   
 
The tac promoter (Ptac) was amplified from pGEX4T-1 and included all the necessary 
components to initiate transcription, the -10 and -35 regions, the RBS site and the initial ATG 
start site followed by a BglII site for directional cloning of the α-toxin truncated genes.  The 
amplified Ptac was cloned into pBluescript SKII via the EcoRV site.  Restriction enzyme 
analysis of plasmids with XbaI was used to identify inserts of Ptac ligated in the opposite 
direction of lacZ.  Such a plasmid, pBTac3 was isolated, sequenced and used in the cloning of 
the α-toxin gene truncates (Figure 5.1). 
Chapter 5. Vaccination against the α-toxin of C. perfringens by use of the STM1 delivery vector                
 212
 
 
 
Figure 5.1: The development of the pBTac3 expression vector. (A) Amplification of Ptac 
from pGEX4T-1. Lane 1, λ-PstI, Lane 2, PCR of Ptac; Lane 3, purification of pBluescript 
from DH5α.  (B) Cloning of Ptac into pBluescript. Lane 1, λ-PstI; Lane 2, pBTac3 digested 
with XbaI. (C) Restriction map of pBTac3. Ptac was cloned into the EcoRV site of 
pBluescript.  
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The α-toxin truncated genes plcInv3 and plc104 (developed in Chapter 3), of which their gene 
products have previously shown to protect mice from a challenge against C. perfringens 
(Chapter 4) were amplified without their CAT x 6 sequences (coding for affinity His-tags) 
with primers containing BglII and NotI sites at their 5’ and 3’ termini respectively.  As the 
amplified products lacked a CAT x 6, their names were changed to αInv (for plcInv3) and 
α104 (for plc104).  The two products were cloned downstream of the two expression vectors 
pBPAGC21 and pBTac3 via the same RE sites of the vectors (Figures 5.2 to 5.5) creating 4 
new expression vectors, pBTCαInv (Figure 5.2) and pBTCα104 (Figure 5.3) from the 
original pBTac3 vector and pBPCαInv (Figure 5.4) and pBPCα104 (Figure 5.5) from the 
original pBPAGC21. 
 
The third promoter, the htrA promoter (PhtrA), was amplified from the genome of 
S. Typhimurium.  Primers for its amplification were designed from the sequenced 
S. Typhimurium htrA deposited in GenBank (accession number 18802).  The amplified PhtrA 
was first ligated to either the amplified αInv or α104 via the common BglII sites present on 
the primers.  Following confirmation of ligation via PCR using the forward PHtrA primer 
(HtrAF), and the reverse α-toxin gene truncate primer (pRSETNotI), the newly created gene 
products were digested with XbaI and NotI, and directionally cloned into pBluescript to create 
expression vectors pBHAαInv and pBHAα104 (Figures 5.6 and 5.7). 
 
5.3.2 Expression of α-toxin truncates in STMI 
All recombinant plasmids were transformed into STM1 via the restriction minus, modification 
positive host S. Typhimurium LT2.  Plasmids were purified using the Wizard miniprep kits 
(Figure 5.8) as the standard alkaline lysis miniprep procedure constantly resulted in poorly 
purified plasmid extracts, due to the high protein content of the bacterium. 
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Figure 5.2: Construction of plasmid pBTCαInv. (A) The αInv gene fragment was 
amplified from plasmid pRplcInv9. Lane 1, λ-PstI; Lane 2, amplification of αInv gene. (B) 
Cloning of αInv into pBTac3. Lanes 1-2 and 8-9, empty pBTac3 digested with HindIII; Lanes 
3-7, pBTCαInv digested with HindIII; Lane 10, λ-PstI. (C) Restriction map of pBTCαInv. 
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Figure 5.3: Construction of plasmid pBTCα104. (A) The α104 was amplified from 
plasmid pRplc104. Lane 1, λ-PstI; Lane 2, amplification of α104. (B) Cloning of α104 into 
pBTac3. Lane 1, λ-PstI; Lanes 2 and 6, pBTCα104 digested with XbaI and NotI, Lanes 3-5, 
empty pBTac3 digested with XbaI and NotI. (C) Restriction map of pBTCα104. 
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Figure 5.4: Construction of plasmid pBPCαInv. (A) Restriction map of pBPAGC21. (B) 
Cloning of αInv into pBPAGC21. Lanes 1, 3 and 4, empty pBPAGC21 digested with HindIII; 
Lane 2, pBPCαInv digested with HindIII. (C) Restriction map of pBPCαInv. 
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Figure 5.5: Construction of plasmid pBPCα104. (A) Cloning of α104 into pBPAGC21. 
Lane 1, λ-PstI; Lanes 2 and 4, pBPCα104 digested with HindIII; Lane 3, empty pBPAGC21 
digested with HindIII. (B) Restriction map of pBPCα104. 
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Figure 5.6: Construction of plasmid pBHAαInv. (A) PCR of PhtrA from S. Typhimurium. 
Lane 1, λ-PstI; Lane 2-3, PCR of PhtrA. (B) PCR of the PhtrA:αInv ligation. Lane 1, λ-PstI; 
Lanes 2-3, PCR of PhtrA:αInv ligation. (C) Directional cloning of the PhtrA:αInv fragment into 
pBluescript. Lanes 1-5, pBHAαInv digested with HindIII; Lane 6, λ-PstI. (D) Restriction map 
of the plasmid pBHAαInv. 
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Figure 5.7: Construction of plasmid pBHAα104. (A) PCR of PhtrA:α104 ligation. Lanes 1-
2, PCR of PhtrA:α104 ligation; Lane 3, λ-PstI marker. (B) Directional cloning of PhtrA:α104 
fragment into pBluescript. Lanes 1-2, pBHAα104 digested with HindIII; Lane 3, λ-PstI. (C) 
Restriction map of the plasmid pBHAα104. 
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Figure 5.8: Isolation of expression plasmids containing α-toxin truncated gene inserts 
from vaccine strain STM1. (A) Plasmids pBTCαInv (Lane 1) and pBPCαInv (Lane 3) 
digested with HindIII; Lane 2, λ-PstI. (B) Plasmids pBHAα104 (Lane 2), pBTCα104 (lane 
3), pBHAαInv (Lane 4) and pBPCα104 (Lane 5) digested with HindIII; Lane 1, λ-PstI. 
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Transformation efficiency of pBHAαInv into STM1 was very low (4-6 colonies) and growth 
of the resultant transformant STM(pBHAαInv) was much poorer than the other vaccines 
developed.  Mid-log phase was constantly reached at about 6 h of growth as opposed to 3-4 h 
for the other STM1 vaccines. 
 
5.3.2.1 Expression of α-toxin truncated proteins from pBPCαInv and pBPCα104 
Expression of αInv and α104 from the PpagC was controlled by the presence or absence of 
MgCl2.  Expression of αInv from STM1(pBPCαInv) was induced in the absence of MgCl2, 
and in the presence of low levels of MgCl2 (1 and 10 mM) whereas high levels (100 mM) of 
MgCl2 repressed the expression of protein αInv (Figure 5.9A). 
 
Expression of α104 from STM1(pBPCα104) could not be detected in the immunoblot in the 
absence or presence of MgCl2. 
 
5.3.2.2 Expression of α-toxin truncated proteins from pBTCαInv and pBTCα104 
Expression of αInv from STM1(pBTAαInv) was constitutive from Ptac (Figure 5.9C) and did 
not require specific induction of any kind.  As with STMI(pBPCα104), expression of α104 
from STM1(pBTCα104) was not detected in the immunoblots probed with horse anti-α-toxin 
polyclonal antisera. 
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Figure 5.9: The detection of αInv expression from STM1 harbouring expression 
plasmids via immunoblots probed with horse anti-α-toxin polyclonal antibodies. (A) 
STM1(pBPCαInv) induced with: 0 mM MgCl2 (Lane 1), 1 mM MgCl2 (Lane 3), 10 mM 
MgCl2 (Lane 4), 100 mM MgCl2 (Lane 5); Lane 2, SeeBlue protein marker (B) 
STM1(pBHAαInv) induced with: 1 mM H2O2 (Lane 1), 10 mM H2O2 (Lane 3), or 0 mM 
H2O2 (Lane 4); Lane 2, SeeBlue protein marker. (C) STM1(pBTCαInv): Lane 1, SeeBlue 
protein marker; Lane 2, STM1(pBTCαInv). 
 
   1      2       3         4         5  
       1         2          3         4 
    1          2  
(B) 
(A) 
(C) 
50 
64 
98 
16 
22 
36 
kDa 
50 
98 
16 
22 
36 
kDa 
64 
50 
98 
16 
22 
36 
kDa 
64 
Chapter 5. Vaccination against the α-toxin of C. perfringens by use of the STM1 delivery vector                
 223
5.3.2.3 Expression of α-toxin truncated proteins from pBHAαInv and pBHAα104 
Expression of αInv from PhtrA was controlled by the addition of H2O2.  In the absence of 
H2O2, a very low level of αInv expression could be detected from STM1(pBHAαInv) in 
immunoblots probed with polyclonal anti-α-toxin antisera, but low levels (1 mM) of H2O2 
enhanced the expression and detection of αInv from the same strain (Figure 5.9B).  The 
addition of 10 mM H2O2 dramatically reduced the level of expression of αInv when compared 
to the addition of 1 mM H2O2 but expression was still higher than in the absence of H2O2. 
 
As with expression from plasmids pBPCα104 and pBTCα104, expression of α104 from 
STM1(pBHAα104) could not be detected in the immunoblots. 
 
5.3.3 Stability assays 
The stability of the recombinant plasmids within STM1 in the absence of the selective 
antibiotic ampicillin was determined in vitro.  STM1 harbouring recombinant plasmids were 
incubated in LB in the absence of ampicillin, and then spread plate onto HA with or without 
ampicillin.   
 
The percentage of STM1 cells retaining the different recombinant plasmids was determined 
over a 5 day period (Figure 5.10). 
 
STM1(pBPAGC21) was used as a reference between each stability assay as this plasmid 
contains no gene downstream of PpagC, and therefore represents an expressionless plasmid.  
Although, pBPAGC21 is lost over time, it is a gradual loss, with some colonies tested 
retaining the plasmid longer than others (as depicted by the standard deviation bars).   
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Figure 5.10: Stability of expression plasmids within STM1 in the absence of the selective 
antibiotic ampicillin. The control plasmid pBPAGC21 (no α-toxin gene insert) was included 
with each graph (dark blue) as a reference for comparison between plasmids. The pink line 
within the graphs represents the mean results of triplicate plasmid stability assays of: (A) 
pBPCαInv (B) pBPCα104 (C) pBTCαInv, (D) pBTCα104, (E) pBHAαInv or (F) 
pBHAα104.  Standard deviations are shown as positive and negative bars. 
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By the end of day one most of the STM1 colonies retained the plasmid, and by day two there 
was a slight drop with approximately 80% of the colonies retaining the plasmid. 
 
Both recombinant plasmids pBHAαInv and pBHAα104 carrying PhtrA were lost within 1 day 
(approximately 20 generations) in all 3 colonies selected (Figure 5.10E & F).   
 
STM1 strains carrying recombinant plasmids controlled by Ptac were also not very stable.  A 
large deviation can be seen in the pBTCα104 graph (Figure 5.10D).  This deviation is due to 
the fact that 2/4 colonies examined were more stable over a longer period of time than the 
other 1 examined.  This prompted the examination of a fourth colony, which also resulted in 
the rapid loss of the plasmid. 
 
Plasmid pBTCαInv was also unstable (Figure 5.10C).  Two of three colonies examined lost 
their plasmid within 1 day, whereas 6% of cells from the third colony examined retained the 
plasmid. A fourth colony was examined and found to retain the plasmid for up to 2 days 
(50%) which was then was completely lost by the following day. 
 
Even though plasmid pBPCαInv was being expelled from STM1 as early as 1 day (20 
generations), this plasmid was still present up until day 3 (0.05%).  Each colony examined 
gave a similar result (small deviations).  
 
Recombinant plasmid pBPCα104 was maintained within STM1 longer than the other 
plasmids, including pBPAGC21.  The plasmid was present in 72% of colonies by the end of 
day 5 (approximately 100 generations). 
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5.3.4 Immunisation of BALB/c mice 
The ability of STM1 harbouring the recombinant plasmids to induce specific immune 
responses targeted towards the α-toxin of C. perfringens was examined.  Mice were orally 
vaccinated with STM1 harbouring each of the recombinant plasmids.  Production of specific 
IgG targeted against the recombinant gene product (αInv or α104) expressed from STM1 was 
assessed using an ELISA coated with plc3 (α-toxin).  Anti-α-toxin IgG responses were quite 
low and specific titres did not reach an OD450 of 0.2 (generally the end-point of the assay).  
Therefore the absorbance of the wells following sulphuric acid addition was measured at a 
dilution of 1 in 20 (Figure 5.11).  No significant immune responses against α-toxin were 
observed in any of the vaccines tested when compared to control strain STM1(pBPAGC21).  
 
Cytokine profiles of the same groups of mice were examined using the ELIspot assay.  
Capture antibodies against interferon-gamma (IFN-γ) and interleukin-4 (IL-4) were coated 
onto 96-well nitrocellulose backed plates.  Following the addition of homogenised 
splenocytes and stimulation of cytokine production with α-toxin (plc3), cytokine producing 
cells were probed with biotin-labelled anti-cytokine antibodies.  The IFN-γ or IL-4 producing 
cells were then detected following EXTRAvidin binding, and substrate addition.  The number 
of IFN-γ producing cells was very low in all vaccines examined (Figure 5.12). 
 
STM1(pBHAαInv) produced, on average 4 cells secreting IFN-γ out of 106 cells in total.  The 
groups of mice vaccinated i.p with toxoid emulsified in FIA also induced only a few IFN-γ 
secreting cells.  Concanavalin A stimulated-cells induced the secretion of IFN-γ from so many 
splenocytes that it was impossible to count individual cells (over 600). 
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Figure 5.11: Anti-α-toxin IgG response of mice immunised with STM1 harbouring 
expression plasmids for the expression of α-toxin truncated genes. Serum was obtained 20 
days following the final vaccination and assayed for anti-α-toxin IgG against purified plc3 (α-
toxin) by an indirect ELISA.  Each column represents the average absorbance at OD450 of 5 
mice at a dilution of 1 in 20 (+-/ standard deviation). No significant differences were observed 
between groups of mice. 
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Figure 5.12:  The induction of an interferon gamma response of splenocytes isolated 
from STM1 (harbouring expression plasmids) vaccinated mice via stimulation by α-
toxin (plc3).  Each column is representative of the average cell count of 5 mice vaccinated 
with STMI harbouring plasmids (+/- standard deviation): pBPCαInv (PI), pBTCαInv (TI), 
pBHAαInv (HI), pBPCα104 (P104), pBTCα104 (T104), pBHAα104 (H104), the negative 
control pBPAGC21 (PagC) or toxoid.  
 
 
0
1
2
3
4
5
6
7
PI TI HI P104 T104 H104 PagC TOXOID
Vaccine
IF
N
- γγ γγ
 s
e
c
re
ti
n
g
 s
p
le
n
o
c
y
te
s
/1
0
6
 
s
p
le
n
o
c
y
te
s
 
Chapter 5. Vaccination against the α-toxin of C. perfringens by use of the STM1 delivery vector                
 229
A much larger population of cells secreted IL-4 following stimulation by α-toxin (Figure 
5.13).  In fact all vaccines carrying the α-toxin truncated genes stimulated enhanced IL-4 
secretion from spleen cells (p<0.05) when compared to the control group pBPAGC21, the 
group lacking an α-toxin truncate gene.   
 
Vaccination with STM1(pBHAα104) and STM1(pBPCαInv) resulted in the highest number 
of splenocytes secreting IL-4 and were significantly higher than groups STM1(pBHAαInv) 
and STM1(pBPCα104) (p<0.05). 
 
Toxoid immunised mice also resulted in IL-4 secreting splenocytes.  On average, this vaccine 
group stimulated the production and secretion of IL-4 from about 220 splenocyte per 106 
spleen cells.  A significant difference between toxoid immunised mice and STM1(plasmid) 
immunised mice was not observed due to the large variation in IL-4 secretion from the toxoid 
immunised mice.  Concanavalin-A also stimulated the production of IL-4 from spleen cells, 
and again there were too many cells too count (over 600/106 cells). 
 
5.3.5 Challenge of mice immunised with STMI harbouring recombinant α-
toxin expression plasmids 
Mice were orally vaccinated with STM1 harbouring the recombinant vaccine plasmids and 
prior to challenge with C. perfringens 60, serum from mice was collected for IgG detection 
(Figure 5.14).  Antibody levels were quite low, with only 3 of the vaccines (pBTCαInv, 
pBHAαInv and pBPCα104) reaching an average absorbance (OD450) above 0.2 when sera 
was examined at a dilution of 1/20.   
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Figure 5.13: The induction of an interleukin-4 response of splenocytes isolated from 
STM1 (harbouring expression plasmids) vaccinated mice via stimulation by α-toxin 
(plc3).  Each column is representative of the average cell count of 5 mice (+/- standard 
deviation) vaccinated with STMI harbouring plasmids: pBPCαInv (PI), pBTCαInv (TI), 
pBHAαInv (HI), pBPCα104 (P104), pBTCα104 (T104), pBHAα104 (H104), the negative 
control pBPAGC21 (PagC) and toxoid.  
 
*Splenocytes from all STM1 constructs harbouring α-toxin gene truncates produced a 
significant amount of IL-4 when stimulated with α-toxin in vitro (p<0.05) when compared to 
the control STM1(pBPAGC21).  
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Figure 5.14:  Serum anti-α-toxin IgG responses of mice vaccinated with STM1 
harbouring plasmids for the expression of αInv and α104 prior to challenge with 
C. perfringens. Serum obtained from mice 11 days following the final (third) vaccination was 
analysed using an ELISA for the presence of anti-α-toxin-IgG.  Each column is representative 
of the average absorbance at OD450 of 6 mice when serum was examined at a diluted of 1/20 
(+/- standard deviation).   
 
*TI and P104 are significantly different from PagC (p<0.05) according to the 2-tailed 
independent t-tests.  
 
Plasmid abbreviations: pBPCαInv (PI), pBTCαInv (TI), pBHAαInv (HI), pBPCα104 (P104), 
pBTCα104 (T104), pBHAα104, or pBPAGC21 (PagC). 
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Pooled sera were examined for the presence of anti-S. Typhimurium IgG (Figure 5.15).  It is 
quite clear that STM1 cells harbouring the control expressionless plasmid pBPAGC21 
induced the production of a much higher IgG response towards S. Typhimurium antigens in 
mice when compared to STM1 harbouring expressed α-toxin gene truncates.  Antibodies 
from the toxoid immunised mice also recognised some S. Typhimurium antigen, but this was 
most likely due to the presence of minute quantities of E. coli proteins that may have been 
present following purification of α-toxin from TOP10F’ cells prior to toxoiding and 
vaccination (Chapter 3). 
 
The percentage of the cumulative score over the maximum score achievable was used to 
graph the development of gas-gangrene following the C. perfringens challenge (Figure 5.16).  
Most mice developed clinical signs of gas-gangrene and even one toxoid vaccinated mouse 
succumbed to the challenge, with gangrene encompassing the challenged thigh.  The 
percentage of mice affected by the challenge at the end of the scoring period is shown in 
Table 5.5.   
 
The vaccine groups with lower overall gangrenous signs included STM1(pBHAα104), 
STM1(pBTCαInv), and STM1(pBPCαInv).   
 
These groups exhibited a reduction and latency in the development of gas-gangrene and were 
also the groups with lower percentages of overall infection (Table 5.5).  Although the results 
of vaccine group STM(pBHAα104) may be skewed as 2 mice from this group died during the 
vaccine trial prior to challenge (from unrelated causes) therefore reducing the power of the 
results.  Following termination of the experiment, swabs (from 1-2 mice per group) of the 
infected and uninfected thigh, liver and spleen were taken and cultured for the presence of 
C. perfringens (incubated both aerobically and anaerobically on SBA and EYA).  
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Figure 5.15: Serum anti-S. Typhimurium IgG immune response of mice vaccinated with 
STMI harbouring plasmids for the expression of αInv and α104 prior to challenge with 
C. perfringens. Serum obtained from mice 11 days following the final vaccination was 
assayed for anti-Salmonella IgG against S. Typhimurium whole cell antigens by ELISA.  
Each bar on the graph represents the OD450 value of pooled sera when examined at a dilution 
of 1/640.  
 
Plasmid abbreviations: pBPCαInv (PI), pBTCαInv (TI), pBHAαInv, pBPCα104 (P104), 
pBTCα104 (T104), pBHAα104, or pBPAGC21 (PagC). 
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Figure 5.16: Gross pathology of mice infected with 5 x 10
6
 C. perfringens cells following 
oral vaccination with STM1 harbouring α-toxin truncate expression plasmids. (A) 
pBPCαInv (PI), pBTCαInv (TI), pBHAαInv (HI) or (B) pBPCα104 (P104), pBTCα104 
(T104), or pBHAα104 (H104). pBPAGC21 (Pag) was used as the control in the experiments 
and consisted of an expressionless plasmid. A 50 µL dose of C. perfringens was administered 
to the left thigh of BALB/c mice. Mice were then observed over a 66 hour period for the overt 
signs of disease (Table 4.3). The data reflects the % cumulative score of disease progression 
over 66 h. 
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Table 5.5: Percentage of mice within each vaccine group afflicted with signs of gas-
gangrene (at 66 h). 
Vaccine Percentage of mice 
affected 
pBPCαInv 66.6 
pBHAαInv 80 
pBTCαInv 75 
pBHAα104 40 
pBPCα104 83 
pBTCα104 80 
Toxoid 16.6 
pBPAGC21 100 
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All mice examined-including the toxoid vaccinated group, showed the presence of 
C. perfringens in the infected thigh.  The infection was localised, but bacteria survived.   
 
The Pearson product-moment correlation (Zar, 1999) indicated a strong negative association 
between the number of IL-4 secreting cells and the level of gangrene development in the 
different vaccine groups (r2=0.63, p<0.05) (Figure 5.17).  STM1 vaccines resulting in a 
reduced infection in mice were also the same vaccines which resulted in higher IL-4 
producing splenocytes.  This included the vaccines STM1(pBPCαInv), STM1(pBTCαInv) 
and STM1(pBHAα104).  
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Figure 5.17: Correlation between the induction of IL-4 release by stimulated splenocytes 
and levels of gas-gangrene development in groups of vaccinated mice.  Data represent the 
average score of disease and the average number of IL-4 producing cells per vaccine group.  
The Pearson product-moment correlation indicated a strong negative association between the 
number of IL-4 secreting cells and the level of gangrene development in the different vaccine 
groups (r2=0.63, p<0.05). 
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5.4 Discussion 
STM1, an attenuated S. Typhimurium (∆aroA), is a registered vaccine currently used to 
immunise poultry to effectively eliminate or reduce the numbers of S. Typhimurium within 
their gastrointestinal tract (Alderton et al., 1991; Coloe et al., 1995; Jackson and Underwood, 
2006).  STM1 has the potential to be used as a combined vaccine by the incorporation of a 
heterologous antigenic gene carried on a plasmid, in effect stimulating cell-mediated and 
humoral responses to itself and the carrier protein (Khan et al., 1994; Roberts et al., 1998; 
Wang et al., 1999b).  The oral immunisation of mice with attenuated S. Typhimurium 
expressing heterologous antigens, is also able to elicit secretory IgA against the heterologous 
antigen within the intestinal mucosa of the host (Maskell et al., 1987; Paton et al., 1993; Ward 
et al., 1999; Wang et al., 1999b; Allen et al., 2000).  Necrotic enteritis of chickens is an 
enteric disease and vaccination with antigenic determinants delivered by a vector such as 
STM1 capable of stimulating intestinal secretory responses, along with other cell-mediated 
and humoral responses, may have the potential of protecting chickens from the disease.  
 
The α-toxin of C. perfringens is a known virulence factor important in the pathogenicity of 
necrotic enteritis in chickens and other agriculturally important animals, and gas-gangrene in 
humans (Al-Sheikhly and Truscott, 1977b; Fukata et al., 1988; Awad et al., 1995; Songer, 
1996; Awad et al., 2001).  Mutants of the α-toxin have been developed (Chapter 3) and 
immune responses induced following vaccination with the mutated α-toxin proteins have 
shown to provide protection against a C. perfringens challenge (Chapter 4).  The current study 
was aimed at determining the potential of using STM1 as a delivery vehicle to direct the 
delivery and expression of the α-toxin truncated proteins αInv and α104 within mice.   
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Expression of recombinant antigens in vitro from commercial vectors is usually controlled by 
chemicals such as IPTG.  In this study, a number of recombinant plasmids were created for 
the specific induction of protein expression under environmentally controlled conditions.  
These conditions would induce the expression of proteins on entry of STM1 into macrophages 
and therefore reduce the risks of overloading the metabolic machinery due to constitutively 
expressed heterologous proteins from high copy vectors. 
 
The pagC is part of a locus within the S. Typhimurium genome controlled by a two 
component regulatory system, the PhoQ/PhoP system (Garcia Vescovi et al., 1996; Vescovi et 
al., 1997).  The sensor, PhoQ represses transcription of the PhoP regulated genes in the 
presence of elevated MgCl2 levels.  When present in the extracellular environment of the 
eukaryote host, the PhoP/PhoQ system is switched off, repressed by the presence of high 
(>1mM) levels of MgCl2.  Once inside the membrane-bound Salmonella-containing vacuoles 
of macrophages, where MgCl2 levels are very low (<50 µM), the system is switched on and 
activation of PhoP by PhoQ results in the expression of numerous virulence genes including 
pagC (Garcia Vescovi et al., 1996; Vescovi et al., 1997). 
 
Expression of heterologous proteins from PpagC have previously shown to induce a high level 
of antibody towards heterologous proteins, therefore this system was chosen to determine its 
ability to express, and elicit immune responses targeted to α-toxin truncated proteins 
(Dunstan et al., 1999; Bullifent et al., 2000; Chen and Schifferli, 2001).   
 
The vector pBPCαInv containing PpagC and αInv as shown in Figure 5.9A induces high levels 
of αInv expression at low levels of MgCl2.  Although levels up to 10 mM did not completely 
repress the expression, it did result in reduced expression.  At a level of 100 mM MgCl2 αInv 
expression was not detected by immunoblots indicating the repression of PpagC.   
Chapter 5. Vaccination against the α-toxin of C. perfringens by use of the STM1 delivery vector                
 240
 
The htrA is a stress response gene in S. Typhimurium (Johnson et al., 1990; Johnson et al., 
1991).  It is a virulence gene required for the survival of bacteria within macrophages during 
induction of an oxidative burst (e.g. release of NADPH oxidase) which occurs within the 
Salmonella-containing vacuoles of macrophages (Johnson et al., 1990; Johnson et al., 1991; 
Mutunga et al., 2004).  Like PpagC, PhtrA has also been used for the expression of heterologous 
antigens within attenuated S. Typhimurium, and when administered to mice has resulted in the 
induction of strong immune response towards the heterologous antigen, and protection against 
challenge (Roberts et al., 1998; Foynes et al., 2003).   
 
Oxidative stress can be mimicked in vitro by the addition of H2O2 to the media.  The htrA 
promoter (PhtrA) used in this study was activated in the presence of H2O2 (Figure 5.9B).  Other 
authors have documented the induction of protein expression from PhtrA in the presence of 
elevated temperatures (42ºC) (Roberts et al., 1998; Foynes et al., 2003).  This was also tested 
but no αInv or α104 expression was evident at 42ºC.  The discrepancies cannot be explained 
at present, although the htrA of E. coli (also known as degP) has been shown to be expressed 
at both elevated temperatures and during oxidative stress (Pogliano et al., 1997; Skorko-
Glonek et al., 1999). 
 
The tac promoter (Ptac) is a hybrid promoter composed of the -10 region of lacUV5 and the -
35 region of the trp promoter making it a high level inducible promoter (Amann et al., 1983; 
de Boer et al., 1983).  Normally this promoter is repressed by the product of lacI.  Due to the 
lack of machinery required to ferment lactose and hence the absence of the repressor lacI 
within S. Typhimurium, Ptac results in constitutive expression of the downstream gene within 
STM1 (Sellitti et al., 1987; Chatfield et al., 1992a).  This promoter was chosen as a 
comparison with the in vivo inducible promoters for the expression of αInv and α104.  
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Protein αInv was constitutively expressed from STM1 carrying Ptac (pBTCαInv) as expected 
(Figure 5.9C). 
 
Whilst αInv was expressed from all expression vectors, expression of α104 from each vector 
was unsuccessful under all inducive conditions examined.  The α104 gene was amplified 
from pRplc104, a pRSETA expression vector containing the C-terminal domain of the α-
toxin of C. perfringens.  Expression from this vector resulted in a stable product containing an 
affinity N-His tag which included a total of 42 aa’s prior to the start of the plc104 sequence.  
Amplification and cloning of this gene into STM1 expression plasmids omitted the initial 42 
aa coding region for the N-His tag creating α104.  This 42 aa N-His tag coding region may 
have been essential for the stable expression of the small protein α104.  Other proteins such 
as the diphtheria toxin of Corynebacterium diphtheriae and the glutathione-S-transferase 
(GST) of Schistosoma mansoni when expressed alone in S. Typhimurium or E. coli 
expression systems results in poor expression of the protein.  Ligation to the fragment C of the 
tetanus toxin gene stabilises the expression, with vaccination inducing antibodies against both 
fragments (Gomez-Duarte et al., 1995; Barry et al., 1996; Lee et al., 2000).  Ligation of α104 
to stabilising antigens such as the fragment C portion of the tetanus toxin gene or recloning of 
the 42 aa N-His tag coding region upstream of α104 could possibly improve expression of 
α104 within STM1 (Gomez-Duarte et al., 1995).  Transcription and translation analysis via 
mRNA and pulse chase experiments could be used to determine the fate of α104, whether or 
not lack of detectable expression is related to mRNA secondary structure formation or protein 
instability (Schmidt et al., 1999). 
 
Even though α104 was not detected in immunoblots, it was expressed in amounts high 
enough to induce an immune response.  Splenocytes isolated from mice vaccinated with 
STM1 α104-expressing vectors (pBPCα104, pBTCα104 and pHAα104) actively secreted IL-
Chapter 5. Vaccination against the α-toxin of C. perfringens by use of the STM1 delivery vector                
 242
4 when stimulated with α-toxin (Figure 5.13).  This IL-4 response was absent in the 
expressionless plasmid pBPAGC21, indicating that T-helper cells recognised the epitopes on 
α-toxin due to previous encounters with α104. 
 
High copy number plasmids were used in this study in order to maximise the level of antigen 
expression following vaccination of mice (Cardenas and Clements, 1993).  To counter-act the 
effects that high-copy number plasmids have within their hosts (Su et al., 1992; Turner et al., 
1993; Dunstan et al., 2003), that is, increased instability and reduced growth rates, in vivo 
inducible promoters were cloned upstream of the α-toxin truncated genes to prevent their 
constitutive expression which would otherwise result in further destabilisation of the vector. 
 
Incorporation of the in vivo inducible promoters PhtrA and PpagC did little to maintain plasmid 
stability in vitro as shown by the graphs in Figure 5.10.  Most STM1 cells harbouring plasmid 
lost their plasmid within one to two days.  Even in the absence of selection for plasmid 
encoded functions (the vector itself without insert), plasmid carriage can reduce host fitness 
(Abromaitis et al., 2005).  This was evident with plasmid pBPAGC21.  The expressionless 
plasmid was lost over a 5 day period in the absence of the selective pressure ampicillin.  
However, the loss of this plasmid was gradual, with a 20% loss over 2 days, which was not as 
dramatic as the loss of plasmids expressing antigenic genes. 
 
The only other stable vector within STM1 was pBPCα104.  The two main differences 
between this vector and pBPCαInv is their size (pBPCαInv has an extra 822 bp) and the lack 
of protein expression of α104 in vitro from pBPCα104.  Therefore the size difference and the 
expression levels of the two could have influenced the stability of the high-copy number 
vector within STM1.   
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Protein expression from PhtrA is minimal in the absence of H2O2 (Figure 5.9B) yet plasmids 
pBHAαInv and pBHAα104 were both very unstable in STM1 with their elimination 
occurring within the first day (Figure 5.11E-F).  Transformation of STM1 with pBHAαInv 
also constantly resulted in a very low number of transformants (1-4 colonies) with reduced 
growth rates in vitro.  This cannot be explained by the size of the plasmid (as it wasn’t the 
largest of the plasmids) nor by the metabolic load caused by expression (as expression was 
reduced in the absence of H2O2), but perhaps regulation of the promoter required an increased 
energy expenditure, applying a metabolic burden on the host.  It is possible that the presence 
of the high number of copies of PhtrA  was titrating regulatory proteins away from the genome 
of STM1 (Garmory et al., 2005) in turn affecting the growth and survival of the bacterium.  
Characterisation of the few positive transformants may help elucidate the nature of the 
reduced growth rate and reduced plasmid maintenance.  
 
Immunogenicity of the vaccines was assessed by cytokine profiling using the ELIspot assay.  
Humoral responses were also examined using an ELISA assay. 
 
When T-lymphocytes in a spleen cell population of vaccinated mice were incubated with α-
toxin, they were activated and produced detectable amounts of IL-4 (Figure 5.13).  Although 
this indicated a humoral response, a very low level of IgG was detected from mouse serum 
samples (Figures 5.11 and 5.14) and this level was not significantly different from the control 
vaccine group STMI(pBPAGC21).  The presence of some IgG binding in the ELISA assays 
prompted the use of an immunoblot consisting of α-toxin probed with pooled mouse sera to 
confirm whether this low level of IgG was specific to the α-toxin.  Unfortunately the 
immunoblot was negative for the detection of anti-α-toxin IgG.  Perhaps employing a more 
sensitive assay such as an ELIspot for the detection of antibody secreting cells (by sampling 
cells from the bone marrow, spleen and Peyer’s patches) in future could be used to determine 
Chapter 5. Vaccination against the α-toxin of C. perfringens by use of the STM1 delivery vector                
 244
if a serum and mucosal antibody response is developed (Allen et al., 2000).  Serum was not 
collected for re-examination from mice following challenge.  Strugnell et al., (1992) detected 
an increase in the humoral response following Bordetella pertussis aerosol challenge of mice 
vaccinated with attenuated S. Typhimurium expressing the p69 antigen.  Had sera been re-
examined in this study, a boost in the humoral response may have been detected, as 
challenged mice did show signs of reduced infection (Figure 5.16). 
 
An effective immune response against infection by S. Typhimurium relies on the induction of 
cell mediated immunity (CMI) also referred to as a TH1 response, and is usually detected by 
the presence of IFN-γ secreting T-helper lymphocytes (Pashine et al., 1999; Raupach and 
Kaufmann, 2001b; Norimatsu et al., 2004).  Due to the adjuvant effect of attenuated 
S. Typhimurium, delivery of heterologous antigens that do not generally produce a TH1 
response are capable of inducing such responses when delivered within attenuated 
S. Typhimurium (Brown et al., 1987; Strugnell et al., 1992; Foynes et al., 2003).   
 
Although, the response of an STM1 delivered protein antigen is not entirely determined by the 
delivery vector but also influenced by inherent properties of the heterologous antigen.  
Differences in affinity and duration of stimulation between the antigen presenting cell and T-
cell determine the final pattern of cytokine response secreted by the T-cells (Harokopakis et 
al., 1997; Santana and Rosenstein, 2003).  Therefore whilst STM1 generally elicits a TH1 
response (Bachtiar et al., 2003), the delivery and expression of recombinant α-toxin from 
STM1 primes a TH2 response.  In this case the properties of the α-toxin truncated proteins 
αInv and α104 influenced the pattern of cytokine secretion more so than the delivery vector 
itself. Cytokine profiling at different time points would have to be conducted in order to 
confirm the TH2 pattern.  
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The strong correlation between IL-4 secretion and C. perfringens challenge data of vaccinated 
mice (Figure 5.17) indicate that IL-4 is necessary for protection against the lethal effects of 
C. perfringens.  Vaccination of mice with the toxoid emulsified in FIA induced a large 
number of IL-4 secreting cells, a lack of IFN-γ secreting cells, a high level of anti-α-toxin IgG 
production, and the complete protection against challenge by C. perfringens.  Although all 
STM1 harbouring the α-toxin recombinant expression vectors developed significant amounts 
of IL-4, a significant IgG response towards the α-toxin was undetected.  This data suggests 
that protection from a gas-gangrene infection caused by a C. perfringens challenge is 
mediated by a TH2-cell response with a requirement for high levels of anti-α-toxin antibody 
production.  
 
The level of antigen expressed affects the ability of mice to mount a humoral response 
(Fairweather et al., 1990; Wick et al., 1994) with the induction of protective antibodies 
requiring the presence of a threshold amount of antigen (Redman et al., 1995).  Such a 
threshold amount of antigen may not have been expressed in this study due to the instability 
of the plasmids expressing both αInv and α104, and the lack of detectable expression of 
α104.  The number of STM1 harbouring plasmids is dramatically decreased within 20 
generations (Figure 5.10).  It is possible that in vivo the plasmid is lost even quicker than in 
culture, therefore reducing the potential immunogenicity of the constructs (Dunstan et al., 
2003; Foynes et al., 2003).   
 
Indirect evidence also exists indicating that the presence of the expression plasmids reduces 
the viability of the STM1 when within the mice.  Higher anti-Salmonella IgG responses were 
observed with the control expressionless vaccine STM1(pBPAGC21) (Figure 5.15) indicating 
that this expressionless vaccine persisted longer in the host and was therefore able to stimulate 
a much stronger IgG response against S. Typhimurium whole cell antigens.  On the other 
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hand, all vaccines expressing the α-toxin truncates resulted in poor IgG responses against 
S. Typhimurium indicating poor survival within the host.  Plasmids expressing αInv and α104 
were larger and more complex than pBPAGC21, and the presence of these high-copy number 
vectors actively expressing antigen may have lead to an increased metabolic burden on STM1 
which compromised its colonising abilities, growth rate and survival (Su et al., 1992; Coulson 
et al., 1994a; Coulson et al., 1994b; Dunstan et al., 1998; Dunstan et al., 2003).   
 
Alternatives to the use of high copy number vectors relying on antibiotic selection includes 
the integration of antigenic genes into the genome of STM1 with the use of strong promoters 
to constitutively express the antigens at high levels, the use of balanced lethal plasmid 
systems, and the use of lower-copy number vectors (Curtiss et al., 1989; Curtiss et al., 1990; 
Chatfield et al., 1992a; Chatfield et al., 1992b; Hohmann et al., 1995; Bullifent et al., 2000; 
Chen and Schifferli, 2001; Dunstan et al., 2003; Foynes et al., 2003; Garmory et al., 2003; 
Wyszynska et al., 2004).  These may be future approaches for the current work. 
 
The timing and location of expression of the truncated α-toxin proteins αInv and α104 could 
have also lead to the lack of efficient antibody responses against the α-toxin.  The high 
expression of antigens during the initial phase of invasion are crucial for the development of 
appropriate humoral responses (Wick et al., 1994; Covone et al., 1998).   
 
The induction of immune responses from the macrophage inducible promoters would require 
invasion of Peyer’s patches, phagocytosis into macrophages, induction of recombinant protein 
expression, processing of STMI and the associated recombinant protein within vacuoles, and 
presentation on the macrophage surface via MHC class II (Gahring et al., 1990; Jones et al., 
1994; Lindgren et al., 1996; Dunstan et al., 1998).  Bacterial viability was low within mice (as 
assessed by anti-S. Typhimurium IgG responses) and plasmid instability high, suggesting that 
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the number of viable STM1 cells retaining expression-plasmids and successfully reaching the 
macrophages may have been much lower than anticipated.  This inturn resulting in only low 
levels of αInv or α104 expression.  The metabolic load placed on STM1 by carriage of 
expression plasmids may have also reduced their ability to survive within the macrophages.  
For the induction of a humoral response, it may be better to use a system whereby protein is 
constantly expressed, that way increasing the chances of processing within all areas of the 
body involved in antigen sampling.   
 
Expression of αInv and α104 from STM1 harbouring expression plasmids also lead to 
intracellular localisation of αInv and α104.  Perhaps the constitutive expression of αInv and 
α104 leading to extracellular presentation, via secretion or surface expression, may hold more 
future promise in eliciting stronger humoral immune responses .  The constitutive expression 
(timing), and extracellular presentation (location) of the recombinant proteins would ensure 
their immediate and constant delivery into the extracellular environment, increasing their 
chances of presentation to all APC’s (Newton et al., 1989; Su et al., 1992; Hess et al., 1997; 
Titball et al., 1997; Chen and Schifferli, 2000; Ruiz-Perez et al., 2002; Garmory et al., 2003; 
Kang and Curtiss, 2003).  This method may be a more plausible approach for induction of 
humoral responses and was evidenced with the toxoid immunised mice.  Intraperitoneal 
administration of toxoid enabled its immediate presentation to APC’s including B-cells, 
within the extracellular fluids (Janeway et al., 2005).  The depot effect provided by 
administration with FIA allowed the toxoid to remain within the host for a considerable length 
of time in order for the induction of an adequate humoral response (Aucouturier et al., 2001; 
Billiau and Matthys, 2001) and ultimately protection from challenge.   
 
Other options that could be examined to improve the humoral response of mice vaccinated 
with STM1 harbouring plasmids for the expression of αInv and α104 include the 
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augmentation of the immune response by the co-expression of auxiliary molecules known to 
enhance cytokines and receptors for induction of the TH2 response.  Such molecules include 
the non-toxic subunit of pertussis toxin, fragment C of tetanus toxin and the non-toxic 
component of cholera toxin (Harokopakis et al., 1997; Ryan et al., 1998; Guillobel et al., 
2000; Lee et al., 2000).  The co-expression of other immuno-modulatory proteins such as IL-6 
could also be examined to assist in the initiation of the TH2 response (Li et al., 2003). 
 
A comparison of the different αInv expression systems showed that IL-4 responses were not 
significantly different between the three promoters examined.  Following challenge with 
C. perfringens, mice vaccinated with STM1(pBPCαInv) or STM1(pBTCαInv) resulted in 
lower levels of gas-gangrene.  As mentioned earlier, pBHAαInv was not efficiently 
transformed into STM1 and the plasmid was very unstable in vitro which may have accounted 
for its reduced protective efficacy.  Therefore both the constitutively expressed vector 
pBTCαInv, and the macrophage-inducible expression vector pBPCαInv should be used in 
future trials, perhaps placed into lower copy number vectors with greater long-term stability, 
to further assess their vaccine potential. 
 
It is difficult to draw any conclusion from plasmids expressing α104 as detectable levels of 
expression were absent in vitro.  Furthermore, vaccine pBHAα104 which resulted in some 
level of protection when challenged with C. perfringens only had four mice in the group, 
which may have biased the results.  
 
Some clostridial antigens successfully expressed from attenuated S. Typhimurium include the 
fragment C of tetanus toxin, the toxin A fragment of C. difficile and a recombinant botulinum 
toxin, with vaccination inducing antibody production and protection against challenge 
(Fairweather et al., 1990; Ward et al., 1999; Foynes et al., 2003).   
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This study demonstrated the feasibility of using STMI as a carrier for the in vivo expression of 
the C. perfringens α-toxin recombinant proteins αInv and α104.  It is the first study to 
express C. perfringens antigens within an attenuated strain of S. Typhimurium, STM1.  
Activation of the TH2 arm of the immune system was observed, but it seems at this time, the 
level of activated IL-4 cells stimulated in response to vaccination with STM1 expressing the 
α-toxin truncated proteins αInv and α104 was not efficient enough to induce a detectable 
humoral response or to completely protect mice from a C. perfringens infection. 
 
Future studies are focussing on chromosomal integration of αInv and α104 within STM1 
downstream of strong promoters.  The use of the hlyA secretion system of E. coli for the 
secretion of αInv and α104 is currently being examined within medium copy number vectors 
to improve α-toxin recombinant delivery from STM1.  
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 Chapter 6 
General discussion 
Necrotic enteritis is an insidious infection of poultry caused by the proliferation of 
C. perfringens and its associated toxins (Al-Sheikhly and Truscott, 1977a; Al-Sheikhly and 
Truscott, 1977b; Al-Sheikhly and Truscott, 1977c; Fukata et al., 1988).  NE in chickens is 
often left untreated due to the difficulties in its detection with most diagnoses occurring 
retrospectively via on-farm necropsy (Parish, 1961a; van der Sluis, 2000).  This can lead to 
significant economic losses due to unprecedented death of chickens, and an increased food 
conversion ratio in chickens with sub-clinical NE (Kaldhusdal and Hofshagen, 1992; Lovland 
and Kaldhusdal, 1999; van der Sluis, 2000).  The only currently successful and commercially 
available preventative measure against NE is via antibiotic treatment (Watkins et al., 1997; 
APVMA, 2006), but the pressure to reduce the use of antibiotics in food animals due to risks 
of antibiotic resistant bacteria developing, suggests the need for alternative methods of 
prophylaxis (Simonsen et al., 1998; Molbak, 2004; Shea, 2004). 
 
Vaccination of chickens is a possible option.  One major contributing factor in the 
development of NE is the action of α-toxin expressed from C. perfringens (Al-Sheikhly and 
Truscott, 1977a; Fukata et al., 1988; Heier et al., 2001; Lovland et al., 2004).  Vaccines 
raising antibodies targeted towards the α-toxin of C. perfringens may be successful in 
preventing the development of NE. 
 
This study involved the development of inactive truncated versions of the α-toxin as potential 
vaccine candidates for the prevention of NE.  The first two proteins developed were based on 
truncation of the α-toxin from its α-helical N-terminal domain.  The resulting proteins 
expressed from E. coli were quite insoluble and upon resolubilisation in chaotropic agents and 
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refolding in Tris buffer, began to re-aggregate over time.  Amino acids at the extremity of the 
N-terminal domain of α-toxin are hidden within a hydrophobic pocket (Nagahama et al., 
1994; Guillouard et al., 1996), and deletion of the N-terminal α-helices resulted in exposure 
of this hydrophobic region leading to misfolding of the protein.  Immunisation of mice with 
both these proteins resulted in lower anti-α-toxin antibodies most likely due to the loss of 
essential conformational epitopes. 
 
The α-toxin is a zinc metalloenzyme with the requirement of three zinc molecules in the 
active site for effective catalytic activity, and three calcium molecules for the successful 
docking to biological phospholipid membranes (Krug and Kent, 1984; Nagahama et al., 1995; 
Guillouard et al., 1997; Naylor et al., 1999).  Development of a third inactivated α-toxin 
protein involved the deletion of a region known to bind two of the zinc molecules.  The 
deletion resulted in the removal of the catalytic activity of the α-toxin without affecting its 
phospholipid membrane binding properties.  This newly developed protein, named plcInv3 
was also capable of eliciting an antibody response within mice following intraperitoneal 
vaccination in FIA.  These antibodies led to protection against a live intramuscular challenge 
with C. perfringens demonstrating the presence of essential epitopes within plcInv3 which led 
to the development of a protective immune response.  
 
The C-terminal domain (cpa247-370) has previously been shown to induce the production of 
protective antibodies within mice leading to protection against challenge with α-toxin and 
C. perfringens (Williamson and Titball, 1993).  The study by Williamson and Titball (1993) 
prompted the author to examine the effects of further deleting this C-terminal region and 
examining its vaccine potential.  Protein plc104 developed in this study was composed of 
seven of the eight β-sheets located within the C-terminus.  The first β-sheet located at the N-
terminus of cpa247-370 was deleted.  Protein plc104 lost its ability to bind phospholipid 
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membranes but retained some epitopes necessary for the development of antibodies and 
protective immune responses.  However some breakthrough in protection was observed with 
some of the mice indicating that one or more conformational epitopes may be located in the 
deleted area, and their absence reduced the overall protectiveness of the plc104 antigen. 
 
Delivery of the successful test vaccines plcInv3 and plc104 within mice was accomplished via 
the intraperitoneal administration within an emulsion of FIA.  Even though this resulted in 
protective immune responses, it is not a feasible delivery system for domestic livestock, as 
FIA can cause localised inflammation (Aucouturier et al., 2001), and parenteral delivery 
would be too laborious for animals such as chickens which are maintained at high stocking 
densities. 
 
One approach to eliminate the side-effects of chemical adjuvants whilst reducing the labour 
required in administration of vaccines is the use of live vectored vaccines for the delivery of 
heterologous proteins.  The attenuated S. Typhimurium aroA- mutants are one such approach 
(Alderton et al., 1991; Wang et al., 1999b). Attenuated S. Typhimurium has been shown to 
elicit cell mediated and humoral responses to both the heterologous protein and itself (Wang 
et al., 1999b; Bachtiar et al., 2003).  An added advantage for use of S. Typhimurium mutants 
such as STM1, in the delivery of heterologous antigens, is the ability to stimulate an intestinal 
mucosal response to the foreign antigen when delivered orally to mice (Paton et al., 1993; 
Ward et al., 1999; Wang et al., 1999b; Allen et al., 2000).   
 
As NE is an enteric disease, intestinal mucosal responses would be pivotal to the protection 
against this infection (Holmgren et al., 1992).  Therefore proteins plcInv3 and plc104 were 
examined for their immune-stimulating abilities when administered orally within the 
S. Typhimurium vaccine strain, STM1.  The region coding for the affinity His tag of plcInv3 
Chapter 6 General disscusion                
 253
and plc104 was removed prior to cloning into STM1 and hence forth the proteins were known 
as αInv and α104 respectively. 
 
One major drawback of using live vectored vaccines for the delivery of antigens to the host is 
the increased instability of the expression plasmids used in the absence of selective pressure, 
particularly when high levels of antigen are expressed (Strugnell et al., 1992; Coulson and 
Titball, 1993; Coulson et al., 1994a; Garmory et al., 2003).  One solution to overcome this 
problem is the use of plasmids containing in vivo inducible promoters (Dunstan et al., 1999).  
The in vivo induction of antigen expression has also been shown to stimulate better immune 
responses over constitutively expressed antigens (Dunstan et al., 1999).   
 
The plasmids developed in this study were based on two in vivo inducible systems and one 
constitutive expression system.  They included the use of the macrophage inducible promoters 
pagC (PpagC) and htrA (PhtrA) and the strong constitutive tac promoter (Ptac).  Unfortunately, 
unlike other results reported (Chatfield et al., 1992a; Roberts et al., 1998; Dunstan et al., 
1999; Bullifent et al., 2000) these plasmids containing genes for the expression of αInv and 
α104 were not very stable in vitro  (Figure 5.10), and there is a high possibility that the 
plasmids were lost even quicker in vivo, therefore reducing the potential immunogenicity of 
the constructs (Dunstan et al., 2003; Foynes et al., 2003).   
 
The instability of the plasmids would have also affected the metabolic processes of STM1, 
resulting in loss of cell viability within the mouse host (Su et al., 1992; Coulson et al., 1994b; 
Dunstan et al., 2003). This was indirectly observed by the examination of anti-Salmonella-
IgG responses following vaccination of mice.  STM1 harbouring protein-expressing plasmids 
produced much lower anti-Salmonella titers than the expressionless plasmid pBPAGC21.  
The metabolic load of the bacterium was compromised when expression plasmids were used, 
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and this negatively impacted on the growth of STM1, resulting in shorter survival time within 
mice, and the lack of induction of detectable levels of anti-α-toxin antibodies. 
 
Although humoral responses were not observed directly through the detection of specific 
antibodies targeting the α-toxin, cytokine profiling with INF-γ and IL-4 revealed the 
stimulation of a TH2 response.  Unfortunately, this response was not sufficient enough to 
completely protect mice from a challenge with a strain of C. perfringens producing the α-
toxin.  Protection was seen with mice immunised via the intraperitoneal route with toxoid in 
FIA suggesting a considerable amount of antibodies needs to be present for protection against 
C. perfringens to occur. 
 
The partial protection of mice immunised with vaccines composed of STM1 expressing αInv 
and α104 indicate there is potential for this vectored vaccine system to be used in the 
protection of C. perfringens diseases caused by the α-toxin, although the system needs to be 
optimised for the maximal production of a humoral immune response.  Some options for 
future work include the secretion of the α-toxin truncates from STM1 using the hlyA E. coli 
secretory system (Garmory et al., 2003), the use of lower copy number vectors to aid in the 
stability of plasmids (Coulson et al., 1994a; Coulson et al., 1994b; Dunstan et al., 2003), or 
the integration of the α-toxin truncated genes within the STM1 chromosome under the control 
of strong promoters (Strugnell et al., 1990; Hohmann et al., 1995; Garmory et al., 2003).  
Different attenuating mutations within S. Typhimurium strains can also dramatically affect the 
induction of immune responses to the expression of foreign antigens in bacteria (Schodel et 
al., 1990; Karem et al., 1995; Chabalgoity et al., 1996; Dunstan et al., 1998; Raupach and 
Kaufmann, 2001a).  Therefore the use of other attenuated S. Typhimurium strains to deliver 
αInv and α104 may also provide induction of stronger humoral responses.  
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The development of an orally delivered vaccine targeted against the α-toxin of C. perfringens 
for the prevention of NE in chickens would be beneficial as it would reduce the use of 
antibiotics and reduce the losses incurred by the presence of undetectable sub-clinical forms 
of the disease. 
 
An orally based vaccine is preferred to a parenteral administered vaccine due to the relative 
ease of manufacture, the ease of delivery to the chicken, and the benefit of local mucosal 
immune responses.  Optimisation of the STM1 αInv and α104 expression systems is 
underway and focussed on chromosomal integration, and the use of the HlyA secretory 
system for the extracellular secretion of αInv and α104.  
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Appendix 1. Antigens delivered and expressed from attenuated Salmonella Typhimurium and 
the immune response(s) developed in the host 
Antigen (from Organism) S. Typhimurium 
attenuation 
Protection/immune 
response 
Reference 
Viruses 
 
  
Immediate early protein ICP27  
(Herpes simplex virus-HSV) 
∆cya (adenylate cyclate) 
∆crp (cyclic AMP 
receptor protein) ∆asd 
(aspartate b-semialdehyde 
dehydrogenase) 
Protection (73%) 
CMI^ (no humoral) 
(Karem et al., 1997) 
Glycoprotein D  
(HSV)  
∆cya ∆crp ∆asd Low protection (31%) 
Humoral response (no 
CMI) 
(Karem et al., 1997) 
E7 protein  
(Human papilloma virus- HPV)  
∆aroA ∆aroD CMI-IgG2a and 
Humoral-IgA 
(Londono et al., 1996) 
Nucleoprotein 
(Influenza virus) 
∆aroA Humoral and CMI (Brett et al., 1993) 
Core antigen/preS2-middle surface 
antigen (Hepatitis B virus) 
∆aroA Humoral and CMI-
IgG2a 
(Schodel et al., 1990) 
Bacteria    
Fragment C of Tetanus toxin  
(Clostridium  tetani) 
∆aroA Protection, humoral 
(CMI ND*) 
(Fairweather et al., 1990) 
 
Botulinum toxin type F   
(Clostridium botulinum) 
∆aroA Protection, CMI 
(IgG2a) and humoral 
(IgG1) 
(Foynes et al., 2003) 
Toxin A (C-terminal)  
(Clostridium difficile) 
∆aroA ∆aroD Humoral (CMI ND) (Ward et al., 1999) 
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Antigen (from Organism) S. Typhimurium 
attenuation 
Protection/immune 
response 
Reference 
P60  
(L. monocytogenes) 
∆aroA Protection CMI 
(humoral ND)  
(Hess et al., 1997) 
Protective antigen  
(Bacillus anthracis)  
∆aroA Protection, humoral-
IgG1 and CMI-IgG2a 
(Coulson et al., 1994a; Garmory 
et al., 2003) 
F1 (capsular) antigen  
(Yersinia pestis)  
∆aroA Protection, CMI and 
humoral 
(Titball et al., 1997) 
Filamentous hemagglutinin 
(Bordetella pertussis) 
∆aroA Humoral-IgG, IgA 
(CMI ND) 
(Guzman et al., 1991) 
Pertussis toxin S1 subunit 
(B. pertussis) 
∆aroA Humoral-IgG and IgA 
(CMI ND) 
(Walker et al., 1992) 
P69 Antigen  
(B. pertussis)  
∆aroA ∆aroD Protection, CMI (no 
humoral) 
(Strugnell et al., 1992) 
Pertussis toxin subunits  
(B. pertussis) 
∆aroA Humoral -not 
protective, (CMI ND) 
(Dalla Pozza et al., 1998) 
BCSP31-31 kDa protein  
(Brucella abortus) 
∆cya ∆crp Humoral, (No CMI) (Stabel et al., 1990; Stabel et 
al., 1991) 
Heat-labile enterotoxin B subunit (LT-B) 
(Escherichia coli) 
∆aroA Humoral-IgA and IgG 
(CMI ND) 
(Maskell et al., 1987) 
0111 O antigen  
(E. coli) 
∆aroA (STMI) Humoral (CMI ND) (Wang et al., 1999b) 
β-galactosidase  
(E. coli)  
∆aroA Humoral and CMI (Brown et al., 1987) 
Pilin subunit (BfpA)  
(Enteropathogenic E. coli)  
∆aroA Humoral (Schriefer et al., 1999) 
Type 5 M protein 
(S. pyogenes) 
∆aroA Protection, Humoral-
IgG IgA (CMI ND) 
(Poirier et al., 1988) 
Superoxide dismutase  
(Listeria monocytogenes) 
∆aroA Protection CMI 
(humoral ND)  
(Hess et al., 1997) 
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Antigen (from Organism) S. Typhimurium 
attenuation 
Protection/immune 
response 
Reference 
SBR (salivary binding region of AGI/II  
surface protein antigen) 
(Streptococcus mutans)  
∆aroA ∆aroD Humoral and CMI (Harokopakis et al., 1997) 
Parasites    
Sm-14 (Schistosoma mansoni antigen) S. 
mansoni cercaria (partial protection 
achieved-as good as parenterally admin 
alone 
∆aroA Partial protection, 
humoral (IgG) (CMI 
ND) 
(Pacheco et al., 2005) 
Schistosoma mansoni Glutathione-S-
transferase (P28) 
∆aroA Humoral (CMI ND) (Khan et al., 1994) 
Circumsporozoite protein of Plasmodium 
berghei Sporozoite challenge (partial 
protection 70%) 
WR4017 (previously 
M206-unable to multiply 
in macrophages) 
Protection, CMI (no 
humoral) 
(Sadoff et al., 1988) 
Copper/zinc superoxide dismutase 
(Acanthocheilonema viteae) 
∆aroA Humoral, partial 
protection, (CMI ND) 
(Lattemann et al., 1999) 
β-galactosidase antigen (against a b-gal 
tumour developed in mouse model)  
∆aroA Humoral-IgG, IgM 
CMI-CD8+ CTL, 
depletion in tumour 
size, prevention of 
tumour growth 
(Medina et al., 1999) 
^CMI: Cell mediated immunity 
* ND= Not determined 
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Appendix 2. Lambda DNA digested with PstI 
Numbers in brackets indicate approximate DNA quantity of each fragment when 1µg of PstI 
digested λ-DNA is separated by agarose gel electrophoresis 
 
 
 
 
 
 
 
(237.1 ng) 
(96.9 ng) 
(57.7 ng) 
(44 ng) 
(35 ng) 
(24 ng) 
(23 ng) 
(17 ng) 
(10.5 ng) 
(9.7 ng) 
(5.1 ng) 
(9.2 ng) 
(7.0 ng) 
(5.4 ng) 
(50.7 ng) 
(105.2 ng) 
(92.8 ng) 
(50 ng) 
(41 ng) 
(52.7 ng) 
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Appendix 4. DNA and predicted amino acid sequence of 
plc from C. perfringens type A strain 61. 
 
DNA (black letters) and predicted amino acid sequence (green letters).  The added 6 x CAT 
and its corresponding amino acid sequence is coloured purple. 
 
   1  ATG AAA AGA AAG ATT TGT AAG GCG CTT ATT TGT GCT GCG CTA GCA ACT   
        M   K   R   K   I   C   K   A   L   I   C   A   A   L   A   T   
 
  49  AGC CTA TGG GCT GGG GCA TCA ACT AAA GTC TAC GCT TGG GAT GGA AAA   
        S   L   W   A   G   A   S   T   K   V   Y   A   W   D   G   K   
 
  97  ATT GAT GGA ACA GGA ACT CAT GCT ATG ATT GTA ACT CAA GGG GTT TCA   
        I   D   G   T   G   T   H   A   M   I   V   T   Q   G   V   S   
 
 145  ATC TTA GAA AAT GAT CTG TCT AAA AAT GAA CCA GAA AGT GTA AGA AAA   
        I   L   E   N   D   L   S   K   N   E   P   E   S   V   R   K   
 
 193  AAC TTA GAG ATT TTA AAA GAG AAC ATG CAT GAG CTT CAA TTA GGT TCT   
        N   L   E   I   L   K   E   N   M   H   E   L   Q   L   G   S   
 
 241  ACT TAT CCA GAT TAT GAT AAG AAC GCC TAT GAT CTA TAT CAA GAT CAT   
        T   Y   P   D   Y   D   K   N   A   Y   D   L   Y   Q   D   H   
 
 289  TTC TGG GAT CCT GAT ACA GAT AAT AAT TTC TCA AAG GAT AAT AGT TGG   
        F   W   D   P   D   T   D   N   N   F   S   K   D   N   S   W   
 
 337  TAT TTA GCT TAT TCT ATA CCT GAC ACA GGG GAA TCA CAA ATA AGA AAA   
        Y   L   A   Y   S   I   P   D   T   G   E   S   Q   I   R   K   
 
 385  TTT TCA GCA TTA GCT AGA TAT GAA TGG CAA AGA GGA AAC TAT AAA CAA   
        F   S   A   L   A   R   Y   E   W   Q   R   G   N   Y   K   Q   
 
 433  GCT ACA TTC TAT CTT GGA GAG GCT ATG CAC TAT TTT GGA GAT ATA GAT   
        A   T   F   Y   L   G   E   A   M   H   Y   F   G   D   I   D   
 
 481  ACT CCA TAT CAT CCT GCT AAT GTT ACT GCC GTT GAT AGC GCA GGA CAT   
        T   P   Y   H   P   A   N   V   T   A   V   D   S   A   G   H   
 
 529  GTT AAG TTT GAG ACT TTT GCA GAG GAA AGA AAA GAA CAG TAT AAA ATA   
        V   K   F   E   T   F   A   E   E   R   K   E   Q   Y   K   I   
 
 577  AAC ACA GCA GGT TGC AAA ACT AAT GAG GAT TTT TAT GCT GAT ATC TTA   
        N   T   A   G   C   K   T   N   E   D   F   Y   A   D   I   L   
 
 625  AAA AAC AAA GAT TTT AAT GCA TGG TCA AAA GAA TAT GCA AGA GGT TTT   
        K   N   K   D   F   N   A   W   S   K   E   Y   A   R   G   F   
 
 673  GCT AAA ACA GGA AAA TCA ATA TAC TAT AGT CAT GCT AGC ATG AGT CAT   
        A   K   T   G   K   S   I   Y   Y   S   H   A   S   M   S   H   
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 721  AGT TGG GAT GAT TGG GAT TAT GCA GCA AAG GTA ACT TTA GCT AAC TCT   
        S   W   D   D   W   D   Y   A   A   K   V   T   L   A   N   S   
 
  
769  CAA AAA GGA ACA GCA GGA TAT ATT TAT AGA TTC TTA CAC GAT GTA TCA   
        Q   K   G   T   A   G   Y   I   Y   R   F   L   H   D   V   S   
 
 817  GAG GGT AAT GAT CCA TCA GTT GGA AAG AAT GTA AAA GAA CTA GTA GCT   
        E   G   N   D   P   S   V   G   K   N   V   K   E   L   V   A   
 
 865  TAC ATA TCA ACT AGT GGT GAA AAA GAT GCT GGA ACA GAT GAC TAC ATG   
        Y   I   S   T   S   G   E   K   D   A   G   T   D   D   Y   M   
 
 913  TAT TTT GGA ATC AAA ACA AAG GAT GGA AAA ACT CAA GAA TGG GAA ATG   
        Y   F   G   I   K   T   K   D   G   K   T   Q   E   W   E   M   
 
 961  GAC AAC CCA GGA AAT GAT TTT ATG ACT GGA AGT AAA GAC ACT TAT ACT   
        D   N   P   G   N   D   F   M   T   G   S   K   D   T   Y   T   
 
1009  TTC AAA TTA AAA GAT GAA AAT CTA AAA ATT GAT GAT ATA CAA AAT ATG   
        F   K   L   K   D   E   N   L   K   I   D   D   I   Q   N   M   
 
1057  TGG ATT AGA AAA AGA AAA TAT ACA GCA TTC CCA GAT GCT TAT AAG CCA   
        W   I   R   K   R   K   Y   T   A   F   P   D   A   Y   K   P   
 
1105  GAA AAC ATA AAG ATA ATA GCA AAT GGA AAA GTT GTA GTA GAC AAA GAT   
        E   N   I   K   I   I   A   N   G   K   V   V   V   D   K   D   
 
1153  ATA AAT GAG TGG ATT TCA GGA AAT TCA ACT TAT AAT ATA AAA CAT CAT  
        I   N   E   W   I   S   G   N   S   T   Y   N   I   K   H   H   
 
1200  CAT CAT CAT CAT TAA   
        H   H   H   H   - 
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Appendix 5. Sequence of region upstream from the plc 
start site (ATG) of vector pCplc3. 
 
 
The lacZ ribosome binding site is boxed, the lacZ ATG site is highlighted green and plc3 
ATG start site is highlighted purple. No RBS is present 8-12 bp upstream of the plc3 ATG. 
 
 
 
1   ACA GGA AAC AGC TAT GAC CAT GAT TAC GCC AAG CTT GGT  
40  ACC GAG CTC GGA TCC ACT AGT AAC GGC CGC CAG TGT GCT  
79  GGA ATT CGG CTT TAA CGC TGC AGA TAA AAA ATG AAA AGA 118 
AAG ATT TGT AAG GCG CTT ATT TGT GCT   
 
 
 
